Ayrshire and Arran Health Board Annual Report and Accounts for the year to 31 March 2015

7

Contents

ANNUAL REPORT MANAGEMENT COMMENTARY: TRATEGIC REPORT IRECTORS' REPORT	3
TATEMENT OF THE CHIEF EXECUTIVE'S RESPONSIBILITIES AS THE CCOUNTABLE OFFICER OF THE HEALTH BOARD	
TATEMENT OF HEALTH BOARD MEMBERS' RESPONSIBILITIES IN RESPEC	T 28
OVERNANCE STATEMENT	
NDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF AYRSHIRE AND RRAN HEALTH BOARD, THE AUDITOR GENERAL FOR SCOTLAND AND THE COTTISH PARLIAMENT	_
RIMARY FINANCIAL STATEMENTS	
OTES TO THE ACCOUNTS4	
RECTION BY THE SCOTTISH MINISTERS9	5

ANNUAL REPORT MANAGEMENT COMMENTARY:

STRATEGIC REPORT

The strategic report has been prepared in accordance with the government Financial Reporting Manual and complies with best practice.

1. Strategy, Principal Activities and Review of the Year

The Board was established in 1974 under the National Health Service (Scotland) Act, 1972 and is responsible for commissioning healthcare services for the residents of Ayrshire and Arran, a total population of 368,000.

Health Boards form a local health system, with single governing boards responsible for improving the health of their local populations and delivering the healthcare they require. The overall purpose of the unified NHS Board is to ensure the efficient, effective and accountable governance of the local NHS system and to provide strategic leadership and direction for the system as a whole.

The role of the unified NHS Board is to:

- improve and protect the health of the local people;
- improve health services for local people;
- focus clearly on health outcomes and people's experience of their local NHS system;
- promote integrated health and community planning by working closely with other local organisations; and
- provide a single focus of accountability for the performance of the local NHS system

The functions of the unified NHS Board comprise:

- strategy development
- resource allocations
- implementation of the Local Delivery Plan
- performance management

Health and Social Care

In May 2012, the Scottish Government launched a public consultation to inform recommendations for legislation to support the integration of adult health and social care in Scotland and replace Community Health Partnerships with Health and Social Care Partnerships. The Public Bodies (Joint Working) (Scotland) Bill was passed on 25 February 2013 and received Royal Assent in April 2014 with commencement in April 2015.

The NHS Board at its meetings on 24 June and 30 September 2013 considered papers on the integration of health and social care, and agreed the arrangements to be put in place to prepare for the formation of Health and Social Care Partnerships between NHS Ayrshire and Arran and North, East and South Ayrshire Councils. Three Transition Integration Boards were created and met during 2013/14.

During 2013/14 the three councils in Ayrshire agreed the scope of services to be included in partnerships. At its meeting on 31 March 2014 the Health Board

approved the services to be managed in the partnerships. These ran in shadow form in 2014/15 as Shadow Integration Boards. In February 2015, Schemes of Establishment for three Integration Joint Boards were submitted to, and approved by, Scottish Government and the Cabinet Secretary signed orders establishing them from 1 April 2015.

In 2014/15, £5.5 million of the Health Board funding was earmarked for a change fund for older people's services. The use of the money is agreed by partners (health, local authorities, voluntary organisations and private sector). The Shadow Integration Boards in Ayrshire and Arran had responsibility for the preparation and delivery of the Change Plans including minimising delayed discharge from hospital and preventing emergency admissions. In 2015/16 the Integration Joint Boards in Ayrshire will prioritise the use of £2.3 million of delayed discharge investment and £7.7 million of Integrated Care Fund.

Acute Services

The NHS Board approved an Outline Business Case for a combined assessment unit at University Hospital Crosshouse and a new accident and emergency at University Hospital Ayr (Building for Better Care) in December 2012 and this was approved by Scottish Government Health and Social Care Directorate (SGHSCD) Capital Investment Group in February 2013. In June 2013 the Board approved an addendum to include a Combined Assessment Unit at University Hospital Ayr. The Full Business Case (FBC) with a capital value of £28.6 million was approved at the 1 February 2014 Board meeting then at the Capital Investment Group at Scottish Government. The new facilities will become operational in 2016. Additional revenue investment of £1.5 million recurring is required for the increased facilities cost and £1 million for extra nurses.

In June 2013 the Board submitted to Scottish Government a Local Unscheduled Care Action Plan which outlined desired service developments to help achieve the maximum 4 hours wait target. Scottish Government will provide £500,000 non-recurring in 2014/15 and 2015/16; however the Board has invested the full £2.1 million recurringly in GP assessment units, a clinical decisions unit and various staffing. This investment complements the Building for Better Care Business Case.

Mental Health / North Ayrshire Community Hospital

In January 2008, the Board considered and approved planned community investments in mental health services. An additional £2.8 million was invested in 2008/09 in mental health services. A "Mind Your Health" option appraisal was undertaken in 2008 around the future location of acute mental health in-patient services and a consultation exercise was undertaken. The outcome from this was reported to the NHS Board meeting on 19 November 2008 with the preferred option being the move of most adult in-patient services to a new build facility at the Ayrshire Central Hospital site.

An original Outline Business Case (OBC) combining the mental health provision with a new North Ayrshire Community Hospital was approved at the December 2010 Board meeting and then submitted to the SGHSCD. In July 2011, SGHSCD asked the Board to pursue a Non Profit Distribution (NPD) procurement route for this project and submit a refreshed OBC reflecting this procurement route. The refreshed OBC was submitted to SGHSCD in December 2011 following local Board approval. SGHSCD approval to the OBC submission was received in a letter dated 31 May 2012. Following European procurement and evaluation, Balfour Beatty was appointed as preferred bidder and a Full Business Case with a capital value of £54.7 million was approved at the March 2014 Board meeting. Financial close was achieved on 19 June 2014 and building of the new facility commenced in July 2014, with completion expected in March 2016. This will allow consolidation of mental health inpatient beds from three sites and the modern premises will allow better clinical care, better observation and a much improved environment for patients.

Capital Schemes

Capital expenditure totalling £13.94 million has been incurred in the year, which matches the capital allocation for the year. The following are the main capital spend areas during 2014/15.

	£000
Building for Better Care	6,865
Car parking and paths	2,187
Isolation rooms	766
North Ayrshire Community Hospital – Adviser Fees	323
Energy saving projects	421
Renal unit plant	237
Lift upgrade	243
IT projects	1,387
Theatre instrumentation	305
Electro medical equipment	1,801
Furniture and equipment	165
Air condition units	144
Other small capital projects	307
Capital receipts less profit and fees	(1,212)
TOTAL	13,939

As noted above, in June 2014 the Board achieved financial close with Balfour Beatty to build a mental health and community hospital in Irvine. This is to be financed through the non-profit distributing model therefore there is no initial capital outlay for the Board, instead it is revenue financed through payment of an annual service payment for twenty five years. Treasury guidance requires that the Board accounts, on our balance sheet, for the value of work in progress at 31 March 2015 and this amounts to £21.38 million.

During 2014/15 some £378,000 of demolition costs were incurred to maximise the value of a site. Scottish Government agreed to meet this cost which would be repaid in 2015/16 from the profit on sale of the land.

Counter Fraud Service

The National Counter Fraud Service has calculated an estimated potential level fraud / error for calendar year 2014 in relation to Ayrshire and Arran patients wrongly claiming exemption from dental and ophthalmic charges. These are based on extrapolation of a small sample and are shown in the table below:

	Estimated Potentia	Fraud/Error
	2014	2013
	£	£
Dental Fees	640,909	581,488
Ophthalmic Fees	213,189	145,087

2. Financial performance and position

		Limit as set by SGHSCD £'000	Actual Outturn £'000	Variance (Over)/Under £'000
1	Revenue Resource limit:			
	Core	682,898	682.552	346
	Non-core	14,987	14,987	0
2	Capital Resource Limit:			
	Core	13,941	13,939	2
	Non-core	21,380	21,380	0
3	Cash Requirement	738,000	737,275	725
MEI	MORANDUM FOR IN YEAR	OUTTURN		£'000
Brou	ught forward surplus from pr	evious financial y	ear	2,051
Defi	Core 682,898 682,552 Non-core 14,987 14,987 2 Capital Resource Limit: Core 13,941 13,939 Non-core 21,380 21,380 21,380			
Cun	nulative savings against reve	enue resource lim	it	<u>(1,705)</u> 346

The revenue resource underspend of £346,000 is fully committed for use in 2015-16 as shown below:-

Revenue resource underspend - commitments	£000
Evaluation of asset based project	90
Ophthalmology quality initiative	50
Unscheduled care patient flow redesign	90
Access support	83
Other	33
Total	346

The accounts have been prepared under an accounts direction and on a going concern basis.

Non-current Assets

The balance sheet shows an increase in property, plant and equipment from £313 million at 1 April 2014 to £345 million at 31 March 2015.

Outstanding Liabilities

Current and non-current liabilities are presented in the Balance Sheet in the financial statements and include liabilities outstanding in relation to Private Finance Initiative contracts.

Public Finance Initiative/Public Private Partnerships

Ayrshire Maternity Unit (AMU)

The AMU is situated within the grounds of University Hospital Crosshouse, Kilmarnock and provides obstetric in-patient, neonatal, day case and specialist outpatient facilities for women and babies of Ayrshire and Arran. The capital value of the project was £19.5 million, which is now on balance sheet under IFRS. The contract with Ayrshire Hospitals Limited (AHL) commenced on 1 July 2006 and runs for 30 years to 30 June 2036. At the end of the contract period the building will transfer, free of charge to the NHS Board from the PFI Project Company.

East Ayrshire Community Hospital (EACH)

Situated in Cumnock, EACH provides inpatient services to frail elderly, elderly with mental illness and GP acute. It also provides day facilities to frail elderly and elderly mentally ill, and outpatient services to the local area. The assets have a net book value of £14 million on the balance sheet as at 31 March 2015. The contract with HBG Construction Scotland Limited runs for 25 years to August 2025. At the end of the contract term, the NHS Board has the option to acquire the building at a market valuation price from the PFI Project Company Special Purpose Vehicle (SPV).

Details of the new mental health and community hospital in Irvine which is being built under the non-profit distributing model is shown under capital schemes. Details of all are provided in Note 23a of the financial statements.

Prior year adjustments

A prior year adjustment, arising from nationally agreed changes in accounting treatment for Clinical Negligence and Other Risks Insurance Scheme (CNORIS), has been made to reflect retrospective restatements and adjustments to opening balances. A detailed disclosure note providing further information has been added to the financial statements at note 17(b).

3. Performance against Key Non Financial Targets

Ayrshire and Arran Health Board is monitored by the Scottish Government against a number of national targets known as the 'HEAT Targets'. Each Health Board routinely reports performance against trajectories set in a Local Delivery Plan (LDP). The LDP is effectively a contract between the Scottish Government and the Health Board. Trajectories were set against the key targets in the LDP for financial year 2014/15. Outcomes are discussed at an Annual Review meeting held between the Scottish Government and Ayrshire & Arran Health Board.

Performance Summary

HEAT 2014/15 has 17 key performance indicators in total. The performance has been summarised in table 1 below, detailing a description of:

- Indicator;
- Unit;
- Baseline performance;
- Latest performance (Actual and Planned) and Performance score; and
- Target detail.

The Performance scores are also shown in table 1 below. The key is as follows:

GREENCurrently meeting or better than trajectory (plan)AMBERCurrently within 5% of trajectory (plan)REDCurrently outwith the acceptable control limit of >5% of trajectory
(plan)

۳.	TABLE 1: HEAT indicators 2014/15	15		s ver ver en en en senare a se a						
			an Medantur , and a narrow and a statement			ann ger VV ger ger ann a gans a' se gar ann a saona				
			Baseline	line		Lates	Latest Performance	ace	Targe	Target Detail
₽	Indicator	Units	Date	Value	Date	Actual	Planned	Performance Score	Date	Target
H6.1*	Smoking Cessation -SIMD	Number of successful quits after 12 weeks for people residing in the 40% most- deprived datazones	Apr-14	49	Feb-15	364	735		Mar-15	814
H10.1	Detect Cancer Early (Breast, Percentage of people Colorectal and Lung) diagnosed and treater first stage of breast, colorectal and lung ca	Percentage of people diagnosed and treated in the first stage of breast, colorectal and lung cancer	Dec-13	24.8%	Dec-13	24.8%	18%	CREEN GREEN	Mar-15	20%
H11.1	Early Access to Antenatal Services	% of pregnant women booked for antenatal care by 12th week of gestation	03 2011/12	83.1%	Q2 2013/14	79.80%	76%	GREEN	Mar-15	80%
E5.1b* F6.1*	Financial Performance	£000s	n/a	n/a	Mar-15	£346	9	GREEN	Mar-15	ĒŪ
1 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	Cash Enricencies Reduce carbon emissions	rounes	Nar-11	n/a 10224	Mar-15 Dec-14	£18,567 5,418	£18,567 5,937	GREEN	Mar-15 Mar-15	£18,567 9,191
E8.2*	Reduce Energy Consumption GI	ß	Mar-11	281639	Dec-14	184,612	187,186	SREN	Mar-15	252,044
A12.1*	Faster Access to CAMHS - 18 Percentage of patients who weeks started treatment within 18 weeks of referral	Percentage of patients who started treatment within 18 weeks of referral	Apr-13	79.27%	Feb-15	93.75%	%06	GREEN	Mar-15	%06
A12.2*	Faster Access to psychological therapies - 18 weeks (adjusted)	Percentage of patients who started treatment within 18 weeks of referral	Apr-13	81.81%	Feb-15	81.86%	%06		Mar-15	100%
A13.1	IVF Treatment Waiting Times n/a	e/u	Sep-14	100.00%	Dec-14	100%	100%	GREEN		

Page 8 of 96

Target Detail	95%	0.24	0.32	4073	÷-1	All people newly diagnosed with dementia will have a minimum of a year's worth of post-diagnostic support	74%
Target	Mar-15	Q4 2014/15	Q4 2014/15	Mar-15	Mar-15	Ail people nev with dementi minimum of a y post-diagno	Q4 2014/15
			2				
Latest Performance	95% •	0.24	0.32	4141	1		71%
Latest Pe	87.45%	0.35	0.37	5058	<u></u> б	Under development	83.24%
	Mar-15	Q4 2014/15	Q4 2014/15	Nov-14	Mar-15	Under d	Q3 2014/15
Į'n	833% 6	0.28	0.48	4714	80		71.86%
Baseline	Jun-12	01 2012/13	Q1 2012/13	Apr-11	Apr-13		01 2014/15
	Percentage of patients attending emergency departments being seen within 4 Hours	Staphrylococcus aureus bacteraemia cases per 1,000 acute occupied bed days	Clostridium difficile infections in patients aged 15 and over per 1000 total occupied bed days	Rate per 1,000 pop (75+)/yr	Number waiting > 2 weeks	% people newly diagnosed with a year's worth of post diagnostic support	% people receiving appropriate bundle of care
	A&E 4 hour Waits	MRSA/MSSA Reduction	C.Diff Reduction	Reduction in emergency bed Rate per 1,000 pop (75+)/yr days for patients aged 75+	Delayed Discharges - 2 week Number waiting > 2 weeks waits	Dementia Post Diagnostic Support	Stroke Bundle
	A14.1*	111.1	T11.2	Т12.1	T15.1*	T16.1	117,1

HEAT 2014/15 had seventeen key performance indicators in total. Based on the most up to date data available regarding the end of year position, seven of the seventeen indicators were showing a Red position, and nine were showing a Green position. The remaining indicator had no data available. The performance has been summarised in the lists below where Red, Amber, Green status is available.

1. The following indicators scored a RED (outwith >5% of trajectory)

- H6.1: Smoking Cessation
- A12.2: Faster Access to Psychological Therapies 18 weeks (adjusted)
- A14.1: A&E 4 hour waits
- T11.1: MRSA/MSSA Reduction
- T11.2: C Diff Reduction
- T12.1: Reduction in emergency bed days for patients aged 75+
- T15.1: Delayed Discharges 2 week wait

2. The following indicators scored as GREEN (meeting or exceeding plan).

- H10.1: Detect Cancer Early (Breast, Colorectal and Lung)
- H11.1: Early Access to Antenatal Services
- E5.1b: Financial Performance
- E6.1: Cash Efficiencies
- E8.1: Reduce Carbon Emissions
- E8.2: Reduce Energy Consumption
- A12.1: Faster Access to CAMHS 18 wks
- A13.1: IVF Treatment Waiting Times
- T17.1: Stroke Bundle

The Board has a Performance Governance Committee whose remit includes providing assurance to the Board that systems and procedures are in place to monitor, manage and improve overall performance.

For those indicators which were scored as **Red** (outwith >5% of trajectory) the following comment and remedial action was provided by the service responsible.

H6.1: Smoking Cessation

Analysis: The most up to date data are showing a **RED** and **IMPROVING** position as at February 2015 of 364 clients having successfully refrained from smoking for a period of 12 weeks against a trajectory of 735.

Remedial Action: The implementation of the HEAT target coincided with the implementation of a new method of electronic recording for Pharmacies. Furthermore, the new specification for the delivery of smoking cessation within Pharmacies now requires them to carry out the follow up review with their clients after 3 months. Previously, the specialist service carried out the follow up review. Work is being carried out to minimise the impact of these changes to the recording process at both local and national levels. Ongoing training, advice and support in recording has been provided to Pharmacies. As the implementation has proceeded, the problems

have minimised. It is therefore expected that the numbers of 3 month quits recorded will gradually begin to increase. Local publicity has also been undertaken to raise awareness of smokers that smoking cessation support and Nicotine Replacement Therapy (NRT) is provided free.

A12.2: Faster Access to Psychological Therapies – 18 weeks (adjusted)

Analysis: These data are showing a **RED** and **IMPROVING** position of 81.86% of patients being seen within 18 weeks in February 2015, up from 76.69% in January 2015. This is based on 'adjusted' figures, i.e. excluding periods of patient unavailability.

Remedial Action: In 2013/14 there was additional recurring investment of £268,000 in psychology services to increase capacity so as to reduce waiting times. Five work streams of the Psychological Therapies and CAMHS Programme are taking forward the work required to ensure the service delivers the 18 week RTT target. Work continues to ensure that data capture of Psychological Therapy activity is increased to cover all areas of the organisation.

A14.1: A&E 4 Hour Waits

Analysis: These local data are showing a **RED** and **IMPROVING** position from 82.63% in February 2015 to 87.45% in March 2015, against a target of 95%.

Demand for A&E services has increased since the same time last year, particularly at Crosshouse.

A number of patients have been delayed waiting for beds in downstream wards and waiting for home care, impacting on beds available for new patients. Acute staff are working closely with Health & Social Care Partnership colleagues to reduce these delays and new measures have been put in place including weekend working in the emergency department by home care staff and additional beds in Cumbrae Lodge Care Home, Ayrshire Central Hospital, to increase capacity.

Crosshouse has also increased bed capacity, increased weekend medical staff cover, expanded acute receiving capacity over 24 hours and obtained short term assistance from experienced nursing staff to support effective discharge of patients.

Remedial Action: In 2014/15 the Board recurringly invested £2.15 million in additional unscheduled care capacity such as 6 additional GP assessment beds at each hospital and a clinical decisions unit at UH Ayr. Staffing was also increased by 3 acute medical consultants, enhanced pharmacy input as well as additional nurse staffing. Plans have been developed covering common improvement areas across both UH Crosshouse and UH Ayr, with additional site specific improvements included where appropriate.

T11.1: MRSA/MSSA Reduction

Analysis: The published data for Q4 2014/15 for Staphylococcus aureus bacteraemia (SABs) exceeds the expected trajectory position therefore showing a **RED** and **WORSENING** position. This is reflected in the number of MRSA/MSSA cases as shown in the supplementary measure T11.1N which shows there was a total of 126 cases against an overall target of 84. The rate as at the end of year position was 0.35 against a target of 0.24.

Remedial Action The Board suffered a significant reversal in its SAB reduction strategy in 2014-15, which saw a 30% increase from the 88 cases recorded in the previous year. This resulted in our annual rate rising to 0.35 cases per 1,000 acute beds days compared with 0.25 in 2013-14. The Board has shifted from having the lowest rate amongst mainland territorial Boards to being above the Scottish mean during the year. The cause of a SAB is varied and multi-factorial. In order to determine the most likely cause, each SAB is reviewed at a multidisciplinary meeting involving the Infection Control Nurses (ICNs) and the Consultant Microbiologists. For those SABs assessed as being potentially preventable by healthcare intervention a review meeting is held with the patient's clinical team to determine if there are any learning points.

Vascular access related SABs are those caused by peripheral vascular catheters (PVCs); central vascular catheters (CVCs); renal fistulas and blood culture contaminants. These accounted for 29% of all SABs during the year. These are amenable to preventative healthcare intervention programmes; however this does not mean that all are preventable as accessing the vascular system will always carry an infection risk. However the Board has previously achieved lower numbers of PVC, fistula; and blood culture contaminant related SABs and can do so again. Central line related SABs are at their lowest level since surveillance commenced however vigilance is required as the last year has demonstrated that a deterioration in the numbers can happen much more quickly than an improvement.

There are a significant proportion of SABs for which there are no healthcare preventative measures and no cohesive programme of interventions that would tackle significant numbers. These include skin and soft tissue, 'others', intravenous drug use as well as those with an unknown cause. Combined, these categories accounted for 58% of all SABs. This limits the areas of intervention for future reductions.

T11.2: C Diff Reduction

Analysis: The published data at Q4 2014/15 show an increase for Clostridium difficile infection (CDI) and performance now shows as **RED** and **WORSENING** with the rate for the end of year position at 0.37 against a target of 0.32. This is reflected in the number of CDIs reported as shown in the supplementary measure T11.2N as a maximum of 10 cases per month are allowed and as at the end of year position there have been 134 cases recorded against an overall target of 120. The number of bed days recorded, used as the denominator for this rate has an impact on the status of this indicator.

Remedial Action: Following a number of years of significant reductions the Board's CDI rate began to level off in 2014-15. Although an 8% reduction on the previous

year was achieved the year end rate of 0.37 cases per 1,000 occupied bed days was above the HEAT Target. The HEAT target includes all cases of CDI from both primary and secondary care. Of the 134 cases of CDI in 2014-15, 73 were identified in hospital, a 22% reduction on the previous year. This was partly offset by a rise of 13% in those cases identified in primary care. A sharp rise in primary care identified cases during the July – September quarter impacted significantly on the Board's ability to meet the HEAT target. Moving forward, the Board's Antimicrobial Stewardship programme led by the Antimicrobial Management Team will focus on reducing the overall level of antimicrobial prescribing within NHS Ayrshire & Arran. The key driver is minimising the spread of antimicrobial resistance however, overall reductions in the use of antibiotics also support the reduction CDI.

T12.1: Reduction in Emergency Bed Day Rates for Patients Aged 75+

Analysis: These data are showing a **RED** and **WORSENING** position from 4,997 bed days per 1,000 population in October 2014 to 5,058 in November 2014 against a trajectory of 4,141.

Remedial Action: The figures indicate that although there has been continued and indeed increased use of community based anticipatory and early interventions, there has also recently been a small increase in the attendance and admission rates. In 2014/15 there was a £5.5 million Change Fund available through health funding for partnerships to pilot initiatives to prevent emergency admissions to hospital. The Change Fund was targeted at older people whereas the £7.7 million Integrated Care Fund established for 2015/16 has a wider age range to cover all adults and focuses on prevention, early intervention and care and support for people with complex and multiple conditions. There will be continued focus on early intervention approaches to try to re-establish and sustain the previously improving trend, however, the end of year target will not be met.

T15.1: Delayed Discharges - 2 week waits

Analysis: These local data are showing a **RED** and **IMPROVING** position of 9 patients waiting more than 2 weeks to be discharged from hospital in March 2015, against a trajectory of 1. The local authority breakdown shows that 8 patients waited more than 2 weeks in South Ayrshire, with the one remaining patient waiting more than 2 weeks to be discharged in North Ayrshire.

Remedial Action: The Delayed Discharge Group remains concerned about the ability to meet the 2 week target. Ayrshire and Arran have some Care Homes and Care at Home providers with moratoriums in place and some Care Homes have restricted admissions. This has a negative impact on the ability to facilitate discharges within 2 weeks. In 2015/16 there is however £2.31 million additional health funding which has been made available to tackle delayed discharges and the three Health and Social Care Partnerships well prioritise where to invest this money for greatest impact and with the goal of reducing delays in discharge to 72 hours maximum.

4. Sustainability and Environmental Reporting

NHS Ayrshire a	and Arran -	Utilities ana	lysis					
Period	12 Months t	o end March	2014	12 Months to end March 2015				
		2013-14		2014-15				
Utility			CO ₂ emissions			CO ₂ emissions		
	Raw Data	Kw	Tonnes	Raw Data	Kw	Tonnes		
Gas	44,573,628	44,573,628		41,007,738	41,007,738			
Pellets	1,476	7,084,800	No emissions	1,264	6,067,200	No emissions		
Gas + Pellets		51,658,428			47,074,938			
Electricity	23,731,813	23,731,813		23,755,544	23,755,544	12,852		
Oil	86,082	1,007,159	238	58,536	684,871	162		
Water	386,502			340,112				
Total		76,397,400	21,260		71,515,353	20,542		
Percentage Incr	ease/Decrea	se compare	d to Current Yea	ar	NY 16 1 16 1 16 10 10 10 10 10 10 10 10 10 10 10 10 10			
Gas + Pellets	-8.87%	Decrease			·····			
Electricity	0.10%	Increase				•••••••••••••••••••••••••••••••••••••••		
Oil	-32.00%	Decrease						
Overall utilities	-6.39%	Decrease						
CO2	-3.38%	Decrease						
Water (m ³)	-12.00%	Decrease						

Developments in-year

- The reduction of carbon emissions was achieved by a continued focus on ٠ making biomass work within the various hospitals. A 199kW biomass boiler was installed in Arran War Memorial hospital which provides the heating and hot water. The project uses fuel sourced sustainably on the island and local teams to maintain the boiler. This project won an award as part of the H&V --Renewable Project of the year - Public Sector 2014. This hospital was fuelled by oil previous to its installation, hence a 32% reduction in the oil consumption for this year.
- New gas boiler control units were introduced to remove the unnecessary dry cycling of gas boilers. Biggart Hospital and Ailsa hospital both had this technology installed and we have seen reductions of 12% in consumption this year following their installation.
- A continuation of our Ecocent boiler installation at University Hospital Crosshouse, where the full kitchen is now being supplied domestic hot water from the waste heat produced by the kitchen.
- LED lighting installation has been continued across the estates, and new lighting has been purchased for the A&E and the main corridors at University Hospital Crosshouse. New solar LED lighting was installed in the Ayrshire Maternity car park.

- Water savings have been achieved through various means. Consumption reduction has been seen by the focus of repair and finding water leaks with the water systems across the estate. Four main water leaks were repaired at, Ailsa Hospital, Arrol Park, University Crosshouse Hospital, and Kirklandside Hospital.
- Sustainability Development Action Plan 2014/15. The Board has developed the above action plan which can be viewed using the following link. http://www.nhsaaa.net/media/335687/sdaplan1415.pdf

5. Social Community and Human Rights

NHS Ayrshire & Arran strives to continue to embed the equalities agenda and meet the requirements of the Equality Act 2010, Public Sector Equality Duty and Equality Act 2010 (Specific Duties) (Scotland) Regulations 2012. We do this by ensuring that our services are person-centred (including patients, their families, carers, and staff) and that our core function of providing health care and prevention of ill-health for all meets the needs of those who access it.

Services need to be accessible, appropriate and sensitive to the needs of all service users. No-one should be excluded or experience particular difficulty in accessing and effectively using our services due to their protected characteristics of age, disability, gender reassignment, marriage/civil partnership, pregnancy/maternity, race/ethnicity, religion or belief, sex or sexual orientation.

In 2013, NHS Ayrshire & Arran published its first Mainstreaming Report including equality outcomes to support meeting the needs of some of our most vulnerable communities. In April 2015 we published our two year progress report to highlight the progress made to embed equalities into our day to day functions. The report shows our commitment to ensuring the ever-changing demography and diversity of our population are reflected in services which are person-centred and aim to meet the needs of all who access it.

Gender Analysis

An analysis of the number of persons of each gender who were directors, senior managers and employees of the Board is set out in the table:

	31	March 201	5	31 March 2014				
Description	Female	Male	Total	Female	Male	Total		
Directors	7	12	19	7	12	19		
Senior managers	18	7	25	19	10	29		
Employees	8,943	1,773	10,716	8,913	1,791	10,704		
Totals	8,968	1792	10,760	8,939	1,813	10,752		

6. Accounting Convention

The Annual Accounts and Notes have been prepared under the historical cost convention modified by the revaluation of property, plant and equipment, intangible assets, inventories, available-for-sale financial assets and financial assets and liabilities at fair value through the Statement of Consolidated Comprehensive Net Expenditure. The Accounts have been prepared under a direction issued by Scottish Ministers, which is reproduced as an annex to these accounts.

The statement of the accounting policies which have been adopted is shown at note 1.

NVAS Signed Chief Executive

DIRECTORS' REPORT

7. Naming convention

NHS Ayrshire and Arran is the common name for Ayrshire and Arran Health Board.

8. Date of Issue

Financial statements were approved and authorised for issue by the Health Board on 23 June 2015.

9. Appointment of auditors

The Public Finance and Accountability (Scotland) Act 2000 places personal responsibility on the Auditor General for Scotland to decide who is to undertake the audit of each health body in Scotland. The Auditor General appointed Fiona Mitchell-Knight, Assistant Director of Audit, Audit Scotland to undertake the audit of Ayrshire and Arran Health Board. The general duties of the auditors of health bodies, including their statutory duties, are set out in the Code of Audit Practice issued by Audit Scotland and approved by the Auditor General.

10. Board membership

Under the terms of the Scottish Health Plan, the Health Board is a board of governance whose membership will be conditioned by the functions of the Board. Members of Health Boards are selected on the basis of their position or the particular expertise which enables them to contribute to the decision making process at a strategic level.

The Health Board has collective responsibility for the performance of the local NHS system as a whole, and reflects the partnership approach, which is essential to improving health and health care.

Dr M Cheyne, Chairman Mr J Burns, Chief Executive Mrs L Bowie, Non Executive Director Mr J Callaghan, Employee Director Dr K Darwent, Vice Chair Dr C Davidson, Director of Public Health Councillor W Gibson, Non-Executive Director Dr A Graham, Medical Director Dr A Gunning, Director for Strategic Planning, Policy and Performance Councillor H Hunter, Non-Executive Director Mr D Lindsay, Director of Finance Mr R Martin, Non Executive Director Dr J McKay, Non-Executive Director Mr S McKenzie, Non-Executive Director Mr A McKie, Non-Executive Director Professor F McQueen, Director of Nursing (until 16 November 2014) Councillor D Reid, Non-Executive Director Miss L Tennant, Non-Executive Director Mr I Welsh, Non-Executive Director

The board members' responsibilities in relation to the accounts are set out in a statement following this report.

11. Board Members' and Senior Managers' Interests

Details of any interests of board members, senior managers and other senior staff in contracts or potential contractors with the Health Board as required by IAS 24 are disclosed in note 29. A register of interests, which includes details of company directorships or other significant interests held by Board members that may conflict with their management responsibilities, is available by contacting the NHS Board, Eglinton House, Ailsa Hospital, Dalmellington Road, Ayr KA6 6AB, or can be accessed on the Board's website at: register of board members interests.

All Directors appointed by the Cabinet Secretary (shown in the remuneration report) are also Trustees of the Ayrshire and Arran Endowments.

12. Directors third party indemnity provisions

The Board has provided an indemnity to Ayrshire Medical Support Ltd to the effect that it will reimburse the company for any additional VAT determined to be chargeable by HMRC on a specified sale of property by the company to the Board.

13. Pension liabilities

The accounting policy note for pensions is provided in Note 1 and disclosure of the costs is shown within Note 24 and the remuneration report.

14. Remuneration for non- audit work

No remuneration was paid to external auditors in respect of any non audit work carried out on behalf of Ayrshire and Arran Health Board.

15. Value of Land

Land is shown in the balance sheet at market value.

16. Public Services Reform (Scotland) Act 2010

Sections 31 and 32 of the Public Services Reform (Scotland) Act 2010 impose new duties on the Scottish Government and listed public bodies to publish information on expenditure and certain other matters as soon as is reasonably practicable after the end of each financial year.

This information is available on our website at the following link <u>Public Services</u> <u>Reform (Scotland) Act-2010.</u>

17. Sickness absence data

Sickness absence in 2014/2015 was 5.00% which is a decrease from 5.35% in 2013/2014. Sickness absence will continue to be reviewed under the terms of the Staff Health, Safety and Wellbeing Strategy.

18. Personal data related incidents

Throughout the year no personal data related incidents were considered to meet the criteria for notification to the Information Commissioner's Office. NHS Ayrshire & Arran have no open cases with the Information Commissioner's Office.

19. Payment policy

The Scottish Government is committed to supporting businesses during the current economic situation by paying bills more quickly. The intention is to achieve

payment of all undisputed invoices within 10 working days, across all public bodies.

The target has been communicated to all non-departmental public bodies, who are working towards the accelerated payment target of 10 working days.

Prior to this, the Health Board did endeavour to comply with the principles of The Better Payment Practice Code (<u>http://www.payontime.co.uk/</u>) by processing suppliers' invoices for payment without unnecessary delay and by settling them in a timely manner.

In 2014/15 average credit taken was 10 days from date invoice received. (2013/14 = 12 days from invoice date).

In 2014/15 the Health Board paid 92% by volume and 94% by value of non NHS suppliers within 30 days of the invoice being received, (compared to 90% and 92% in 2013/14).

Based on the date of invoices being received, 86% by value and 81% by volume were paid within 10 days in 2014/15 (compared to 81% and 76% in 2013/14).

20. Corporate governance

The board meets regularly during the year to progress the business of the Health Board. In December 2012 the Board agreed revised governance, assurance and scrutiny structures to operate from January 2013 and the resultant changes to standing committees is detailed below.

The 30 March 2015 Board meeting approved an updated Code of Corporate Governance including members' code of conduct, standard of business conduct for NHS staff, standing financial instructions and scheme of delegation.

Healthcare Governance Committee

The remit of the Healthcare Governance Committee is to provide assurance to the NHS Board systems and procedures are in place to monitor healthcare governance in line with the Board's statutory duty for quality of care.

Members of the Healthcare Governance Committee and attendance during 2014/15 were:

Dr Kirsty Darwent (Chair) (7/7) Councillor William Gibson (4/7) Mr Alistair McKie (3/7) Dr Janet McKay (3/7) Miss Lisa Tennant (4/7 – on maternity leave from August 2014) Mr Ian Welsh (3/7)

The Healthcare Governance Committee met seven times from 1 April 2014 – 31 March 2015.

Audit Committee

The Audit Committee met five times during 2014/15 to consider reports received

from internal audit (PricewaterhouseCoopers LLP) and external audit (Audit Scotland). The committee monitors corporate governance, probity and issues around internal control.

Membership of the Audit Committee and attendance during 2014/15 were:

Mr Alistair McKie (Chair) (5/5) Mr John Callaghan (5/5) Councillor William Gibson (2/5) Dr Janet McKay (4/5) Mr Robert Martin (3/5) Councillor Douglas Reid (0/5)

Staff Governance Committee

The Committee met five times during 2014/15. The Committee monitors compliance with the Staff Governance Standards and is supported by the Area Partnership Forum and the Remuneration Committee.

Membership of the Staff Governance Committee and attendance during 2014/15 were:

Mr Ian Welsh (Chair) (4/5) Mrs Lesley Bowie (3/5) Mr John Callaghan(4/5) Councillor Hugh Hunter (2/5) Dr Janet McKay (4/5) Councillor Douglas Reid (2/5)

Performance Governance Committee

The Performance Governance Committee met on three occasions between 1 April 2014 and 31 March 2015. The committee has a remit to consider a range of areas including; HEAT/Local Delivery Plan, Investment Scrutiny, Benefits Realisation, Post Project Evaluation and Finance and Service Performance. Membership of the Performance Governance Committee and attendance during 2014/15 were:

Dr Martin Cheyne (Chair until 31 December 2014) (3/3) Mr John Callaghan (3/3) Councillor Hugh Hunter (3/3) Mr Robert Martin (Chair from 1 January 2015) (3/3) Mr Stephen McKenzie (3/3) Mr Ian Welsh (3/3)

Information Governance Committee

The Information Governance Committee has a remit to consider a range of areas including; Caldicott Principles, Freedom of Information, NHS Code of Practice on Confidentiality, Data Protection, Information Assurance, e-Health and Data Sharing.

Further to that the Information Governance Committee is also responsible for overseeing the development and implementation of a Records Management Plan

for NHS Ayrshire & Arran to ensure records, both clinical and corporate are being managed throughout their lifecycle in compliance with Public Records (Scotland) Act 2011.

The Information Governance Committee met five times in the period from 1 April 2014 to 31 March 2015. Membership of the committee and attendance during 2014/15 were:

Mr Stephen McKenzie (Chair until 31 December 2014) (4/5) Mrs Lesley Bowie (Chair with effect from 1 January 2015) (5/5) Dr Kirsty Darwent (with effect from 1 January 2015) (0/1) Councillor Hugh Hunter (4/5) Mr Robert Martin (4/5) Miss Lisa Tennant (0/5 – on maternity leave from August 2014)

Integrated Governance Committee

The Integrated Governance Committee was established to coordinate cross cutting issues such as risk management following approval at the 25 August Board Meeting. It met twice during 2014/15. Membership of the Integrated Governance Committee and attendance during 2014/15 was:

Dr Martin Cheyne (Chair)(1/2) Mrs Lesley Bowie (from 1 January 2015) (1/2) Dr Kirsty Darwent (1/2) Mr Robert Martin (0/2) Mr Stephen McKenzie(until 31 December 2014) (2/2) Mr Alistair McKie (1/2) Mr Ian Welsh (2/2)

21. Disclosure of information to auditors

The directors who held office at the date of approval of this directors' report confirm that, so far as they are each aware, there is no relevant audit information of which the Health Board's auditors are unaware; and each director has taken all the steps that he/she ought reasonably to have taken as a director to make himself/herself aware of any relevant audit information and to establish that the Health Board's auditors are aware of that information.

22. Human resources

As an equal opportunities employer, the Health Board welcomes applications for employment from disabled persons and actively seeks to provide an environment where they and any employees who become disabled can continue to contribute to the work of the Health Board.

The Health Board provides employees with information on matters of concern to them as employees through a Daily Digest, two monthly Team Talk and more regular Stop Press updates and consults employees or their representatives through the Area Partnership Forum so their views are taken into account in decisions affecting their interests.

23. Events after the end of the reporting period

There have been no important events affecting the Health Board since the yearend.

24. Financial instruments

Information in respect of the financial risk management objectives and policies of the Health Board, the exposure to price risk, credit risk, liquidity risk, and cash flow risk is disclosed in Note 27.

25. Approval and signing of the directors' report

The Accounting Officer authorised these financial statements for issue on 23 June 2015.

Signed Chief Executive

REMUNERATION REPORT

BOARD MEMBERS' AND SENIOR EMPLOYEES' REMUNERATION

The Health Board has a Remuneration Committee, which is a sub-committee of the Staff Governance Committee. Membership of the sub-committee consists of Non-Executive Board members including the Employee Director. The Chair of the NHS Board is the Chair of the Remuneration Committee.

The Remuneration Committee membership is as follows:-

Dr Martin Cheyne, Chair Councillor William Gibson Mr John Callaghan Dr Kirsty Darwent

The committee met three times during 2014/15. The committee is responsible for providing assurance to the NHS Board regarding the probity and corporate governance aspects of the appointment, appraisal and remuneration of those covered by Executive Pay Arrangements and to monitor terms and conditions of employment in accordance with central direction.

Remuneration

Remuneration of the Chief Executive, Executive Directors, Directors and Senior Managers is determined in line with directions issued by the Scottish Government. All posts at this level are subject to rigorous job evaluation arrangements by the National Evaluation Committee and the pay scales applied reflect the outcomes of these processes. All extant policy guidance issued by the SGHSCD has been appropriately applied and agreed by the Remuneration Committee.

Performance Appraisal

Performance appraisals, for those covered by Executive Pay Arrangements, are carried out in line with the guidance from the National Performance Management Committee and overseen by the Remuneration Committee. The Committee agrees the individual in-year objectives of the Board's Executive Directors and Directors and approves their annual performance assessments each year. Annual pay rises, for those covered by Executive Pay Arrangements, are dependent on achieving specified levels of performance, in line with National agreement.

Payments to Non-Executive Directors and Executive Directors'

The following tables provide a breakdown of Non Executive Directors' and Executive Directors' remuneration.

Remuneration (salary, benefits in kind and pensions) 2014-15

Board Members	Directors' Gross Salary (Bands of £5,000)	Bonus Payments (Bands of £5,000)	Benefits in kind (£'000)	Total Earnings in Year (Bands of £5,000)	****Pension Benefits (£'000)	Total Remuneration (Bands of £5,000)
Executive	2014/15	2014/15	2014/15	2014/15	2014/15	2014/15
Mr J Burns, Chief Executive						
Mr D Lindsay, Director of Finance	130 - 135	0	0	130 - 135	51	180 - 185
	100 - 105	0	1.6	100 - 105	11	115 - 120
Dr A Gunning, Director for Strategic Planning, Policy and Performance Dr A Graham, Medical Director	115 - 120	0	0	115 - 120	14	130 - 135
	155 - 160	0	3.1	160 - 165	20	180 - 185
Dr C Davidson, Director of Public Health	170 - 175	00	0	170 - 175	42	210 - 215
*Mrs F McQueen, Nurse Director (to 16 November 2014)	60 ~ 65	0	1,1	65 - 70	31	95 - 100
Non-executive						······
Dr M Cheyne, Chairman	25 - 30	0	0	25 - 30	0	25 - 30
Dr K Darwent, Vice Chair	5 - 10	0	0	5 - 10	0	5 - 10
Mrs L Bowie	5 - 10	0	0	5 - 10	0	5 - 10
**Mr J Callaghan	45 - 50	0	2.1	50 - 55	7	55 - 60
Councillor W Gibson	5 - 10	0	0	5 - 10	0	5 - 10
Councillor H Hunter	5 - 10	0	0	5 - 10		5 - 10
Mr R Martin	5-10	o o	0	5-10	0	
***Dr J McKay	65 - 70	0	2.0	65 - 70		5 - 10
Mr S McKenzie	5 - 10	0			4	70 - 75
Mr A McKie	5-10	0	0	5-10	0	5 - 10
Councillor D Reid	5-10	0	0	5 - 10	0	5 - 10
Miss L Tennant	5-10		0	5 - 10	0	5 - 10
Vr I Welsh	3-10	0	0	5 - 10	0	5 - 10

Although Professor Fiona McQueen, the former Director of Nursing, continues to be employed and paid by NHS Ayrshire and Arran, her remuneration since November 2014 is fully recharged to the Scottish Government Health and Social Care Directorate on a secondment basis, and is included in Notes 2(a) and 2(b) to the Annual Accounts.

*** Cailaghan is the employee director and £40,964 of his salary and all pension benefits are in respect of non-Board duties. *** J McKay is a stakeholder director for the Area Clinical Forum and £57,069 and all pension benefits are in respect of non-Board duties.

****The above column for pension benefits is net of employee pension contributions to their pensions whereas the pension benefits below include employee contributions.
Pension Benefits

Pension Benefits					
Board Members	Accrued		γ	1	r
	pension at				
	pension age	Real Increase	Cash	***** Cash	
	asat	in pension	Equivalent	Equivalent	1
	31/03/2015	and related	Transfer	Transfer	ĺ
	and related	lump sum at	Value (CETV)		
	lump sum	pension age	at	at	Real Increase
	(Bands of	(Bands of	31/03/2015	31/03/2014	in CETV
	£5,000)	£2,500)	£'000	£'000	£'000
Executive					
Mr J Burns, Chief Executive	50 - 55 plus	2.5 - 5 plus	1,023	925	68
	lump sum of	lump sum of			
	150 - 155	7.5 - 10			
Mr D Lindsay, Director of Finance	25 - 30 plus	0 - 2.5 pius	496	458	19
	lump sum of	lump sum of			
	80 - 85	2.5 - 5			
Dr A Gunning, Director for Strategic Planning, Policy and Performance	45 - 50 plus	0 - 2.5 plus	1,095	1,022	44
	lump sum of	lump sum of	-		
	145 - 150	2.5 - 5			
Dr A Graham, Medical Director	50 - 55 plus	0 - 2.5 plus	1,028	954	40
	lump sum of	lump sum of 5			
	160 - 165	- 7.5			
Dr C Davidson, Director of Public Health	50 - 55 plus	2.5 - 5 plus	1,184	1,077	74
	lump sum of	lump sum of		ŗ	
	155 - 160	7.5 - 10			
Mrs F McQueen, Nurse Director	35 - 40 plus	0 - 2.5 plus	805	741	48
	lump sum of	lump sum of 5			
	115 - 120	- 7.5			
Ar J Callaghan, Non-executive Director	20 - 25 pius	0 - 2.5 plus	478	460	9
	lump sum of	lump sum of 0		ĺ	
	60 - 65	- 2.5			
or J McKay, Non-executive Director	20 - 25 plus	0 - 2.5 plus	420	394	14
	lump sum of	lump sum of 0	_	/	
· · · · · · · · · · · · · · · · · · ·	1 1	- 2.5			

***** The real discount rate used to evaluate CETV has been as advised by the UK Government Actuaries Department.

Payments to Non-Executive Directors' and Executive Directors'

The following tables provide a breakdown of Non- Executive Directors' and Executive Directors' remuneration.

Remuneration (salary, benefits in kind and pensions)

2013-14

Single total figure of remuneration Board Members	Directors'	Bonus	Benefits in	Totai	***Pension	Total
	Gross Salary	Payments	kind (£'000)	Earnings in	Benefits	Remuneration
	(Bands of	(Bands of		Year (Bands	(£'000)	(Bands of
	£5,000}	£5,000)		of £5,000)		£5,000)
	2013/14	2013/14	2013/14	2013/14	2013/14	2013/14
Executive						
Mr J Burns, Chief Executive	125 - 130	0	0	125 - 130	24	145 - 150
Mr D Lindsay, Director of Finance	100 - 105	0	1.4	100 - 105	6	105 - 110
Dr A Gunning, Director for Strategic Planning, Policy and Performance	115 - 120	0	0	115 - 120	0	115 - 120
Dr A Graham, Medical Director	155 - 160	0	2,1	155 - 160	0	155 - 160
Dr C Davidson, Director of Public Health	165 - 170	0	0	165 - 170	9	175 - 180
Mrs F McQueen, Nurse Director	95 - 100	0	2.7	100 - 105	9	105 - 110
Non-executive						
Dr M Cheyne, Chairman	25 - 30	0	0	25 + 30	0	25 - 30
Mrs K Darwent, Vice Chair	5 - 10	0	0	5 - 10	0	5 - 10
Mrs L Bowie (from 01.11.13)	0-5	Ó	0	0+5	0	0-5
*MrJ Cailaghan	45 - 50	0	1.8	50 - 55	4	50 - 55
Mrs S Dunn (until 30.09.13)	0-5	0	0	0-5	0	0-5
Councillor W Gibson	5 - 10	0	0	5 - 10	0	5 - 10
Councillor H Hunter	5 - 10	0	0	5 - 10	0	5 - 10
Mr R Martin (from 01.11.13)	0-5	0	0	0-5	0	0 - 5
**Mrs J McKay	65 - 70	0	1.7	65 - 70	12	75 - 80
Mr S McKenzie	5 - 10	0	0	5 - 10	0	5 - 10
Mr A McKie	5 - 10	0	0	5 - 10	0	5 - 10
Councillor D Reid	5 - 10	0	0	5 - 10	0	5 - 10
Miss L Tennant (on sabbatical 01.09.13 to 31.12.13)	5 - 10	0	0	5 - 10	0	5 - 10
Ms G Watson (until 30.04.13)	0-5	0	0	0-5	Ð	0-5
l Welsh	5 - 10	0	0	5 - 10	0	5 - 10

*J Callaghan is the employee director and £40,558 of salary and all pension benefits are in respect of non-Board duties.

J McKay is a stakeholder director for the Area Clinical Forum and £57,144 of salary and all pension benefits are in respect of non-Board duties. **J McKay is a stakeholder director for the Area Clinical Forum and £57,144 of salary and all pension benefits are in respect of non-Board duties. *The above column for pension benefits is net of employee pension contributions to their pensions whereas the pension benefits below include employee contributions. Pension Benefits

Pension Benefits					
Board Members	Accrued				
	pension at				
	pension age	Real increase	Cash	Cash]
	as at	in pension	Equivalent	Equivalent	
	31/03/2014	and related	Transfer	Transfer	
	and related	lump sum at	Value at	Value at	Real increase
	lump sum	pension age	31/03/2014	31/03/2013	in CETV
	£'000	£'000	£'000	£'000	£'000
Executive					
Mr J Burns, Chief Executive	45 - 50 plus	0 - 2.5 pius	925	848	35
	lump sum of	lump sum of 5			1
	140 - 145	- 7.5			
Mr D Lindsay, Director of Finance	25 - 30 plus	0 - 2.5 plus	458	424	14
	lump sum of	lump sum of 0			
	80 - 85	- 2.5			
Dr A Gunning, Director for Strategic Planning, Policy and Performance	45 - 50 plus	0 - 2.5 plus	1,022	963	12
	lump sum of	lump sum of 0			
	140 - 145	- 2.5			
Dr A Graham, Medical Director	50 - 55 plus	(0 - 2.5) plus	954	917	(7)
·	lump sum of	lump sum of			
	150 - 155	(0 - 2.5)			
Dr C Davidson, Director of Public Health	45 - 50 plus	0 - 2.5 plus	1,077	1,001	26
	lump sum of	lump sum of			
	145 - 150	2.5 - 5			
Mrs F McQueen, Nurse Director	35 - 40 plus	0 - 2.5 plus	741	690	18
	lump sum of	lump sum of			
	110 - 115	2.5 - 5			
Mr J Callaghan, Non-executive Director	15 - 20 plus	0 - 2.5 pius	460	431	8
	lump sum of	lump sum of 0			
	55 - 60	- 2.5			
Mrs J McKay, Non-executive Director	20 - 25 plus	0 - 2.5 plus	394	363	14
	lump sum of	lump sum of 0			
	60 - 65	- 2.5			

Additional Disclosure Required

2014/15		2013/14	
Highest Earning Director's Total Remuneration	170-175	Highest Earning	165 - 170
(£000's)		Director's Total Remuneration (£000's)	
Median Total		Median Total	
Remuneration	28,887	Remuneration	28,995
Ratio	5.97	Ratio	5.78

Commentary

Boards are required to disclose the relationship between the remuneration of the highestpaid director and the median remuneration of the Board's workforce. The banded total remuneration of the highest-paid director in NHS Ayrshire and Arran in the financial year 2014/15 was £170,000-£175,000 (2013/14, £165,000-£170,000). In 2014/15 this was 5.97 times the median remuneration of the workforce, which was £28,887. In 2013/14 this was 5.78 times the median remuneration which was £28,995.

There was a marginal reduction year on year in the median remuneration of the workforce. During 2013/14 there were 24 clinical members of staff whose remuneration was higher than the highest earning director. During 2014/15 there were 24 clinical members of staff whose remuneration was higher than the highest paid director.

Total remuneration for this purpose includes salary, non-consolidated performance related pay, as well as severance payments. It does not include employer pension contributions, the cash equivalent transfer value of pensions or benefits in kind.

... Date. <u>73/6/15</u>... Signed..... Chief Executive as Accountable Officer /

AYRSHIRE & ARRAN HEALTH BOARD

ANNUAL ACCOUNTS 2014/15

STATEMENT OF THE CHIEF EXECUTIVE'S RESPONSIBILITIES AS THE ACCOUNTABLE OFFICER OF THE HEALTH BOARD

Under Section 15 of the Public Finance and Accountability (Scotland) Act, 2000, The Principal Accountable Officer (PAO) of the Scottish Government has appointed me as Accountable Officer of Ayrshire & Arran Health Board.

This designation carries with it, responsibility for:

- the propriety and regularity of financial transactions under my control;
- for the economical, efficient and effective use of resources placed at the Board's disposal; and
- safeguarding the assets of the board.

In preparing the accounts I am required to comply with the requirements of the government's Financial Reporting Manual and in particular to:

- observe the accounts direction issued by Scottish Ministers including the relevant accounting and disclosure requirements and apply suitable accounting policies on a consistent basis;
- make judgements and estimates on a reasonable basis;
- state whether applicable accounting standards as set out in the government Financial Reporting Manual have been followed and disclose and explain any material departures; and
- prepare the accounts on a going concern basis

I am responsible for ensuring proper records are maintained and that the Accounts are prepared under the principles and in the format directed by Scottish Ministers. To the best of my knowledge and belief, I have properly discharged my responsibilities as accountable officer as intimated in the Departmental Accountable Officer's letter to me of the 1 February 2012.

Date.... Signed...... Chief Executive

AYRSHIRE & ARRAN HEALTH BOARD

ANNUAL ACCOUNTS 2014/15

STATEMENT OF HEALTH BOARD MEMBERS' RESPONSIBILITIES IN RESPECT OF THE ACCOUNTS

Under the National Health Service (Scotland) Act 1978, the Health Board is required to prepare accounts in accordance with the directions of Scottish Ministers which require that those accounts give a true and fair view of the state of affairs of the Health Board as at 31 March 2015 and of its operating costs for the year then ended. In preparing these accounts the Directors are required to:

- Apply on a consistent basis the accounting policies and standards approved for the NHS Scotland by Scotlish Ministers.
- Make judgements and estimates that are reasonable and prudent.
- State where applicable accounting standards as set out in the financial reporting manual have not been followed where the effect of the departure is material.
- Prepare the accounts on the going concern basis unless it is inappropriate to presume that the Board will continue to operate.

The Health Board members are responsible for ensuring that proper accounting records are maintained which disclose with reasonable accuracy at any time the financial position of the Board and enable them to ensure that the accounts comply with the National Health Service (Scotland) Act 1978 and the requirements of the Scottish Ministers. They are also responsible for safeguarding the assets of the Board and hence taking reasonable steps for the prevention of fraud and other irregularities.

The NHS Board members confirm they have discharged the above responsibilities during the financial year and in preparing the accounts.

Director of Finance Derek	Lindsay
Chairman	Jugne

Date 23 June 2015

Governance Statement

Scope of Responsibility

As Accountable Officer, I am responsible for maintaining an adequate and effective system of internal control that supports compliance with the organisation's policies and promotes achievement of the organisation's aims and objectives including those set by Scottish Ministers. Also, I am responsible for safeguarding the public funds and assets assigned to the organisation.

Purpose of Internal Control

The system of internal control is based on an ongoing process designed to identify, prioritise and manage the principal risks facing the organisation. The system aims to evaluate the nature and extent of risks and manage risks efficiently, effectively and economically.

The system of internal control is designed to manage rather than eliminate the risk of failure to achieve the organisation's aims and objectives. As such, it can only provide reasonable and not absolute assurance.

The process within the organisation accords with guidance from Scottish Ministers in the Scottish Public Finance Manual (SPFM) and supplementary NHS guidance, and has been in place for the year up to the date of approval of the Annual Report and Accounts.

The SPFM is issued by Scottish Ministers to provide guidance to the Scottish Government and other relevant bodies on the proper handling and reporting of public funds. The SPFM sets out the relevant statutory, parliamentary and administrative requirements, emphasises the need for efficiency, effectiveness and economy and promotes good practice and high standards of propriety. The Board has complied with the SPFM during 2014/15.

Governance Framework

During financial year 2012/2013 the Chairman and Chief Executive agreed to review the Board's governance arrangements in order to ensure a focus of continuous improvement and to strengthen the arrangements in place for NHS Ayrshire & Arran. This work resulted in a refreshed Governance Framework being presented and approved at the NHS Board meeting held on 5 December 2012. The Governance Framework introduced the following committees:

- Audit Committee;
- Healthcare Governance Committee;
- Information Governance Committee;
- Performance Governance Committee; and,
- Staff Governance Committee.

These committees have operated throughout 2014/15 and the Board has considered and discussed the annual report for 2014/15 produced by each of these committees, which confirm that they have fulfilled their remit. The remit of the Audit Committee is to provide assurance to the NHS Board on corporate governance and financial probity. The Audit Committee receives reports from internal and external auditors. The Information Governance Committee was created in early 2013 to provide assurance to the Board on how the organisation handles patient identifiable information in line with Caldicott guidance and ensure compliance with legislation such as the Data Protection Act 1998 and Freedom of Information Act 2000 Details of Personal Data Related Incidents are in the Directors' Report.

The Board approved at its meeting on 25 August 2014 the establishment of an Integrated Governance Committee comprising the chairs of each of the above governance committees and is chaired by the Board Chair and attended by the lead executive director for each of these areas. This group allows an overview and coordination of governance work such as the internal audit programme and corporate risk register.

The function of the Board and its committees during the year was effective due to an appropriate balance of skills, experience, independence and knowledge, to challenge and scrutinise the work of NHS Ayrshire & Arran. An internal audit review of Board Governance arrangements reported to the September 2014 Audit Committee only one low risk recommendation. New Board members received induction and during the year there were Board Workshops for all Board members to discuss particular topics in depth. The Board have a robust performance management approach through the Performance Governance Committee monitoring performance against the targets set in the Local Delivery Plan.

The Board meeting on 3 February 2014 approved "Our Health 2020 : A health and wellbeing framework for Ayrshire and Arran". Specific strategies were approved by the Board during 2014/15 on mental health and wellbeing, healthy weight, and risk management. Each Board meeting received reports on:

- healthcare associated infection;
- safer patient work;
- patient experience story;
- waiting times; and
- financial performance.

In addition the Board reviewed its Code of Corporate Governance which brings all aspects of Corporate Governance (including Standing Orders, Standing Financial instructions and Scheme of Delegation) into a single code. The revisions to the Code were agreed by the Health Board at its meeting on 30 March 2015. A process is in place to assign government circulars and directives to a lead director and follow up actions taken. This ensures compliance with relevant laws and regulations. The Board has in place a Whistle Blowing Policy which was updated in April 2013. This policy provides a protective means to raise concerns regarding the delivery of care, the Health and Safety of employees and visitors or the integrity of the organisation without fear of victimisation.

Integration of Health and Social Care has featured prominently in 2014/15 and the Board in partnership with the three local authorities created three Shadow Integration Boards to plan for the establishment of Health and Social Care Partnerships. Three joint appointments of Directors of Health and Social Care were made and the Integration Joint Boards were formally established on 2 April 2015 and have appointed section 95 officers. Each Partnership approved its first strategic plan in April 2015. In March 2015, the Board internal auditors carried out a review of the Board's readiness for the Integration of Health and Social Care and considered compliance with relevant legislation and guidance. This showed full compliance and no exceptions. Updates on financial aspects of integration were received at Audit Committee meetings in February and April 2015.

The NHS Board meets every two months and receives timely, comprehensive and relevant information for discussion and approval. The Board has positive relationships with stakeholders and is a key participant within community planning arrangements across the three councils. A Board effectiveness assessment was commissioned in July 2014 and reported to a Board workshop in October 2014. This involved a questionnaire to all Board members and an interview with ten. The outcome was largely positive, however seven recommendations for improvement were agreed.

The Board Annual Review was conducted by the Cabinet Secretary for Health, Wellbeing and Sport with stakeholders invited to participate. In all material respects the Board has complied with the UK Corporate Governance Code.

Review of Adequacy and Effectiveness

As Accountable Officer I am responsible for reviewing the adequacy and effectiveness of the system of internal control. My review is informed by:

- discussions with and letters of assurance from Executive and Senior Managers who are responsible for developing, implementing and maintaining internal controls across their areas;
- minutes and annual reports from Governance Committees;
- the work of the internal auditors who submit to the Audit Committee regular reports which include their independent and objective opinion on the effectiveness of risk management, control and governance processes together with recommendations for improvement; and,
- comments by the external auditors in their management letters and other reports;
- national reports such as Healthcare Improvement Scotland reviews and the public enquiry report on the Vale of Leven Hospital.

The NHS Board receives minutes from each Governance Committee and receives an annual report from each committee to confirm that their remit has been fulfilled. Where necessary a committee can escalate issues for Board scrutiny.

Audit Scotland carried out an annual review of internal audit to allow reliance to be placed on the work of our internal audit programme. Audit Scotland carried out the review of the internal audit function (provided by PricewaterhouseCoopers) and concluded that the internal audit service operates in accordance with government internal audit standards and has appropriate documentation standards and reporting procedures in place.

The Head of Internal Audit opinion for 2014/15 was that "based on the risk appetite and the internal audit plan agreed with you, we have completed our programme of work and we believe there are adequate and effective governance, risk management and control processes to enable the related risks to be managed and objectives to be met".

Audit Scotland carried out a review of internal controls in April 2015 and their overall assessment was that the key controls within the Board's main financial system are operating satisfactorily.

In accordance with the principles of best value the NHS Board aims to foster a culture of continuous improvement. As part of this Directorates are encouraged to review, identify and improve the efficient and effective use of resources. Business cases and board papers need to demonstrate that consideration has been given to the Best Value characteristics published in the 2011 Best Value Guidance to Accountable Officers. I can confirm that arrangements have been made to secure best value as set out in the SPFM.

The Financial Management Report was discussed at each Board meeting which includes efficiency measures. During the year, significant overspends on medical and nurse staffing budgets were reported as well as overspends relating to new high cost drug treatments for hepatitis C and short supply issues for generic drugs driving up price. Despite this, NHS Ayrshire & Arran achieved all financial targets for the year 2014/15.

At the May 2014 Board meeting the Board authorised the Chief Executive, or Director of Finance to sign contracts with Balfour Beatty Construction Limited, a project company and various other suppliers related to the design, build, finance and maintenance of Woodland View (formerly North Ayrshire Community Hospital). This project is funded through the Non-Profit Distributing Model and financial close was achieved in June 2014.

Risk Assessment

NHSScotland bodies are subject to the requirements of the SPFM and must operate a risk management strategy in accordance with relevant guidance issued by Scottish Ministers. The general principles for a successful risk management strategy are set out in the SPFM.

As part of the continuous improvement during the year, a review of existing risk management systems and practices was undertaken and several areas have been identified for improvement. These include a refresh of the electronic reporting system and risk register, further developing a learning culture and improved integration of risk management across the organisation as a whole. The Board approved an updated Risk Management Strategy at its meeting on 1 December 2014 and this set out the risk management philosophy, objectives and organisational standard. The corporate risk register contains eight high risks in the following areas:

- promoting attendance;
- personal development review;
- mandatory and statutory training;
- statutory management of the estate;
- statutory management of occupational road risk
- · delivery of the approved capital plan
- achieving the legal treatment time guarantee; and
- achieving balanced financial plan for 2015/16.

In addition there is one very high risk identified as lack of medical staff. This has clinical implications for quality of care and financial implications as £4.6 million was spent on agency locum doctors in 2014/15. All of these are being actively management by the Corporate Management Team

Disclosures

An internal audit report on information governance policies and procedures was considered at the June 2013 Audit Committee and contained three high risk recommendations. The report and a detailed action plan were considered at both the Audit Committee and Information Governance Committee. A follow-up review showed that these recommendations had not yet been implemented. Since then the Corporate Management Team approved a corporate governance controlled document policy which addresses the main recommendations.

In the first nine months of 2014/15 the Board had 45 patients who breached the 12 week Treatment Time Guarantee (TTG). Due to emergency service pressure over winter, most orthopaedic elective operations were cancelled in January and February 2015 resulting in 388 patients who breached the 12 week TTG in the last quarter.

In late February 2014 it was discovered that there were a number of cystoscopes and resectoscopes missing from the urology theatre and day surgery unit at University Hospital Ayr. This was reported to Counter Fraud Service as well as the Audit Committee and subsequent investigation established that scopes were also missing from University Hospital Crosshouse theatres. The total value of losses amounts to £1.3 million and approval was received from Scottish Government to write these off (£592,748 in 2013/14 accounts and £725,471 in 2014/15 accounts). In July 2014 a member of staff in the central decontamination unit was arrested and subsequently charged with theft. The Board has now extended the electronic tracking system used in the central decontamination unit to track scopes in theatres also.

During 2014/15 there were three reports issued following visits by the Healthcare Environmental Inspectorate of Healthcare Improvement Scotland. Two reports related to Ayr Hospital and one for Crosshouse Hospital. Each had a small number of requirements or recommendations which were responded to through an action plan. The reports and action plans were considered at the Healthcare Governance Committee of the Board and are shown on the Board public website using the following link. http://www.nhsaaa.net/publications/hei.aspx

NHS Ayrshire & Arran is committed to continuous improvement and takes cognisance of relevant reviews and developments in best practice. Other than those highlighted above, during 2014/15 no significant control weaknesses or issues have arisen, and no significant failures have arisen in the expected standards for good governance, risk management and control.

In accordance with IAS 27 – Consolidated and Separate Financial Statements, the Financial Statements consolidate the Ayrshire and Arran Health Board Endowment Fund. This statement reflects any relevant disclosure in respect of these Endowment accounts. Assurance has been received from the Endowment Committee as well as the fact that Endowment Funds are subject to audit.

Chief Executive	K	FRU	~ <u>~</u>		
				- 1	
Date	June	2015			

Independent auditor's report to the members of Ayrshire and Arran Health Board, the Auditor General for Scotland and the Scottish Parliament

I have audited the financial statements of Ayrshire and Arran Health Board and its group for the year ended 31 March 2015 under the National Health Service (Scotland) Act 1978. The financial statements comprise the Statement of Consolidated Comprehensive Net Expenditure and Summary of Resource Outturn, the Balance Sheet, the Statement of Consolidated Cashflows, the Consolidated Statement of Changes in Taxpayers' Equity and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards (IFRSs) as adopted by the European Union, and as interpreted and adapted by the 2014/15 Government Financial Reporting Manual (the 2014/15 FReM).

This report is made solely to the parties to whom it is addressed in accordance with the Public Finance and Accountability (Scotland) Act 2000 and for no other purpose. In accordance with paragraph 125 of the Code of Audit Practice approved by the Auditor General for Scotland, I do not undertake to have responsibilities to members or officers, in their individual capacities, or to third parties.

Respective responsibilities of Accountable Officer and auditor

As explained more fully in the Statement of the Chief Executive's Responsibilities as the Accountable Officer of the Health Board, the Accountable Officer is responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and is also responsible for ensuring the regularity of expenditure and income. My responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland) as required by the Code of Audit Practice approved by the Auditor General for Scotland. Those standards require me to comply with the Auditing Practices Board's Ethical Standards for Auditors. I am also responsible for giving an opinion on the regularity of expenditure and income in accordance with the Public Finance and Accountability (Scotland) Act 2000.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the circumstances of the board and its group and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the Accountable Officer; and the overall presentation of the financial statements. It also involves obtaining evidence about the regularity of expenditure and income. In addition, I read all the financial and non-financial information in the annual report and accounts to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by me in the course of performing the audit. If I become aware of any apparent material misstatements, irregularities, or inconsistencies I consider the implications for my report.

Opinion on financial statements

In my opinion the financial statements:

- give a true and fair view in accordance with the National Health Service (Scotland) Act 1978
 and directions made thereunder by the Scottish Ministers of the state of the state of affairs of
 the board and its group as at 31 March 2015 and of their net operating cost for the year then
 ended;
- have been properly prepared in accordance with IFRSs as adopted by the European Union, as interpreted and adapted by the 2014/15 FReM; and
- have been prepared in accordance with the requirements of the National Health Service (Scotland) Act 1978 and directions made thereunder by the Scottish Ministers.

Opinion on regularity

In my opinion in all material respects the expenditure and income in the financial statements were incurred or applied in accordance with any applicable enactments and guidance issued by the Scottish Ministers.

Opinion on other prescribed matters

In my opinion:

- the part of the Remuneration Report to be audited has been properly prepared in accordance with the National Health Service (Scotland) Act 1978 and directions made thereunder by the Scottish Ministers; and
- the information given in the Directors' Report and Strategic Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

Matters on which I am required to report by exception

I am required to report to you if, in my opinion:

- adequate accounting records have not been kept; or
- the financial statements and the part of the Remuneration Report to be audited are not in agreement with the accounting records; or
- I have not received all the information and explanations I require for my audit; or
- the Governance Statement does not comply with guidance from the Scottish Ministers; or
- there has been a failure to achieve a prescribed financial objective.

I have nothing to report in respect of these matters.

Fiona Mitchell-Knight FCA Assistant Director (Audit Services) Audit Scotland 4th Floor, South Suite The Athenaeum Building 8 Nelson Mandela Place Glasgow G2 1BT

Fisna Mirchell-Knut

23 June 2015

STATEMENT OF CONSOLIDATED COMPREHENSIVE NET EXPENDITURE AND SUMMARY OF RESOURCE OUTTURN FOR THE YEAR ENDED 31 MARCH 2015

Restated 2014 £'000		Note	2015 £'000	2015 £'000
	Clinical Services Costs			
580,901	Hospital and Community	4	591,991	
24,714	Less: Hospital and Community Income	<u>4</u> <u>8</u>	26,060	
556,187				565,931
176,132	Family Health	<u>5</u> 8	181,552	
5,243	Less: Family Health Income	<u>8</u>	5,632	
170,889				175,920
727,076	Total Clinical Services Costs			741,851
2,958	Administration Costs	6	2,790	
 14	Less: Administration Income	<u>6</u> <u>8</u>	25	
2,944		× .		2,765
20,767	Other Non Clinical Services	7	11,456	_,, •••
15,780	Less: Other Operating Income	<u>7</u> <u>8</u>	16,842	
4,987		_	· · · · · · · · · · · · · · · · · · ·	(5,386)
735,007	Net Operating Costs			739,230

2014 £'000	OTHER COMPREHENSIVE NET EXPENDITURE	2015 £'000
(20,575)	Net (gain)/loss on revaluation of Property Plant and Equipment	(15,171)
(378)	Net (gain)/loss on revaluation of available for sales financial assets	(729)
(20,953)	Other Comprehensive Expenditure	(15,900)
714,054	Total Comprehensive Expenditure	723,330

The Notes to the Accounts, numbered 1 to 33, form an integral part of these Accounts.

STATEMENT OF COMPREHENSIVE NET EXPENDITURE AND SUMMARY OF RESOURCE OUTTURN (Cont.)

FOR THE YEAR END	ED 31 MARCH 2015		
SUMMARY OF CORE REVENUE RESOURCE OUTTURN		2015 £'000	2015 £'000
Net Operating Costs Total Non Core Expenditure (see below) FHS Non Discretionary Allocation Donated Assets Income Endowment Net Operating Costs Total Core Expenditure Core Revenue Resource Limit Saving/(excess) against Core Revenue Resource Limit		_	739,230 (14,987) (42,075) 324 60 682,552 682,898 346
SUMMARY OF NON CORE REVENUE RESOURCE OUTTURN Capital Grants to / (from) Other Bodies Depreciation/Amortisation Annually Managed Expenditure - Impairments Annually Managed Expenditure - Creation of Provisions Annually Managed Expenditure - Depreciation of Donated Ass Additional SGHSCD non-core funding IFRS PFI Expenditure Total Non Core Expenditure Non Core Revenue Resource Limit Saving/(excess) against Non Core Revenue Resource Lim		320 14,170 645 (2,290) 375 145 1,622 —	14,987 14,987 0
SUMMARY RESOURCE OUTTURN	Resource £'000 682,898	Expenditure £'000 682.552	Saving/(Excess) £'000 346
Non Core Total	14,987 697,885	14,987 697,539	0 346

BALANCE SHEET

FOR THE YEAR ENDED 31 MARCH 2015

			1	FOR THE YEAR ENDED 31 MARCH 2015			
Consolidated 2013	Board 2013	Consolidated 2014	Board 2014			Consolidated 2015	Board 2015
£'000	£'000	£'000	£'000		Note	£'000	£'000
310,647	310,647		315,735	Property, plant and equipment	11	348,429	348,429
010,011	010,017		0	Intangible assets	10	0	0
Ŭ	v	Ū	Ū	Financial assets:	10		
10,875	0	11,102	0	Available for sale financial assets	14	12,563	0
19,285	19,285		23,078	Trade and other receivables	<u>14</u> <u>13</u>	27,350	27,350
340,807	329,932		338,813	Total non-current assets	<u></u>	388,342	375,779
				Current Assets:			
3,296	3,296	3,767	3,767	Inventories	12	3,849	3,849
				Financial assets:			
10,883	10,893	18,812	18,816	Trade and other receivables	<u>13</u>	8,764	8,763
1,133	115	1,258	115	Cash and cash equivalents	<u>15</u>	607	117
0	0	0	0	Available for sale financial assets	14	0	0
2,630	2,630	3,870	3,870	Assets classified as held for sale	11c	2,050	2,050
17,942	16,934	27,707	26,568	Total current assets		15,270	14,779
358,749	346,866	377,622	365,381	Total assets		403,612	390,558
550,145	340,000	517,022	303,301	10141 435013			000,000
				Current liabilities			
(3,173)	(3,173)	(10,653)	(10,653)	Provisions	<u>17</u>	(15,750)	(15,750)
	• • •			Financial liabilities:			
(58,801)	(58,726)	(53,242)	(53,204)	Trade and other payables	<u>16</u>	(54,411)	(54,349)
Ó	Ó		Ó	Derivatives financial liabilities	28	0	0
(61,974)	(61,899)	(63,895)	(63,857)	Total current liabilities		(70,161)	(70,099)
	001007	a 40 707	004 504				200 460
296,775	284,967	313,727	301,524	Non-current assets plus/less net current assets/liabilit	ies	333,451	320,459
				Non-current liabilities			
(43,606)	(43,606)	(55,589)	(55,589)	Provisions	17	(43,666)	(43,666)
(40,000)	(40,000)	(00,000)	(00,000)	Financial liabilities:	<u></u>	(1-1)	(,)
(26,702)	(26,702)	(27,037)	(27,037)	Trade and other payables	16	(47,735)	(47,735)
(70,308)	(70,308)	(82,626)	(82,626)	Total non-current liabilities	10	(91,401)	(91,401)
(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(10)0007	(01)010)	10-10-07				
226,467	214,659	231,101	218,898	Assets less liabilities		242,050	229,058
				Taxpayers' Equity			
161,464	161,464	151,250	151,250	General fund	SOCTE		153,445
53,195	53,195		67,648	Revaluation reserve	SOCTE		75,613
11,808	. 0		0	Fund held on Trust	SOCTE		0
226,467	214,659		218,898	Total taxpayers' equity		242,050	229,058

Adopted by the Board on 7.3 June 2015 Perek Anindagu Director of Finance The Notes to the Adcounts, numbered 1 to 33, form an integral part of these Accounts.

STATEMENT OF CONSOLIDATED CASHFLOWS

FOR THE YEAR ENDED 31 MARCH 2015

2014 £'000			2015 £'000	2015 £'000
	Cash flows from operating activities			
(735,007)	Net operating cost		(739,230)	
21,513	Adjustments for non-cash transactions		16,333	
3,773	Add back: interest payable recognised in net operating cost		3,841	
(320)	Deduct: interest receivable recognised in net operating cost		(397)	
(11,722)	(Increase) / decrease in trade and other receivables		5,790	
(471)	(Increase) / decrease in inventories		(82)	
(5,955)	Increase / (decrease) in trade and other payables		521	
19,463	Increase / (decrease) in provisions		(6,826)	
(708,726)	Net cash outflow from operating activities	<u>33</u>	(0,020) _	(720,050)
	Cash flows from investing activities			
(8,141)	Purchase of property, plant and equipment		(36,191)	
(2,119)	Investment Additions		(4,880)	
355	Proceeds of disposal of property, plant and equipment		1,611	
2,270	Receipts from sale of investments		4,149	
320	Interest received		397	
(7,315)	Net cash outflow from investing activities	<u>33</u>		(34,914)
	Cash flows from financing activities			
720,687	Funding		737,273	
0	Movement in general fund working capital		2	
720,687	Cash drawn down		737,275	
(740)	Capital element of payments in respect of finance leases and on-balance sheet PFI			
(748)	contracts		20,879	
(369)	Interest paid		(326)	
<u>(3,404)</u> 716,166	Interest element of finance leases and on-balance sheet PFI/PPP contracts		(3,515)	
/ 10, 100	Net Financing	<u>33</u>		754,313
125	Net Increase / (decrease) in cash and cash equivalents in the period			(651)
1,133	Cash and cash equivalents at the beginning of the period			1,258
1,258	Cash and cash equivalents at the end of the period		_	607
400	Reconciliation of net cash flow to movement in net debt/cash			
125	Increase/(decrease) in cash in year			(651)
1,133	Net debt/cash at 1 April			1,258
1,258	Net debt/cash at 31 March			607

The Notes to the Accounts, numbered 1 to 33, form an integral part of these Accounts.

CONSOLIDATED STATEMENT OF CHANGES IN

TAXPAYERS' EQUITY FOR THE YEAR ENDED

	31 MARCH 2015 Note	General Fund £'000	Revaluation Reserve £'000	Funds Held on Trust £'000	Total Reserves £'000
Balance at 31 March 2014 Prior year adjustments for changes in accounting policy and material error	nrs <u>25</u>	151,250	67,648 0	12,203	231,101 0
Restated balance at 1 April 2014		151,250	67,648	12,203	231,101
Changes in taxpayers' equity for 2014-15 Net gain/(loss) on revaluation/indexation of property, plant and equipmen Net gain/(loss) on revaluation of available for sale financial assets Impairment of property, plant and equipment Revaluation & impairments taken to operating costs Transfers between reserves Net operating cost for the year Total recognised income and expense for 2014-15	t <u>11</u> <u>14</u> <u>11</u> <u>3</u>	0 4,212 (739,290) (735,078)	15,171 0 (3,773) 779 (4,212) 7,965		15,171 729 (3,773) 779 0 (739,230) (726,324)
Funding: Drawn down Movement in General Fund (Creditor) / Debtor Balance at 31 March 2015	<u>cfs</u> <u>BS</u>	737,275 (2) 153,445	75,613	12,992	737,275 (2) 242,050

CONSOLIDATED SOCTE (PRIOR YEAR)

CONSOLIDATED SOCTE

	Note	General Fund £'000	Revaluation Reserve £'000	Funds Heid on Trust	Total Reserves £'000
Balance at 31 March 2013 Prior year adjustments for changes in accounting policy and material errors	25	178,570	53,195		243,573
Restated balance at 1 April 2013	<u>25</u>	(17,106) 161,464	53,195	0 11,808	<u>(17,106)</u> 226,467
Changes in taxpayers' equity for 2013-14 Net gain/(loss) on revaluation/indexation of property, plant and equipment Net gain/(loss) on revaluation of available for sale financial assets Impairment of property, plant and equipment Revaluation & impairments taken to operating costs Transfers between reserves Net operating cost for the year Total recognised income and expense for 2013-14	<u>11</u> <u>14</u> <u>11</u> <u>3</u>	0 4,123 (735,024) (730,901)	20,575 0 (9,305) 7,306 (4,123) 14,453	378 17 395	20,575 378 (9,305) 7,306 0 (735,007) (716,053)
Funding: Drawn down Movement in General Fund (Creditor) / Debtor Balance at 31 March 2014	<u>BS</u>	720,687 0 151,250	67,648	12,203	720,687 0 231,101

The Notes to the Accounts, numbered 1 to 33, form an integral part of these Accounts.

ACCOUNTING POLICIES

1. Authority

In accordance with the accounts direction issued by Scottish Ministers under section 19(4) of the Public Finance and Accountability (Scotland) Act 2000 appended, these Accounts have been prepared in accordance with the Government Financial Reporting Manual (FReM) issued by HM Treasury, which follows International Financial Reporting Standards as adopted by the European Union (IFRSs as adopted by the EU), IFRIC Interpretations and the Companies Act 2006 to the extent that they are meaningful and appropriate to the public sector. They have been applied consistently in dealing with items considered material in relation to the accounts.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in section 30 below.

(a) Standards, amendments and interpretations effective in current year

The following new standards, amendments and interpretations became effective in 2014/15 for the first time:

IFRS 10 – Consolidated Financial Statements;

IFRS 11 – Joint Arrangements;

IFRS 12 – Disclosure of Interest in Other Entities;

IAS 27 – Separate Financial Statements; and

IAS 28 – Investments in Associates and Joint Ventures.

With the exception of IAS 27 on Separate Financial Statements which requires the Consolidation of the Board's Endowment accounts there is no impact on the financial statements as a result of the above.

(b) Standards, amendments and interpretation early adopted this year

There are no new standards, amendments or interpretations early adopted this year.

(c) Disclosure of New Accounting Standards

IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors requires disclosure of information on the expected impact of new accounting standards that have been issued but not yet in effect. The following standards have been issued but are not yet effective.

IFRS 13 Fair Value Measurement. IFRS 13 has been prepared to provide consistent guidance on fair value measurement for all relevant balances and transactions covered by IFRS (except where IFRS 13 explicitly states otherwise). The standard defines fair value, provides guidance on fair value measurement techniques, and sets out the disclosure requirements. It is not anticipated that this standard will have any material effect on the accounts of the Board or consolidated entity.

IAS 36 – Impairment of assets – this modifies some of the disclosure requirements regarding measurement of the recoverable amount of impaired assets in IFRS 13 above. The impact on the financial statements is expected to be minimal.

2. Basis of Consolidation

In accordance with IAS 27 – Consolidated and Separate Financial Statements, the Financial Statements consolidate the Ayrshire and Arran Health Board Endowment Fund.

NHS Endowment Funds were established by the NHS (Scotland) Act 1978. The legal framework under which charities operate in Scotland is the Charities and Trustee Investment (Scotland) Act 2005. Under the 1978 Act Endowment Trustees are also members of the NHS Board. The Board members (who are also Trustees) are appointed by Scottish Ministers.

Ayrshire and Arran Health Board Endowment Fund is a Registered Charity with the Office of the Charity Regulator of Scotland (OSCR) and is required to prepare and submit Audited Financial Statements to OSCR on an annual basis. The accounts of the charity have been prepared in accordance with applicable UK accounting standards, the Statement of Recommended Practice -"Accounting and Reporting by Charities" (SORP 2005) issued in March 2005 (as amended) and comply with the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006.

The basis of consolidation used is Merger Accounting. Any intra-group transactions between the Board and the Endowment Fund have been eliminated on consolidation.

Note 33 to the Annual Accounts, details how these consolidated Financial Statements have been calculated

3. Prior Year Adjustments

The prior years comparative figures have been restated to take effect of the following:

<u>Retrospective</u> Restatement – Clinical Negligence and Other Risks Indemnity Scheme (CNORIS)

CNORIS is a risk transfer and financing scheme for NHSScotland, and further

details are set out at Note 17b.

The change in accounting treatment in 2014/15 relates to the recognition of the Board's respective share of the total liability of NHSScotland as advised by the Scottish Government and based on information prepared by NHS Boards and the Central Legal Office. To ensure consistency, equivalent adjustments have been made to the position of the prior year as follows:

Provision recognising the Board's liability from participating in the scheme at 31 March : £17,106,000 at 31 March 2013 (£25,264,000 at 31 March 2014).

The movement in the provision between financial years is matched by a corresponding adjustment in Annually Managed Expenditure provision and is classified as non-core expenditure.

4. Going Concern

The accounts are prepared on the going concern basis, which provides that the entity will continue in operational existence for the foreseeable future.

5. Accounting Convention

The Accounts are prepared on an historical cost basis, as modified by the revaluation of property, plant and equipment, intangible assets, inventories, available-for-sale financial assets and financial assets and liabilities at fair value.

6. Funding

6.1 NHS Ayrshire and Arran Board

Most of the expenditure of the Health Board as Commissioner is met from funds advanced by the Scottish Government within an approved revenue resource limit. Cash drawn down to fund expenditure within this approved revenue resource limit is credited to the general fund.

All other income receivable by the board that is not classed as funding is recognised in the year in which it is receivable.

Where income is received for a specific activity which is to be delivered in the following financial year, that income is deferred.

Income from the sale of non-current assets is recognised only when all material conditions of sale have been met, and is measured as the sums due under the sale contract.

Non-discretionary funding outwith the RRL is allocated to match actual expenditure incurred for the provision of specific pharmaceutical, dental or ophthalmic services identified by the Scottish Government. Non-discretionary expenditure is disclosed in the accounts and deducted from operating costs charged against the RRL in the Statement of Resource Outturn.

Funding for the acquisition of capital assets received from the Scottish Government is credited to the general fund when cash is drawn down.

Expenditure on goods and services is recognised when, and to the extent that they have been received, and is measured at the fair value of those goods and services. Expenditure is recognised in the Statement of Comprehensive Net Expenditure except where it results in the creation of a non-current asset such as property, plant and equipment.

6.2 Ayrshire and Arran Health Board Endowment Fund

All incoming resources are recognised once the Ayrshire and Arran Health Board Endowment Funds has received its entitlement to the resources, it is certain that the resources will be received and the monetary value of incoming resources can be measured with sufficient reliability.

Legacies and donations to the Ayrshire and Arran Health Board Endowment Fund are accounted for as incoming resources upon receipt and classified as restricted or unrestricted based on the donors' stated wishes.

Income from investment of charitable endowment funds is earmarked as restricted or unrestricted based on the classification of the original legacy or donation in line with the donor's stated wishes.

All expenditure, including grants, is accounted for on an accruals basis and is only incurred where this will further the charitable objects of the Ayrshire and Arran Health Board Endowment Funds. All expenditure is recognised once there is a legal or constructive obligation committing the fund to the expenditure.

7. Property, plant and equipment

The treatment of capital assets in the accounts (capitalisation, valuation, depreciation, particulars concerning donated assets) is in accordance with the NHS Capital Accounting Manual.

Title to properties included in the accounts is held by Scottish Ministers.

7.1 Recognition

Property, Plant and Equipment is capitalised where: it is held for use in delivering services or for administrative purposes; it is probable that future economic benefits will flow to, or service potential be provided to, the Board; it is expected to be used for more than one financial year; and the cost of the item can be measured reliably.

All assets falling into the following categories are capitalised:

1)Property, plant and equipment assets which are capable of being used for a period which could exceed one year, and have a cost equal to or greater than \pounds 5,000.

2) In cases where a new hospital would face an exceptional write off of items of equipment costing individually less than £5,000, the Board has the option to capitalise initial revenue equipment costs with a standard life of 10 years.

3) Assets of lesser value may be capitalised where they form part of a group of similar assets purchased at approximately the same time and cost over £20,000 in total, or where they are part of the initial costs of equipping a new development and total over £20,000.

7.2 Measurement

Valuation:

All property, plant and equipment assets are measured initially at cost, representing the costs directly attributable to acquiring or constructing the asset and bringing it to the location and condition necessary for it to be capable of operating in the manner intended by management.

All assets are measured subsequently at fair value as follows:

Specialised NHS Land, buildings, equipment, installations and fittings are stated at depreciated replacement cost, as a proxy for fair value as specified in the FReM.

Non specialised land and buildings, such as offices, are stated at fair value.

Valuations of all land and building assets are reassessed by valuers on an annual basis of professional valuations and adjusted in intervening years to take account of movements in prices since the latest valuation. The valuations are carried out in accordance with the Royal Institution of Chartered Surveyors (RICS) Appraisal and Valuation Manual insofar as these terms are consistent with the agreed requirements of the Scottish Government.

Non-specialised equipment, installations and fittings are valued at fair value. Boards value such assets using the most appropriate valuation methodology available (for example, appropriate indices). A depreciated historical cost basis as a proxy for fair value in respect of such assets which have short useful lives or low values (or both).

Assets under construction are valued at current cost. This is calculated by the expenditure incurred to which an appropriate index is applied to arrive at current value. These are also subject to impairment review.

To meet the underlying objectives established by the Scottish Government the following accepted variations of the RICS Appraisal and Valuation Manual have been required:

Specialised operational assets are valued on a modified replacement cost basis to take account of modern substitute building materials and locality factors only.

Subsequent expenditure:

Subsequent expenditure is capitalised into an asset's carrying value when it is probable the future economic benefits associated with the item will flow to the Board and the cost can be measured reliably. Where subsequent expenditure does not meet these criteria the expenditure is charged to the Statement of Comprehensive Net Expenditure. If part of an asset is replaced, then the part it replaces is de-recognised, regardless of whether or not it has been depreciated separately.

Revaluations and Impairment:

Increases in asset values arising from revaluations are recognised in the revaluation reserve, except where, and to the extent that, they reverse an impairment previously recognised in the Statement of Comprehensive Net Expenditure, in which case they are recognised as income. Movements on revaluation are considered for individual assets rather than groups or land/buildings together.

Permanent decreases in asset values and impairments are charged gross to the Statement of Comprehensive Net Expenditure. Any related balance on the revaluation reserve is transferred to the General Fund.

Gains and losses:

Gains and losses on revaluation are reported in the Statement of Comprehensive Net Expenditure.

7.3 Depreciation

Items of Property, Plant and Equipment are depreciated to their estimated residual value over their remaining useful economic lives in a manner consistent with the consumption of economic or service delivery benefits.

Depreciation is charged on each main class of tangible asset as follows:

- 1) Freehold land is considered to have an infinite life and is not depreciated.
- Assets in the course of construction and residual interests in PFI contract assets are not depreciated until the asset is brought into use or reverts to the Board, respectively.
- 3) Property, Plant and Equipment which has been reclassified as 'Held for Sale' ceases to be depreciated upon the reclassification.
- 4) Buildings, installations and fittings are depreciated on current value over the estimated remaining life of the asset, as advised by the appointed valuer. They are assessed in the context of the maximum useful lives for building elements.
- 5) Equipment is depreciated over the estimated life of the asset.
- 6) Property, plant and equipment held under finance leases are depreciated over the shorter of the lease term and the estimated useful life.

Depreciation is charged on a straight line basis.

The following asset lives have been used:

Asset Category/Component	Useful Life (years)
Buildings Structure (Depreciated Replacement Cost)	3 to 72
Buildings Engineering (Depreciated Replacement Cost)	1 to 33
Buildings (Existing Use Value)	2 to 40
Moveable Engineering Plant	15
Furniture and Medium Life Equipment	10
Short/Medium Life Medical Equipment	7
Information Technology	5
Vehicles and Soft Furnishings	5
Office, Short Life Medical and Other Equipment	5

8. Intangible Assets

8.1 Recognition

Intangible assets are non-monetary assets without physical substance which are capable of being sold separately from the rest of the Board's business or which arise from contractual or other legal rights. They are recognised only where it is probable that future economic benefits will flow to, or service potential be provided to, the Board and where the cost of the asset can be measured reliably.

Intangible assets that meet the recognition criteria are capitalised when they are capable of being used in a Board's activities for more than one year and they have a cost of at least $\pounds 5,000$.

The main class of intangible asset recognised by the Board is shown below:

Software licences:

Purchased computer software licences are capitalised as intangible assets where expenditure of at least £5,000 is incurred.

8.2 Measurement

Valuation:

Intangible assets are recognised initially at cost, comprising all directly attributable costs needed to create, produce and prepare the asset to the point that it is capable of operating in the manner intended by management.

Subsequently intangible assets are measured at fair value. Where an active (homogeneous) market exists, intangible assets are carried at fair value. Where no active market exists, the intangible asset is revalued, using indices or some suitable model, to the lower of depreciated replacement cost and value in use where the asset is income generating. Where there is no value in use, the intangible asset is valued using depreciated replacement cost. These measures are a proxy for fair value.

Revaluation and impairment:

Increases in asset values arising from revaluations are recognised in the revaluation reserve, except where, and to the extent that, they reverse an impairment previously recognised in the Statement of Comprehensive Net Expenditure, in which case they are recognised in income.

Permanent decreases in asset values and impairments are charged gross to the Statement of Comprehensive Net Expenditure. Any related balance on the revaluation reserve is transferred to the General Fund.

Temporary decreases in asset values or impairments are charged to the revaluation reserve to the extent that there is an available balance for the asset concerned, and thereafter are charged to the Statement of Comprehensive Net Expenditure.

Intangible assets held for sale are reclassified to 'non-current assets held for sale' measured at the lower of their carrying amount or 'fair value less costs to sell'.

8.3 Amortisation

Intangible assets are amortised to their estimated residual value over their remaining useful economic lives in a manner consistent with the consumption of economic or service delivery benefits.

Amortisation is charged to the Statement of Comprehensive Net Expenditure for software licences. These are amortised over the shorter term of the licence and their useful economic lives. Amortisation is charged on a straight line basis using an asset life of 5 years.

9. Non-current assets held for sale

Non-current assets intended for disposal are reclassified as 'Held for Sale' once all of the following criteria are met:

- the asset is available for immediate sale in its present condition subject only to terms which are usual and customary for such sales;
- the sale must be highly probable i.e.:
 - management are committed to a plan to sell the asset;
 - an active programme has begun to find a buyer and complete the sale;
 - the asset is being actively marketed at a reasonable price;
 - the sale is expected to be completed within 12 months of the date of classification as 'Held for Sale'; and
 - the actions needed to complete the plan indicate it is unlikely that the plan will be dropped or significant changes made to it.

Following reclassification, the assets are measured at the lower of their existing carrying amount and their 'fair value less costs to sell'. Depreciation ceases to

be charged and the assets are not revalued, except where the 'fair value less costs to sell' falls below the carrying amount. Assets are de-recognised when all material sale contract conditions have been met.

Property, plant and equipment which is to be scrapped or demolished does not qualify for recognition as 'Held for Sale' and instead is retained as an operational asset and the asset's economic life is adjusted. The asset is de-recognised when scrapping or demolition occurs.

10. Donated Assets

Non-current assets that are donated or purchased using donated funds are included in the Balance Sheet initially at the current full replacement cost of the asset. The accounting treatment, including the method of valuation, follows the rules in the NHS Capital Accounting Manual.

11. Sale of Property, plant and equipment, intangible assets and non-current assets held for sale

Disposal of non-current assets is accounted for as a reduction to the value of assets equal to the net book value of the assets disposed. When set against any sales proceeds, the resulting gain or loss on disposal will be recorded in the Statement of Comprehensive Net Expenditure. Non-current assets held for sale will include assets transferred from other categories and will reflect any resultant changes in valuation.

12. Leasing

Finance leases

Where substantially all risks and rewards of ownership of a leased asset are borne by the Board, the asset is recorded as Property, Plant and Equipment and a corresponding liability is recorded. Assets held under finance leases are valued at their fair values and are depreciated over the remaining period of the lease in accordance with IFRS.

The asset and liability are recognised at the inception of the lease, and are derecognised when the liability is discharged, cancelled or expires. The minimum lease payments (annual rental less operating costs e.g. maintenance and contingent rental) are apportioned between the repayment of the outstanding liability and a finance charge. The annual finance charge is allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability using either the implicit interest rate or another relevant basis of estimation such as the sum of the digits method. Finance charges are recorded as interest payable in the Statement of Comprehensive Net Expenditure. Contingent rental and operating costs are charged as expenses in the periods in which they are incurred.

Operating leases

Other leases are regarded as operating leases and the rentals are charged to expenditure on a straight-line basis over the term of the lease. Operating lease incentives received are added to the lease rentals and charged to expenditure over the life of the lease.

Leases of land and buildings

Where a lease is for land and buildings, the land component is separated from the building component and the classification for each is assessed separately. Leased land is treated as an operating lease unless title to the land is expected to transfer.

13. Impairment of non-financial assets

Assets that are subject to depreciation and amortisation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value in use. Where an asset is not held for the purpose of generating cash flows, value in use is assumed to equal the cost of replacing the service potential provided by the asset, unless there has been a reduction in service potential. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). Non-financial assets that suffer an impairment are reviewed for possible reversal of the impairment. Impairment losses charged to the Statement of Comprehensive Net Expenditure (SOCNE) are deducted from future operating costs to the extent that they are identified as being reversed in subsequent revaluations.

14. General Fund Receivables and Payables

Where the Health Board has a positive net cash book balance at the year end, a corresponding creditor is created and the general fund debited with the same amount to indicate that this cash is repayable to the SGHSCD. Where the Health Board has a net overdrawn cash position at the year end, a corresponding debtor is created and the general fund credited with the same amount to indicate that additional cash is to be drawn down from the SGHSCD.

15. Inventories

Inventories are valued at the lower of cost and net realisable value. Taking into account the high turnover of NHS inventories, the use of average purchase price is deemed to represent current cost. Work in progress is valued at the cost of the direct materials plus the conversion costs and other costs incurred to bring the goods up to their present location, condition and degree of completion.

16. Losses and Special Payments

Operating expenditure includes certain losses which would have been made good through insurance cover had the NHS not been bearing its own risks. Had the NHS provided insurance cover, the insurance premiums would have been included as normal revenue expenditure.

17. Employee Benefits

Short-term Employee Benefits

Salaries, wages and employment-related payments are recognised in the year in which the service is received from employees. The cost of annual leave and flexible working time entitlement earned but not taken by employees at the end of the year is recognised in the financial statements to the extent that employees are permitted to carry-forward leave into the following year.

Pension Costs

The Board participates in the NHS Superannuation Scheme for Scotland providing defined benefits based on final pensionable pay, where contributions are credited to the Exchequer and are deemed to be invested in a portfolio of Government Securities. The Board is unable to identify its share of the underlying notional assets and liabilities of the scheme on a consistent and reasonable basis and therefore accounts for the scheme as if it were a defined contribution scheme, as required by IAS 19 'Employee Benefits'. As a result, the amount charged to the Statement of Comprehensive Net Expenditure represents the Board's employer contributions payable to the scheme in respect of the year. The contributions deducted from employees are reflected in the gross salaries charged and are similarly remitted to Exchequer. The pension cost is assessed every five years by the Government Actuary and determines the rate of contributions required. The most recent actuarial valuation is published by the Scottish Public Pensions Agency and is available on their website.

Additional pension liabilities arising from early retirements are not funded by the scheme except where the retirement is due to ill-health. The full amount of the liability for the additional costs is charged to the Statement of Comprehensive Net Expenditure at the time the Board commits itself to the retirement, regardless of the method of payment.

18. Clinical and Medical Negligence Costs

Employing health bodies in Scotland are responsible for meeting medical negligence costs up to a threshold per claim. Costs above this threshold are reimbursed to Boards from a central fund held as part of the Clinical Negligence and Other Risks Indemnity Scheme (CNORIS) by the Scottish Government.

NHS Ayrshire and Arran provide for all claims notified to the NHS Central Legal Office according to the value of the claim and the probability of settlement. Claims assessed as 'Category 3' are deemed most likely and provided for in full, those in 'Category 2' as 50% of the claim and those in 'Category 1' as nil. The balance of the value of claims not provided for is disclosed as a contingent liability. This procedure is intended to estimate the amount considered to be the liability in respect of any claims outstanding and which will be recoverable from the Clinical Negligence and Other Risks Indemnity Scheme in the event of payment by an individual health body. The corresponding recovery in respect of amounts provided for is recorded as a debtor and that in respect of amounts disclosed as contingent liabilities are disclosed as contingent assets.

19. Related Party Transactions

Material related party transactions are disclosed in the note 29 in line with the requirements of IAS 24. Transactions with other NHS bodies for the commissioning of health care are summarised in Note 4.

20. Value Added Tax

Most of the activities of the Board are outside the scope of VAT and, in general, output tax does not apply and input tax on purchases is not recoverable. Irrecoverable VAT is charged to the relevant expenditure category or included in the capitalised purchase cost of non current assets. Where output tax is charged or input VAT is recoverable, the amounts are stated net of VAT.

21. PFI /HUB/NPD Schemes

Transactions financed as revenue transactions through the Private Finance Initiative or alternative initiatives such as HUB or the Non Profit Distributing Model (NPD) are accounted for in accordance with the HM Treasury application of IFRIC 12, *Service Concession Arrangements*, outlined in the FReM.

Schemes which do not fall within the application of IFRIC 12 are deemed to be off-balance sheet. Where the Board has contributed assets, a prepayment for their fair value is recognised and amortised over the life of the PFI contract by charge to the Statement of Comprehensive Net Expenditure. Where, at the end of the PFI contract, a property reverts to the Board, the difference between the expected fair value of the residual on reversion and any agreed payment on reversion is built up on the balance sheet over the life of the contract by capitalising part of the unitary charge each year.

Transactions which meet the IFRIC 12 definition of a service concession, as interpreted in HM Treasury's FReM, are accounted for as 'on-balance sheet' by the Board. The underlying assets are recognised as Property, Plant and Equipment and Intangible Assets at their fair value. An equivalent liability is recognised in accordance with IAS 17. Where it is not possible to separate the finance element from the service element of unitary payment streams this has been estimated from information provided by the operator and the fair values of the underlying assets. Assets are subsequently revalued in accordance with the treatment specified for their applicable asset categories.

The annual contract payments are apportioned between the repayment of the liability, a finance cost and the charges for services. The finance cost is calculated using the implicit interest rate for the scheme.

The service charge and the finance cost interest element are charged in the Statement of Comprehensive Net Expenditure.

22. Provisions

The Board provides for legal or constructive obligations that are of uncertain timing or amount at the balance sheet date on the basis of the best estimate of the expenditure required to settle the obligation. Where the effect of the time value of money is significant, the estimated cash flows are discounted using the discount rate prescribed by HM Treasury.

23. Contingencies

Contingent assets (that is, assets arising from past events whose existence will only be confirmed by one or more future events not wholly within the Board's control) are not recognised as assets, but are disclosed in note 19 where an inflow of economic benefits is probable. Contingent liabilities are not recognised, but are disclosed in note 19, unless the probability of a transfer of economic benefits is remote. Contingent liabilities are defined as:

- possible obligations arising from past events whose existence will be confirmed only by the occurrence of one or more uncertain future events not wholly within the entity's control; or
- present obligations arising from past events but for which it is not probable that a transfer of economic benefits will arise or for which the amount of the obligation cannot be measured with sufficient reliability.

24. Corresponding Amounts

Corresponding amounts are shown for the primary statements and notes to the financial statements. Where the corresponding amounts are not directly comparable with the amount to be shown in respect of the current financial year, IAS 1 'Presentation of Financial Statements', requires that they should be adjusted and the basis for adjustment disclosed in a note to the financial statements.

25. Financial Instruments

Financial assets

Classification

The Board classifies its financial assets in the following categories: at fair value through profit or loss, loans and receivables, and available for sale. The classification depends on the purpose for which the financial assets were acquired. Management determines the classification of its financial assets at initial recognition.

(a) Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss comprise derivatives. Assets in this category are classified as current assets. The Board does not trade in derivatives and does not apply hedge accounting.

(b) Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are included in current assets, except for maturities greater than 12 months after the balance sheet date. These are classified as non-current assets. Loans and receivables comprise trade and other receivables and cash at bank and in hand in the balance sheet.

(c) Available-for-sale financial assets

Available-for-sale financial assets are non-derivatives that are either designated in this category or not classified in any of the other categories. They are included in non-current assets unless management intends to dispose of the investment within 12 months of the balance sheet date. Available for sale financial assets comprise investments held by the Ayrshire and Arran Health Board Endowment Fund.

Recognition and measurement

Financial assets are recognised when the Board becomes party to the contractual provisions of the financial instrument.

Financial assets are derecognised when the rights to receive cash flows from the asset have expired or have been transferred and the Board has transferred substantially all risks and rewards of ownership.

(a) Financial assets at fair value through profit or loss Financial assets carried at fair value through profit or loss are initially recognised at fair value, and transaction costs are expensed in the Statement of Comprehensive Net Expenditure.

Financial assets carried at fair value through profit or loss are subsequently measured at fair value. Gains or losses arising from changes in the fair value are presented in the Statement of Comprehensive Net Expenditure.

(b) Loans and receivables

Loans and receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for impairment of loans and receivables is established when there is objective evidence that the Board will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial reorganisation, and default or delinguency in payments (more than 30 days overdue) are considered indicators that the loan and receivable is impaired. The amount of the provision is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. The carrying amount of the asset is reduced through the use of an allowance account, and the amount of the loss is recognised in the Statement of Comprehensive Net Expenditure. When a loan or receivable is uncollectible, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are credited in the Statement of Comprehensive Net Expenditure.

(c) Available-for-sale financial assets

Available-for-sale financial assets are initially recognised and subsequently carried at fair value. Changes in the fair value of financial assets classified as available for sale are recognised in equity in other reserves. When financial assets classified as available for sale are sold or impaired, the accumulated fair value adjustments recognised in equity are included in the Statement of Comprehensive Net Expenditure. Dividends on available-for-sale equity instruments are recognised in the Statement of Comprehensive Net Expenditure.

Investments in equity instruments that do not have a quoted market price in an active market and whose fair value cannot be reliably measured are measured at cost less impairment.

The Board assesses at each balance sheet date whether there is objective evidence that a financial asset or a group of financial assets is impaired. In the

case of equity securities classified as available for sale, a significant or prolonged decline in the fair value of the security below its cost is considered as an indicator that the securities are impaired. If any such evidence exists for available-for-sale financial assets, the cumulative loss – measured as the difference between the acquisition cost and the current fair value, less any impairment loss on that financial asset previously recognised in profit or loss – is removed from equity and recognised in the Statement of Comprehensive Net Expenditure. Impairment losses recognised in the Statement of Comprehensive Net Expenditure on equity instruments are not reversed through the income statement.

Financial Liabilities

Classification

The Board classifies its financial liabilities in the following categories: at fair value through profit or loss, and other financial liabilities. The classification depends on the purpose for which the financial liabilities were issued. Management determines the classification of its financial liabilities at initial recognition.

(a) Financial liabilities at fair value through profit or loss
 Financial liabilities at fair value through profit or loss comprise derivatives.
 Liabilities in this category are classified as current liabilities. The NHS Board

does not trade in derivatives and does not apply hedge accounting.

(b) Other financial liabilities

Other financial liabilities are included in current liabilities, except for maturities greater than 12 months after the balance sheet date. These are classified as non-current liabilities. The NHS Board's other financial liabilities comprise trade and other payables in the balance sheet.

Recognition and measurement

Financial liabilities are recognised when the NHS Board becomes party to the contractual provisions of the financial instrument.

A financial liability is removed from the balance sheet when it is extinguished, that is when the obligation is discharged, cancelled or expired.

(a) Financial liabilities at fair value through profit or loss Financial liabilities carried at fair value through profit or loss are initially recognised at fair value, and transaction costs are expensed in the income statement.

Financial liabilities carried at fair value through profit or loss are subsequently measured at fair value. Gains or losses arising from changes in the fair value are presented in the Statement of Comprehensive Net Expenditure.

(b) Other financial liabilities

Other financial liabilities are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method.

26. Segmental reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments. This has been identified as the senior management of the Board.

Operating segments are unlikely to directly relate to the analysis of expenditure shown in notes 4 to 7 for Hospital & Community, Family Health and Other Service and Administration Costs, the basis of which relates to Scottish Government funding streams and the classification of which varies depending on Scottish Government reporting requirements.

27. Cash and cash equivalents

Cash and cash equivalents includes cash in hand, deposits held at call with banks, cash balances held with the Government Banking Service, balances held in commercial banks and other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities on the balance sheet. Where the Government Banking Service is using Citi and Royal Bank of Scotland Group to provide the banking services, funds held in these accounts should not be classed as commercial bank balances.

28. Foreign exchange

The functional and presentational currencies of the Board are sterling.

A transaction which is denominated in a foreign currency is translated into the functional currency at the spot exchange rate on the date of the transaction. Where the Board has assets or liabilities denominated in a foreign currency at the balance sheet date:

- monetary items (other than financial instruments measured at 'fair value through income and expenditure') are translated at the spot exchange rate on 31 March;
- non-monetary assets and liabilities measured at historical cost are translated using the spot exchange rate at the date of the transaction; and
- non-monetary assets and liabilities measured at fair value are translated using the spot exchange rate at the date the fair value was determined.

Exchange gains or losses on monetary items (arising on settlement of the transaction or on re-translation at the balance sheet date) are recognised in income or expenditure in the period in which they arise.

Exchange gains or losses on non-monetary assets and liabilities are recognised in the same manner as other gains and losses on these items.

29. Third party assets

Assets belonging to third parties (such as money held on behalf of patients) are not recognised in the accounts since the Board has no beneficial interest in them.

However, they are disclosed in note 31 to the accounts in accordance with the requirements of HM Treasury's Financial Reporting Manual.

30. Key sources of judgement and estimation uncertainty

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Board makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The Board makes judgements in applying accounting policies. The estimates, assumptions and judgements that have a significant risk of causing material adjustment to the carrying amounts of assets and liabilities within the financial statements within the next financial year are addressed below.

Clinical and Medical Negligence Claims

The Board's accounting policy relating to the provision for clinical and medical negligence is described in section 18 above. The main elements of uncertainty relate to the timing of settlements which could be many years in the future, the probability of making a settlement and the value associated with these potential future settlements. The timing is based on an assessment made by the Board's litigation manager and financial controller at the end of each year. The assessment of probability is carried out by the Board's legal advisors, Central Legal Office (CLO) based on previous experience and records maintained on a national basis which is then reviewed by the litigation manager.

Estimated settlement values are based on initial claims received by the CLO and advised to the Board which are periodically updated by CLO using reports on expected Pursuer costs and cost of living indices.

Early Retirement and Injury Benefits

The Board has provided for the estimated future costs relating to early retirement and injury benefits. Reliance is placed on information provided by other parties in order to establish the value of such provisions. The Scottish Public Pensions Agency provides details of claimants and the amounts the Board is due to pay over. Future payments are estimated using a discount rate provided by HM Treasury and life tables provided by the Office for National Statistics (ONS). Any future significant changes to the discount rate or the life tables could have a material impact on the level of provision required.

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

2. (a) STAFF NUMBERS AND COSTS

	Executive Board Members £'000	Non Executive Members £'000	Permanent Staff £'000	inward Secondees £000s	Other Staff £'000	Outward Secondees £'000	2015 Total £'000	2014 Total £'000
STAFF COSTS Salaries and wages Social security costs NHS scheme employers' costs Inward secondees Agency staff	731 94 100	122 4	301,553 23,326 35,205	129	5,889	(751) (68) (84)	301,655 23,356 35,221 129 5,889	294,095 22,889 34,038 447 6,234
Compansation for loss of office or early retirement	925	126	360,084 30	129	5,889	(903)	366,250 30	357,703 68
TOTAL	925	126	360,114	129	5,889	(903)	366,280	357,771

STAFF NUMBERS (EMPLOYEES BY WHOLE TIME EQUIVALENT)	2015 ANNUAL MEAN	2014 ANNUAL MEAN
Administration Costs Hospital and Community Services Non Clinical Services Other, including recharge Trading Accounts Inward secondees Agency staff Outward Secondees	53,4 8,567,1 127,5 390,9 3,6 52,0 (15,6)	55.8 8,355.4 121.3 372.8 11.9 72.5 (19.4)
Board Total Average Staff	9,178.9	8,970.3
Disabled staff	55.8	63.6

Note: Staff pension benefits are provided through the NHS Superannuation Scheme for Scotland. Details of the scheme in

2. (b) HIGHER PAID EMPLOYEES REMUNERATION

2. (b) HIGHER PAID EMPLOYEES REMUNERATION	Clinic	ane	Othe	r
	2015 Number	2014 Number	2015 Number	2014 Number
Other employees whose remuneration fell within the following ranges:				
£ 50,001 to £ 60,000	146	136	42	42
£ 60,001 to £ 70,000	57	67	18	21
£ 70,001 to £ 80,000	32	27	8	5
£ 80,001 to £ 90,000	45	50	0	0
£ 90,001 to £100,000	49	38	3	3
£100,001 to £110,000	35	44	2	2
£110,001 to £120,000	40	35	1	1
£120,001 to £130,000	32	27	1	1
£130,001 to £140,000	22	18	0	0
£140,001 to £150,000	21	18	0	0
£150,001 to £160,000	16	16	0	0
£160,001 to £170,000	11	10	0	0
£170,001 to £180,000	7	7	0	0
£180,001 to £190,000	11	6	0	0
£190,001 to £200,000	2	3	0	0
£200,001 and above	5	5	0	0

<u>note 24</u>

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

3. OTHER OPERATING COSTS

2014 £'000		Nete	2015
	Expenditure Not Paid In Cash	Note	£'000
15,625	Depreciation	11	45 700
430	Depreciation Donated Assets	<u>11</u> 11b	15,792 375
6,246	Impairments on PPE charged to SOCNE	<u>11</u>	313
(23)	Reversal of impairments on PPE charged to SOCNE	<u>11</u>	(32)
1,083	Loss on remeasurement of non-current assets held for sale	<u>11</u> <u>11</u> c	498
(183)	Funding Of Donated Assets	<u>11b</u>	(324)
(3)	Loss/(Profit) on disposal of property, plant and equipment	<u> </u>	(289)
(1,662)	Other non cash costs-PPE Transfer		(200)
21,513	Total Expenditure Not Paid In Cash	<u>CFS</u>	16,333
	Interest Payable		
3,404	PFI Finance lease charges allocated in the year		- ··
0,704	Other Finance lease charges allocated in the year	<u>23</u>	3,495
369	Provisions - Unwinding of discount		20
3,773	Total		<u>326</u> 3,841
225	Statutory Audit		
220	External auditor's remuneration and expenses		228
4. HOSPITAL A	ND COMMUNITY HEALTH SERVICES		
2014			2015
£'000	BY PROVIDER		£'000
479,617	Treatment in Board area of NHSScotland Patients		487,080
54,724	Other NHSScotland Bodies		55,897
586	Health Bodies outside Scotland		551
5,054	Primary care bodies		5,338
4,646	Private sector		5,681
	Community Care		0,001
6,064	Support Finance		6,325
24,326	Resource Transfer		24,903
5,426	Contributions to Voluntary Bodies and Charities		5,536
580,443	Total NHSScotland Patients		591,311
458	Treatment of UK residents based outside Scotland		680
580,901	Total Hospital & Community Health Service	SOCNE	591,991

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

5. FAMILY HEALTH SERVICE EXPENDITURE

2014 TOTAL £'000 52,595	Primary Medical Services		Unified Budget £'000 53,822	Non Disc £'000 0	2015 TOTAL £'000 53,822
87,560	Pharmaceutical Services		77,700	13,389	91,089
28,258	General Dental Services		2,618	26,332	28,950
7,719	General Ophthalmic Services	-	224	7,467	7,691
176,132	Total	SOCNE	134,364	47,188	181,552

6. ADMINISTRATION COSTS

2014 £'000			2015 £'000
1,083	Board members' remuneration	<u>Note 2 (a)</u>	1,051
119	Administration of Board Meetings and Committees		95
433	Corporate Governance and Statutory Reporting		437
536	Health Planning, Commissioning and Performance Reporting		454
193	Treasury Management and Financial Planning		187
349	Public Relations		343
245	Other		223
2,958	Total administration costs	SOCNE	2,790

7. OTHER NON CLINICAL SERVICES

7. OTHER NON 2014 £'000	CLINICAL SERVICES		2015 £'000
29	Closed hospital charges		26
10,860	Compensation payments - Clinical		246
378	Compensation payments - Other		500
434	Pension enhancement & redundancy		798
184	Patients' Travel Attending Hospitals		186
11	Patients' Travel Highlands and Islands scheme		10
2,776	Health Promotion		2,876
2,272	Public Health		2,131
120	Emergency Planning		118
97	Post Graduate Medical Education		84
2,276	Shared Services		2,537
1,262	Endowment Expenditure		1,604
68	Other		340
20,767	Total Other Non Clinical Services	SOCNE	11,456

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

8. OPERATING INCOME

2014 £'000			2015 £'000
	Hospital and Community Health Services Income NHSScotland Bodies		
23,131	Boards		04.007
458	NHS Non-Scottish Bodies		24,267 680
	Non NHS		
139	Private Patients		151
912	Compensation Income		904
74	Other Hospital and Community Health Services income	-	58
24,714	Total Hospital and Community Health Services Income	SOCNE	26,060
	Family Health Service Income		
136	Unified		519
	Non Discretionary		
5,107	General Dental Services	_	5,113
5,243	Total Family Health Services Income	SOCNE	5,632
14	Administration Income	SOCNE	25
	Other Operating Income		
3	Profit on disposal of non current assets		289
183	Donated Asset Additions		324
2,123	Shared Services		2,426
1,279	Endowment Income		1,664
12,192	Other	-	12,139
15,780	Total Other Operating Income	SOCNE	16,842
45,751	Total Income	_	48,559
23,131	Of the above, the amount derived from NHS bodies is		24,267

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

9. ANALYSIS OF CAPITAL EXPENDITURE

2014 £'000		Note	2015 £'000
9,620 183 9,803	EXPENDITURE Acquisition of Property, plant and equipment Donated Asset Additions Gross Capital Expenditure	<u>11</u> <u>11b</u>	36,641 324 36,965
352 183 535	INCOME Value of disposal of Non-Current Assets held for sale Donated Asset Income Capital Income	<u>11c</u>	1,322 324 1,646
9,268	Net Capital Expenditure		35,319
	SUMMARY OF CAPITAL RESOURCE OUTTURN		
9,268 9,268	Core capital expenditure included above Core Capital Resource Limit		13,939 13,941
0	Saving/(excess) against Core Capital Resource Limit		2
0 0	Non Core capital expenditure included above Non Core Capital Resource Limit		21,380 21,380
0	Saving/(excess) against Non Core Capital Resource Limit		0
9,268 9,268	Total Capital Expenditure Total Capital Resource Limit		35,319 35,321
0	Saving/(excess) against Total Capital Resource Limit		2

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

10. INTANGIBLE ASSETS - CONSOLIDATED AND BOARD

2014		2015
Software		Software
Licences £'000		Licences
2 000	Cost or Valuation:	£'000
21	As at 1st April 2014	21
21	At 31st March 2015	21
	Amortisation	
21	As at 1st April 2014	21
21	At 31st March 2015	21
0	Net Book Value at 1st April 2014	0
0	Net Book Value at 31 March 2015	<u>BS</u> 0

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

11. (a) PROPERTY, PLANT AND EQUIPMENT (Purchased Assets) - CONSOLIDATED AND BOARD

	Land (including under bulldings) £'000	Buildings (excluding dwellings) £'000	Dwellings £'000	Transport Equipment £'000	Plant & Machinery £'000	Information Technology £'000	Furniture & Fittings £'000	Assets Under Construction £'000	Total £'000
Cost or valuation At 1 April 2014	18,878	271,324	2,461	192	71,221	27,492	9,630	4,236	405,434
Additions	0	4,281	0	0	2,210	1,387	60	28,703	36,641
Revaluation	0	6,108	(14)	0	0	0	-	0	6,094
Impairment Charge	(150) 0	(2,844)	0	U	0 (62)	0		0 (148)	(2,994) (210)
Disposals						·······			
At 31 March 2015	18,728	278,869	2,447	192	73,369	28,879	9,690	32,791	444,965
Depreciation		500	•	192	60,285	25,078	6,551	0	92,634
At 1 April 2014 Provided during the year	0	528 8,877	0 81	192	3,998	20,078	1,902	0	92,634
Revaluation	0	(8,903)	(81)	ő	0,550 D	554		D D	(8,984)
Impairment Charge	ŏ	122	ó	ō	Ō	ō	Ō	191	313
Impairment Reversal	0	(32)	0	0	0	0		0	(32)
Disposals	0	0	0	0	(62)	0	0	(148)	(210)
At 31 March 2015	0	592	0	192	64,221	26,012	8,453	43	99,513
Net book value at 1 April 2014	18,878	270,796	2,461	0	10,936	2,414		4,236	312,800
Net book value at 31 March 2015 BS	18,728	278,277	2,447	0	9,148	2,867	1,237	32,748	345,452
	9,698								
Open Market Value of Land in Land and Dweilings included Above Asset financing:									
Asser manuag. Owned	18,728	243,825	2,447	0	9,148	2,867	1,237	11,368	289,620
Finance leased	0,120	1,675	_,	ŏ	0	_,,0	0	0	1,675
On-balance sheet PFI contracts	0	32,777	0	0	0	0	0	21,380	54,157
Net book value at 31 March 2015	18,728	278,277	2,447	0	9,148	2,867	1,237	32,748	345,452

11. (a) PROPERTY, PLANT AND EQUIPMENT (Purchased Assets) - PRIOR YEAR CONSOLIDATED AND BOARD

Cost or valuation At 1 April 2013 Additions Completions Transfers Transfers (to)/from non-current assets held for sale Revaluation	Land (including under buildings) £'000 20,991 0 0 600 (1,363) 0	Bulldings (excluding dwellings) £'000 255,306 1,427 4,723 1,062 (1,354) 10,608	Dwellings £'000 2,482 0 0 0 0 0 (21)	Transport Equipment £'000 201 0 0 0 0 0 0 0	Plant & Machinery £'000 70,282 1,945 0 0 0 0 0 0	Information Technology £'000 27,037 455 0 0 0 0 0 0 0 0 0 0	Furniture & Fittings £'000 9,564 66 0 0 0 0 0	Assets Under Construction £'000 8,831 5,727 (4,723) 0 0 0	Total £'000 394,694 9,620 0 1,652 (2,717) 10,787
Impairment Charge	(1,350)	(648) 0	Ó	0 (9)	0 (1,006)	0	0	0 (5,599)	(1,998) (6,614)
Disposals	0	0	0	(9)	(1,006)	<u>v</u>	0	• , , ,	
At 31 March 2014	18,878	271,324	<u>2,</u> 461	192	71,221	27,492	9,630	4,236	405,434
Depreciation At 1 April 2013 Provided during the year Transfers (to)/from non-current assets held for sale Revaluation Impairment Charge Impairment Reversal Disposals	0 0 (1,000) 1,000 0 0	466 8,472 (42) (8,591) 246 (23) 0	0 80 0 (80) 0 0 0	201 0 0 0 0 0 (9)	56,642 4,649 0 0 0 0 0 (1,006)	23,660 1,418 0 0 0 0	5,545 1,006 0 0 0 0	598 0 0 5,001 0 (5,599)	87,112 15,625 (42) (9,671) 6,247 (23) (6,614)
At 31 March 2014	0	528	0	192	60,285	25,078	6,551	0	92,634
Net book value at 1 April 2013 Net book value at 31 March 2014 <u>B.S</u> Open Market Value of Land In Land and Dwellings included Above	20,991 18,878 9,848	254,840 270,796	2,482 2,461	0	13,640 10,936	3,377 2,414	4,019 3,079	8,233 4,236	307,582 312,800
Asset financing: Owned Finance leased On-balance sheet PFI contracts Net book value at 31 March 2014	18,878 0 	236,933 1,736 <u>32,127</u> 270,79 6	2,461 0 0 2,451	0 0 0	10,936 0 0 10,936	2,414 0 2,414	3,079 0 0 3,079	4,236 0 0 4,236	278,937 1,736 32,127 312,800

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

11. (b) PROPERTY, PLANT AND EQUIPMENT (Donated Assets) - CONSOLIDATED AND BOARD

Cost or valuation	Buildings (excluding dwellings) £'000	Transport Equipment £'000	Plant & Machinery £'000	Information Technology £'000	Furniture & Fittings £'000	Total £'000
At 1 April 2014	4 400	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~				
Additions	1,489	81	4,664	17	112	6,363
Revaluation	0	0	324	0	0	324
	47	0	0	0	0	47
At 31 March 2015	1,536	81	4,988	17	112	6,734
Depreciation						
At 1 April 2014	0	80	3,229	17	102	3,428
Provided during the year	46	1	318	0	10	375
Revaluation	(46)	00	0	0	0	(46)
At 31 March 2015	0	81	3,547	17	112	3,757
Net book value at 1 April 2014	1,489	1	1,435	0	10	2,935
Net book value at 31 March 2015	1,536	0	1,441	0	0	2,977
Asset financing:						
Owned	1,536	0	1,441	0	0	2,977
Net Book Value at 31 March 2015	1,536	0	1,441	0	0	2,977

11. (b) PROPERTY, PLANT AND EQUIPMENT (Donated Assets) - PRIOR YEAR CONSOLIDATED AND BOARD

Cost or valuation	Buildings (excluding dwellings) £'000	Transport Equipment £'000	Plant & Machinery £'000	Information Technology £'000	Furniture & Fittings £'000	Total £'000
At 1 April 2013	1,416	81	4,481	17	112	6,107
Additions	0	0	183	0	0	183
Revaluation	73	ŏ	0	0	0	73
At 31 March 2014	1,489	81	4,664	17	112	6,363
Depreciation At 1 April 2013	0	67	2,861	17	97	3,042
Provided during the year	44	13	368	0	5	3,042
Revaluation	(44)	0	0	0	0	(44)
At 31 March 2014	0		3,229	17	102	3,428
Net book value at 1 April 2013	1,416	14	1,620	0	15	3,065
Net book value at 31 March 2014	<u>BS</u> 1,489	1	1,435	0	10	2,935
Asset financing:						
Owned	1,489	1	1,435	0	10	2,935
Net book value at 31 March 2014	1,489	1	1,435	0	10	2,935

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

11 (c). ASSETS HELD FOR SALE - BOARD AND CONSOLIDATED

The following assets relate to former hospitals and health centre/clinic sites have been presented as held for sale following the approval for sale by the NHS Board:

Strathlea Resource Centre, Girvan Health Centre, Nightingale House, Seafield Old OPD and Heathfield Site. The completion date for sale is expected to be prior to the 31st March 2016.

Davidson Hospital, Holmhead Hospital Seafield House, Land at Ayrshire Central, Miller Road Ayr, Strathdoon Resource Centre, Kilwinning Clinic and Prestwick Clinic were sold in 2014/15.

2014 Property, Plant & Equipment				2015 Property, Plant & Equipment
£'000 2,630		At 1 April		£'000 3,870
2,675	<u>11a</u>	Transfers (to)/from property, plant and equipment Gain or losses recognised on remeasurement of non-	<u>11a</u>	0
(1,083)		current assets held for sale		(498)
(352)		Disposals for non-current assets held for sale		(1,322)
3,870	<u>BS</u>	As at 31 March	<u>BS</u>	2,050

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

11. (d) PROPERTY, PLANT AND EQUIPMENT DISCLOSURES

Consolidated 2014 £'000	Board 2014 £'000	Net book value of property, plant and equipment at 31		Consolidated 2015 £'000	Board 2015 £'000
312,800	312,800	March Purchased	41.	245 450	045 450
2,935	2,935	Donated	<u>11a</u> <u>11b</u> _	345,452 2,977	345,452 2,977
315,735	315,735	Total	<u>BS</u> _	348,429	348,429
		Net book value related to land valued at open market value			
9,848	9,848	at 31 March	_	9,698	9,698
25,435	25,435	Net book value related to buildings valued at open market value at 31 March	-	25,345	25,345
		Total value of assets held under:			
1,736	1,736	Finance Leases		1,675	1,675
32,127	32,127	PFI and PPP Contracts	_	54,157	54,157
33,863	33,863		_	55,832	55,832
		Total depreciation charged in respect of assets held under:			
61	61	Finance leases		61	61
1,435	1,435	PFI and PPP contracts	_	1,622	1,622
1,496	1,496		_	1,683	1,683

Land and buildings were fully revalued by the Valuation Office Agency as at 31st March 2015 on the basis of fair value (market value or depreciated replacement cost where appropriate).

The net impact was an increase in the value of purchased assets of £11.398m (2013/14 increase of £11.271m) of which £12.177m was charged to the Revaluation Reserve (2013/14 £18.577m) and £0.779m was charged to the Statement of Comprehensive Net Expenditure (2013/14 £7.306m).

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

12. INVENTORIES

Consolidated 2013 £'000	Board 2013 £'000	Consolidated 2014 £'000	Board 2014 £'000		Consolidated 2015 £'000	Board 2015 £'000
3,296	3,296	3,767	3,767 Raw Materials and Consumables		3,849	3,849
3,296	3,296	3,767	3,767 Total Inventories	<u>B S</u>	3,849	3,849

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

13. TRADE AND OTHER RECEIVABLES

Consolidated 2013	Board 2013	Consolidated 2014	Board 2014		Consolidated 2015	Board 2015
£'000	£'000	£'000	£'000	Note Note	£,000	£'0
				NHSScotland		
1,129	1,129	2,279	2,279	Boards	894	8
1,129	1,129	2,279	2,279	Total NHSScotland Receivables	894	8
116	116	179	179	NHS Non-Scottish Bodies	98	
864	864	773	773	VAT recoverable	565	5
2,228	2,228	2,163	2,163	Prepayments	965	g
1,336	1,336	1,202	1,202	Accrued income	1,914	1,9
2,555	2,565	2,604	2,608	Other Receivables	2,863	2,8
2,204 451	2,204 451	9,609 3	9,609 3	Reimbursement of provisions Other Public Sector Bodies	1,462	1,4
10,883	10,893	18,812	18,816	-	3	
		10,0 (2	10,010	Total Receivables due within one year <u>BS</u>	8,764	8,7
				Receivables due after more than one year		
19,285	19,285	23,078	23,078	NHSScotland Reimbursement of Provisions	27,350	27,3
19,285	40.005	00.070				27,0
	19,285	23,078	23,078	Total Receivables due after more than one year <u>B S</u>	27,350	27,3
30,168	30,178	41,890	41,894	TOTAL RECEIVABLES	36,114	36,1
72	72	61	61	The total receivables figure above includes a provision for impairments	of: 46	
		2014	2014		2015	2015
		£'000	£'000	Movements on the provision for impairment of receivables are as follow	s: £'000	2015 £'0
		72	72	At 1 April	61	
		21	21	Provision for impairment	7	
		(32)	(32)	Receivables written off during the year as uncollectible	(22)	(2
	_	61	61	At 31 March	46	
				As of 31 March 2015, receivables with a carrying value of £46k (2014: £61k) were impaired and provided for. The		
				240k (2014, 201k) were impaired and provided for. The		
		2014	2014	amount of the provision was £46k (2014: £61k). The ageing of these receivables is as follows:		
		£'000	£'000	triese receivables is as follows;	2015	2015
		8	8	3 to 6 months past due	£'000 5	£'0
		53	53	Over 6 months past due	41	
		61	61		46	
				The receivables assessed as individually impaired were		
				mainly overseas and dental patients, employees and former employees.		
				Receivables that are less than three months past their due date are not considered impaired. As at 31 March 2015, receivables with a carrying value of £2483k (2014: £3770k)		
				were past their due date but not impaired. The ageing of		
		2014	2014	receivables which are past due but not impaired is as follows:	2015	2015
		£'000 3,635	£'000 3,635	Lin to 3 months nast due	£'000	£'0
		3,635	3,635	Up to 3 months past due 3 to 6 months past due	2,419	2,4
		96	96	Over 6 months past due	5 59	;
	_	3,770	3,770		2,483	2,40

mainly NHS Scotland Health Boards, other Uk Health Authorities, Local Authorities and Universities and there is no history of default from these customers recently.

Concentration of credit risk is limited due to customer base being large and unrelated/government bodies. Due to this, management believe that there is no future credit risk provision required in excess of the normal provision for doubtful receivables.

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

13. TRADE AND OTHER RECEIVABLES

The credit quality of receivables that are neither past due nor impaired is assessed by reference to external credit ratings where available. Where no external credit rating is available, historical information about counterparty default rates is used.

		Receivables that are neither past due nor impaired are shown		
		by their credit risk below;		
2014	2014		2015	2015
£'000	£'000	Counterparties with external credit ratings	£'000	£'00
0	0	A	0	
0	0	BB	0	
0	0	BBB	0	
0	0	Counterparties with no external credit rating:	0	
0	0	New customers	0	
3,770	3,770	Existing customers with no defaults in the past	2,483	2,48
0	0	Existing customers with some defaults in the past	0	
3,770	3,770	Total neither past due or impaired	2,483	2,4
		The maximum exposure to credit risk is the fair value of each		
		class of receivable. The NHS Board does not hold any		
		collateral as security.	0.5.4.5	
2014	2014	The second second of second states are descentioned in the	2015	2015
		The carrying amount of receivables are denominated in the		0100
£'000	£'000	following currencies:	£'000	£'00
41,890	41,894	Pounds	36,114	36,11
41,890	41,894		36,114	36,1

The non-current receivables relate to recoveries from the CNORIS scheme which will be received within 1 month of the associated settlements being made for clinical or employer liability. This could be up to 10 years from the balance sheet date.

The carrying amount of short term receivables approximates their fair value.

The fair value of long term other receivables is £nil (2013-14: £nil)

The effective interest rate on non-current other receivables is 0% (2013-14: 0%). Pension liabilities are discounted at 1.3% (2013-14: 1.8%)

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

14. AVAILABLE FOR SALE FINANCIAL ASSETS

Consolidated 2013 £'000	Board 2013 £'000	Consolidated 2014 £'000	Board 2014 £'000			Consolidated 2015 £'000	Board 2015 £'000
771		0 761	0	Government securities		388	0
10,104		0 10,341	0	Other		12,175	ŏ
10,875		0 11,102	0	TOTAL	<u>B S</u>	12,563	00
9,822		0 10,875	0	At 1 April		11,102	0
3,040		0 2,119	0	Additions		4,880	ŏ
(3,203)		0 (2,270)	0	Disposals		(4,148)	0
1,216		0 378	0	Revaluation surplus/(deficit) transferred to equity		729	<u>0</u>
10,875		0 11,102	0	At 31 March		12,563	0
0		0 0	0	Current	BS	O	0
10,875		0 11,102	0	Non-current	<u>BS</u> BS	12,563	0
10,875		0 11,102	0	At 31 March	20	12,563	0
00		00	0	The carrying value includes an impairment provision of		0_	0

NHS Ayrshire and Arran is entitled to recover the full economic cost of activity within the Hub South West Scotland and has no requirement to under-write any reported trading tosses of the company or its special purpose vehicles. The carrying amount value of the investment is cost less impairment as there is no active market for this equity investment in Hub South West Scotland Ltd.

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

15. CASH AND CASH EQUIVALENTS

	Note	At 01/04/14 £'000	Cash Flow £'000	At 31/03/15 £'000
Government Banking Service account balance		92	2	94
Cash at bank and in hand		23	0	23
Endowment Cash		1,143	(653)	490
Total cash and cash equivalents - balance sheet	<u>B S</u>	1,258	(651)	607
Overdrafts	<u>16</u>		0	0
Total cash - cash flow statement		<u>1,258</u> <u>CFS</u>	(651)	<u>607</u> <u>CFS</u>
CASH AND CASH EQUIVALENTS - PRIOR YEAR	Note	At 01/04/13 £'000	Cash Flow £'000	At 31/03/14 £'000
Government Banking Service account balance		93	(1)	92
Cash at bank and in hand		22	1	23
Endowment Cash		1,018	125	1,143
Total cash and cash equivalents - balance sheet	<u>B S</u>	1,133	125	1,258
Overdrafts	<u>16</u>	0	0	0
Total cash - cash flow statement		<u>1,133</u> <u>CFS</u>	125	1,258 <u>CFS</u>

Cash at bank is with major UK banks. The credit risk associated with cash at bank is considered to be low.

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

	Consolidated 2013 £'000	Board 2013 £'000	Consolidated 2014 £'000	Board 2014 £'000	Payables due within one year	Note	Consolidated 2015 £'000	Board 2015 £'000
3.448 3.448 3.411 3.111 7.111 Train INSEcolutin Dysate 2.310 3.348 1.15 1.13 1.15	2.440	0.440		.	NHSScotland			
1 2 2 1								
115 116 116 <td>2</td> <td>2</td> <td>1</td> <td>. 1</td> <td></td> <td></td> <td></td> <td></td>	2	2	1	. 1				
1136 1132 11080 1038 1038 11392 14522 14322 200 200 1036 10392 10392 14322 14322 14322 200 200 200 10392 10392 10392 11392 <	115	115	115	115	Amounts Payable to General Fund			
20,785 20,785 19,912	3,792							14,522
$\frac{61}{2}$ $\frac{51}{12}$	20,785	20,785	19,912	19,912	Accruals			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	51						306	306
1/221 1/222 1/222 0.000 6,001 6,001 6,001 1/221 1/222 1/221 0.000 1/221 2/2 1/2 2/2 2/2 1/2 2/2 2/2 1/2 1/2 2/2 2/2 1/2 1/2 2/2 1/2 1/2 2/2 1/2 1/2 2/2 1/2 1/2 1/2 2/2 1/2 1/2 1/2 2/2 1/2 1/2 1/2 1/2 1/2 1/2 2/2 1/2 1/2 1/2 2/2 1/2 1/2 1/2 2/2 1/2 1/2					Net obligations under Finance Leases	22		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	7,022	7,022	6,900	6,900		<u>23</u>		
$\frac{1}{200} \frac{0}{200} \frac{1}{200} \frac{1}{200} \frac{1}{200} \frac{1}{200} \frac{1}{200} \frac{1}{2000} \frac{1}{$							4,887	4,887
200 2447 357 EC Garbon Emissions 464 454 58,801 68,725 53,242 54,341 64,341 64,342 64,341 64,342 64,341 64,342 64,341 64,342 64,343 64,343 64,343 64,343 64,343 64,343 64,343 64,343 64,343 64,343 64,343	0	0	D	0	VAT			
$\frac{98,891}{2000} + \frac{8728}{2000} + \frac{53242}{2000} + 53$					EC Carbon Emissions Other payables		454	454
13 13 16 MMSScoland 13 13 16 16 Not obligations under Finance Leases due within 2 years 22 00	58,801				Total Payables due within one year	BS		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$					Payables due after more than one year			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	13	13	16	16				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	48	48	56	56	Net obligations under Finance Leases due after 2 years but within 5 years	22		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$					Net obligations under Finance Leases due after 5 years	22	211	211
$\frac{0}{26,702} \frac{0}{26,702} \frac{1,251}{27,037} \frac{1,251}{27,037} \frac{1,273}{27,037} \frac{1,173}{27,037} \frac{1,173}{27,$	2,591	2,591	3,148	3,148	Net obligations under PPP/PFI Contracts due after 2 years but within 5 years	<u>23</u>		
28,702 28,702 27,037 27,037 27,037 27,037 Total Payables due after more than one year BS $\frac{41,735}{41,735}$ $\frac{41,735}{41,735}$ 85,503 65,428 80,279 80,241 TOTAL PAYABLES 102,146 102,044 $\frac{2000}{20,093}$ 20009 20009 PFI Contracts $\frac{2000}{40,932}$ $\frac{2000}{304}$ $\frac{2000}{304}$ $\frac{2014}{20,409}$ $\frac{2014}{26,409}$ $\frac{2014}{26,409}$ The carrying amount and fair value of the non-current borrowings are as follows $\frac{2015}{2000}$ $\frac{2015}{2000}$ $\frac{2015}{2000}$ $\frac{2015}{2000}$ $\frac{2016}{20,409}$ $\frac{2014}{26,409}$ $\frac{2014}{26,274}$ $\frac{2015}{46,2274}$ $\frac{2015}{2015}$ $\frac{2015}{2000}$ $\frac{2000}{200}$ $\frac{2016}{20,274}$ $\frac{2015}{46,2274}$ $\frac{2015}{46,2274}$ $\frac{2015}{46,2274}$ $\frac{2015}{46,2274}$ $\frac{2015}{46,2274}$ $\frac{2015}{46,2274}$ $\frac{2015}{46,2274}$ $\frac{40,692}{46,274}$ $\frac{40,692}{46,274}$ $\frac{40,692}{46,274}$ $\frac{40,692}{46,274}$ $\frac{40,692}{46,274}$	0				Net obligations under PPP/PFI Contracts due after 5 years Deferred income	<u>23</u>		
$\frac{\mathcal{E}'000}{309} \frac{\mathcal{E}'000}{26,409} = \frac{\mathcal{E}'000}{26,409}$ Borrowings included above comprise: Finance Leases PFI Contracts Borrowings are as follows $\frac{\mathcal{E}'000}{25,402} \frac{\mathcal{E}'000}{25,402} = \frac{\mathcal{E}'000}{26,409}$ The carrying amount and fair value of the non-current borrowings are as follows $\frac{\mathcal{E}'000}{25,402} \frac{\mathcal{E}'000}{25,402} = \frac{\mathcal{E}'000}{26,409}$ The carrying amount and fair value of the non-current borrowings are as follows $\frac{\mathcal{E}'000}{25,402} \frac{\mathcal{E}'000}{26,409} = \frac{\mathcal{E}'000}{26,409}$ Fair value $\frac{\mathcal{E}'000}{200} \frac{\mathcal{E}'000}{200} \frac{\mathcal{E}'000}{\mathcal{E}'000} = \frac{\mathcal{E}'000}{\mathcal{E}'000} \frac{\mathcal{E}'00$	26,702	26,702	27,037			BS		
319 319 319 304 200 2000 2000 46,983 46,983 46,983 46,983 46,983 46,983 46,983 46,983 46,983 47,287 46,274 <td>85,503</td> <td>85,428</td> <td>80,279</td> <td>80,241</td> <td>TOTAL PAYABLES</td> <td></td> <td>102,146</td> <td>102,084</td>	85,503	85,428	80,279	80,241	TOTAL PAYABLES		102,146	102,084
319 319 319 304 200 2000 2000 46,983 46,983 46,983 46,983 46,983 46,983 46,983 46,983 46,983 47,287 46,274 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>								
319 319 319 304 200 2000 2000 46,983 46,983 46,983 46,983 46,983 46,983 46,983 46,983 46,983 47,287 46,274 <td></td> <td></td> <td>£'000</td> <td>£'000</td> <td>Borrowings included above comprise:</td> <td></td> <td>01000</td> <td>01000</td>			£'000	£'000	Borrowings included above comprise:		01000	01000
$\frac{26,408}{26,408} = \frac{26,408}{26,408}$ $\frac{10,903}{47,287} = \frac{40,903}{47,287} = \frac{2015}{47,287} = \frac{2015}{46,274} = \frac{2015}{2015} = \frac{2015}{2000} = \frac{2000}{2000} = \frac{2015}{2000} = 2015$			319	319	Finance Leases			
2014 £'000 3042014 £'000 25,482The carrying amount and fair value of the non-current borrowings are as follows Carrying amount and fair value of the non-current borrowings are as follows2015 £'000 2882015 £'000 2882014 25,78625,78626,57846,274 46,27446,274 46,2742014 20142014The carrying amount and fair value of the non-current borrowings are as follows2015 46,2742015 46,2742014 20142014The carrying amount and fair value of the non-current borrowings are as followsFair value £'000 £'000Fair value £'000 £'000Fair value £'000 £'000The carrying amount and fair value of the non-current borrowings are as followsFair value £'000 £'000 2034Fair value £'000 £'000Fair value £'000 £'000Z015 £'000 2038Z015 £'000 20382014 £'000 2042014 £'000 £'000The carrying amount of short term payables approximates their fair value. The carrying amount of payables are denominated in the following currencies:2015 £'000 £'000 £'0002015 £'000		-			PEIContracts			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		_					47,207	47,207
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			2014	2014	The carrying amount and fair value of the non-current borrowings are as follows		2015	2015
$\begin{array}{c c c c c c c c c c c c c c c c c c c $					Carrying amount		£'000	£'000
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		_						
2014 2014 2015 2015 Fair value £'000 Fair value £'000 The carrying amount and fair value of the non-current borrowings are as follows Fair value Fair value £'000 Fair value £'000 </td <td></td> <td></td> <td>25,786</td> <td>25.786</td> <td></td> <td></td> <td></td> <td></td>			25,786	25.786				
Fair value Fair value <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td>40,002</td> <td>40,302</td>		-					40,002	40,302
£'000 £'000 Fair value Fair value Fair value Fair value 304 304 304 Finance Leases 288 288 288 288 288 288 288 288 288 288 288 288 288 288 26,562 46,562 46,562 46,562 46,562 46,562 2015			2014	2014			2015	2015
304 304 304 Finance Leases 200 2015 2015 2015 2015 2000					The carrying amount and fair value of the non-current borrowings are as follows			
25,482 25,482 PF1 Contracts 200 200 25,786 25,786 46,274 46,274 46,274 25,786 25,786 46,562 46,562 46,562 2014 2014 2014 2015 2015 £'000 £'000 The carrying amount of payables are denominated in the following currencies: 2015 2015 90.270 20.244 Downth Downth 20.244 Downth								
2014 2014 2014 2015 2015 £'000 £'000 The carrying amount of payables are denominated in the following currencies: £'000 £'000 £'000		-	25,482	25,482	PFI Contracts			
2014 2015 2015 £'000 £'000 The carrying amount of payables are denominated in the following currencies: £'000 £'000 \$0.270 \$0.241 Downto Downto \$0.270 \$0.241		-	25,786	25,786			46,562	46,562
£'000 £'000 The carrying amount of payables are denominated in the following currencies: £'000 £'000 £'000			2014	201#	The carrying amount of short term payables approximates their fair value.			
80,279 80,241 Pounds 102,146 102,083					The carrying amount of payables are denominated in the following currencies:		2015 £'000	
			80,279	80,241	Pounds		102,146	102,083

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

17. PROVISIONS - CONSOLIDATED AND BOARD

	Pensions and similar obligations £'000	Clinical & Medical Legal Claims against NHS Board £'000	Participation in CNORIS £'000	Other £'000	2015 Total £'000
At 1 April 2014	7,389	33,431	25,264	158	66,242
Arising during the year	516	5,170		661	6,347
Utilised during the year	(590)	(2,613)		(263)	(3,466)
Unwinding of discount	326			• •	326
Reversed unutilised	(73)	(6,940)	(2,998)	(22)	(10,033)
At 31 March 2015	7,568	29,048	22,266	534	59,416

The amounts shown above in relation to Clinical & Medical Legal Claims against NHS Board are stated gross and the amount of any expected reimbursements are separately disclosed as receivables in note 13.

Analysis of expected timing of discounted flows to 31 March 2015

	Pensions and similar obligations £'000	Clinical & Medical Legal Claims against NHS Board £'000	Participation in CNORIS £'000	Other £'000	2015 Total £'000	
Payable in one year	583	1,506	13,137	524	15,750	<u>B S</u>
Pavable between 2 - 5 years	6,985	27,542	9,129	10	43,666	
At 31 March 2015	7,568	29,048	22,266	534	69,416	

PROVISIONS - CONSOLIDATED AND BOARD (PRIOR YEAR)

	Pensions and similar obligations £'000	Clinical & Medical Legal Claims against NHS Board £'000	Participation in CNORIS £'000	Other £'000	2014 Total £'000
At 1 April 2013	7,622	21,911	17,106	140	46,779
Arising during the year	176	13,659	8,158	248	22,241
Utilised during the year	(586)	(1,142)	0	(207)	(1,935)
Unwinding of discount	369	Ó	0	Ó	369
Reversed unutilised	(192)	(997)	0	(23)	(1,212)
At 31 March 2014	7,389	33,431	25,264	158	66,242

The amounts shown above in relation to Clinical & Medical Legal Claims against NHS Board are stated gross and the amount of any expected reimbursements are separately disclosed as receivables in note 13.

Analysis of expected timing of discounted flows - to 31 March 2014

		Clinical & Medical				
	Pensions and	Legal Claims	Participation in		2014	
	similar obligations	against NHS Board	CNORIS	Other	Total	
	£'000	£'000	£'000	£'000	£'000	
Payable in one year	582	9,917		154	10,653 <u>B S</u>	
Payable between 2 - 5 years	6,807	23,514	25,264	4	55,589	
At 31 March 2014	7,389	33,431	25,264	158	66,242	

PROVISIONS - CONSOLIDATED AND BOARD (2013)

	Pensions and similar obligations £'000	Clinical & Medical Legal Claims against NHS Board £'000	Participation in CNORIS £'000	Other £'000	2013 Total £'000
At 1 April 2012	7,146	12,530		127	19,803
Arising during the year	821	15,573	17,106	218	33,718
Utilised during the year	(601)	(5,272)		(158)	(6,031)
Unwinding of discount	274	Ó		0	274
Reversed unutilised	(18)	(920)		(47)	(985)
At 31 March 2013	7,622	21,911	17,106	140	46,779

Analysis of expected timing of discounted flows - to 31 March 2013

	Pensions and similar obligations £'000	Clinical & Medical Legal Claims against NHS Board £'000	Participation in CNORIS £'000	Other £'000	2013 Total £'000
Pavable in one year	609	2,450		114	3,173 <u>BS</u>
Payable between 2 - 5 years	7,013	19,461	17,106	26	43,606
At 31 March 2013	7,622	21,911	17,106	140	46,779

Pensions and similar obligations

The Board meets the additional costs of benefits beyond the normal National Health Service Superannuation Scheme for Scotland benefits in respect of employees who retire early by paying the required amounts annually to the National Health Service Superannuation Scheme for Scotland over the period between early departure and normal retirement date. The Board provides for this in full when the early retirement programme becomes binding by establishing a provision for the estimated payments discounted by the Treasury Discount Rate of 1.30% in real terms. The Board expects expenditure to be charged to this provision for a period of up to 38 years.

Clinical & Medical Legal Claims against NHS Board

The Board holds a provision to meet costs of all outstanding and potential clinical and medical negligence claims. All legal claims notified to the Board are processed by the Scottish NHS Central Legal Office who decide upon risk liability and likely outcomes of each case. The provision contains sums for settlement awards, legal expenses and third party costs. Clinical and medical negligence cases lodged can be extremely complex. It is expected that expenditure will be charged to this provision for a period of up to ten years. The amounts disclosed are stated gross and the amount of any expected reimbursements are shown separately as debtors in the notes to the accounts.

Participation in CNORIS

The Board is required to participate in the Clinical Negligence and Other Risks Indemnity Scheme (CNORIS) and the above provision relates to its share of future settlements. Further details are given in Note 17(b)

Other This relates to provisions for employer or public liability claims which are processed in the same manner as clinical and medical negligence claims described above by the Scottish NHS Central Legal Office with provisions shown gross and the amount of any expected reimbursements shown separately as debtors in the notes to the accounts. The provisions are expected to be settled within the next 2 years. Other provisions include an amount of £107k in respect of the Board's estimated liability arising from equal pay claims.

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

17b. CLINICAL NEGLIGENCE AND OTHER RISKS INDEMNITY SCHEME (CNORIS)

2013 £'000	2014 £'000	Note	2015 £'000
22,051	33,589 Provision recognising individual claims against the NHS Board as at 31 March	17	29.475
	(32,687) Associated CNORIS receivable at 31 March	13	(28.812)
<u>17,106</u> 17,668	25,264 Provision recognising the NHS Board's liability from participating in the scheme at 31 March	17	22,266
	26,166 Net Total Provision relating to CNORIS at 31 March		22,929

The Clinical Negligence and Other Risks Scheme (CNORIS) has been in operation since 2000. Participation in the scheme is mandatory for all NHS boards in Scotland. The scheme allows for risk pooling of legal claims in relation to clinical negligence and other risks and works in a similar manner to an insurance scheme. CNORIS has an agreed threshold of £25k and any claims with a value less than this are met directly from within boards' own budgets. Participants e.g. NHS boards contribute to the CNORIS pool each financial year at a pre-agreed contribution rate based on the risks associated with their individual NHS board. If a claim is settled the board will be reimbursed by the scheme for the value of the settlement, less a £25k "excess" fee. The scheme allows for the risk associated with any large or late in the financial year legal claims to be managed and reduces the level of volatility that individual boards are exposed to.

When a legal claim is made against an individual board, the board will assess whether a provision or contingent liability for that legal claim is required. If a provision is required then the board will also create an associated receivable recognising reimbursement from the scheme if the legal claim settles. The provision and associated receivable are shown in the first two lines above. The receivable has been netted off against the provision to reflect reimbursement from the scheme.

As a result of participation in the scheme, boards should also recognise that they will be required to make contributions to the scheme in future years. Therefore a second provision that recognises the board's share of the total CNORIS liability of NHSScotland has been made and this is reflected in third line above.

Therefore there are two related but distinct provisions required as a result of participation in the scheme. Both of these provisions as well as the associated receivable have been shown in the note above to aid the reader's understanding of CNORIS.

Further information on the scheme can be found at: http://www.clo.scot.nhs.uk/our-services/cnoris.aspx

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

18. MOVEMENT ON WORKING CAPITAL BALANCES

2014 Net Movement £'000		Note	Opening Balances £'000	Closing Balances £'000	2015 Net Movement £'000
(474)	INVENTORIES	10	3,767	3.849	
	Balance Sheet Net Decrease/(Increase)	<u>12</u>	5,107		(82)
	TRADE AND OTHER RECEIVABLES				
	Due within one year	<u>13</u> 13	18,816	8,763	
(3,793)	Due after more than one year	<u>13</u> _	23,078	27,350	
		_	41,894		
(11,722)	Net Decrease/(Increase)	_		-	5,781
	TRADE AND OTHER PAYABLES				
(5,559)	Due within one year	<u>16</u> <u>16</u>	53,204	54,349	
	Due after more than one year	<u>16</u>	27,037	47,735	
	Less: Property, Plant & Equipment (Capital) included in above		(569)	(1,019)	
•	Less: General Fund Creditor included in above	<u>16</u> <u>16</u> 16	(115)	(117)	
	Less: Lease and PFI Creditors included in above	<u>16</u>	(26,408)	(47,287)	
0	Less: Interest payable included in above	<u>16</u>	0	0	
		_	53,149	53,661	
(5,955)	Net (Decrease)/Increase			-	512
	PROVISIONS				
19,463	Balance Sheet	<u>17</u>	66,242	59,416	
19,463	Net (Decrease)/Increase			-	(6,826)
1,315	NET MOVEMENT (Decrease)/increase	<u>CFS</u>		-	(615)

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

19. CONTINGENT LIABILITIES

The following contingent liabilities have not been provided for in the Accounts:

2014 £'000 8,64	Nature 5 Clinical and medical compensation payments	2015 £'000 6,462
310) Employer's liability	127
24	4 Third party liability	26
8,979	TOTAL CONTINGENT LIABILITIES	6,615

The Board has also entered into the following unquantifiable contingent liabilities by offering guarantees, indemnities or by giving letters of comfort. None of these is a contingent liability within the meaning of IAS 37, since the possibility of a transfer of economic benefits in settlement is too remote.

Guarantees

None

Indemnities

The Board has provided an indemnity to Ayrshire Medical Support Ltd to the effect that it will reimburse the company for any additional VAT determined to be chargeable by HMRC on a specified sale of property by the company to the Board.

Letter of comfort None

CONTINGENT ASSETS

8,000 Clinical and medical compensation payments	2.365
125 Employer's liability	2,000
8,125	2.365

20. EVENTS AFTER THE END OF THE REPORTING YEAR

There are no events after the end of the reporting period which would have a material effect on the accounts.

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

21. COMMITMENTS

2015

2014 £'000	Capital Commitments The Board has the following Capital Commitments which have not been included for in the accounts	Property, plant and equipment: £'000
	Contracted	
6,508 190 6,698	Building for Better Care North Ayrshire Community Hospital Adviser Fees Total	12,121 87 12,208
	Authorised but not Contracted	
278 750 0 0 2,159 2,174 157 30 5,548	Board Infrastructure Crosshouse Hospital Value Adding Capital to Save on Revenue - Energy Schemes Biggart management of Road Risk ACH Fifth Steriliser UHC/UHA Endoscopy Regulations UHC Car Parking Arran War Memorial Rehab Other Small Miscellaneous schemes Total	0 750 540 130 104 0 60 0 0 0 1,584

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

22. COMMITMENTS UNDER LEASES

2014	Operating Leases		2015
£'000	Total future minimum lease payments under operating leases are given in the table below for the each of the following periods.		£'000
			2000
	Obligations under operating leases comprise: Land		
0	Not later than one year		10
0	Later than one year, not later than 2 years		10
0	Later than two year, not later than five years		29
10	Later than five years		84
	Buildings		
0	Not later than one year		46
0	Later than one year, not later than 2 years		35
13	Later than two year, not later than five years		41
43	Later than five years		0
	Other		
229	Not later than one year		205
	Amounts charged to Operating Costs in the year were:		
229	Hire of equipment (including vehicles)		205
65	Other operating leases		70
294	Total		275
2014	Finance Leases		
2014	Total future minimum lease payments under finance leases are given the		2015
£'000	in the table below for the each of the following periods.		£'000
			2000
	Obligations under Finance leases comprise: Buildings		
33	Rentals due within one year	16	22
33	Rentals due between one and two years (inclusive)	<u>16</u> <u>16</u>	33 33
99	Rentals due between two and five years (inclusive)	<u>16</u>	99
289	Rentals due after five years	<u>16</u>	256
454	·		421
(135)	Less interest element		(117)
319			304
	This total net obligation under finance leases is analysed in Note 16 (Payables)		
	Aggregate Rentals Receivable in the year		
219	Total of finance & operating leases		222

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

23. COMMITMENTS UNDER PFI CONTRACTS - On Balance Sheet

The Board has entered into the following PFI contracts-

East Ayrshire Community Hospital is situated in the town of Cunnock. The facility provides inpatient beds, Elderly Mental III, and GP Acute; there are day facilities for Frail Elderly and Elderly Mental III and Outpatient Clinics (including AHP's). The 25 year contract commenced in August 2000 and will end in August 2025. At the end of the 25 year contract period, negotiations will be undertaken to determine options available.

Ayrshire Maternity Unit - is adjoined to Crosshouse Hospital in Kilmarnock. The facility provides Area Midwifery services for in-patients, day patients, and out-patients. The 30 year contract commenced in July 2006 and will be completed in July 2036. At the end of this period, the building is available for transfer to the NHS at no additional cost.

North Ayrshire Community Hospital - Year 1 recognition of Non-Profit Distributing (NPD) element of Work In Progress. Mental Health. Frail Elderly Inpatient Facility due to be handed over in March 2016.

Under IFRIC 12 the asset is treated as an asset of the Board and included in the Board's accounts as a Non current asset. The liability to pay for the property is in substance a finance lease obligation. Contractual payments therefore comprise two elements; imputed finance lease charges and service charges. The imputed finance lease obligation is as follows:

Total obligations under on-balance sheet PFI/PPP contracts for the following periods comprises:

2013 £'000	2014 £'000	Gross Minimum Lease Payments	EACH £'000	AMU 000'£	NACH £'000	2015 Total £'000
3,655	3,852	Rentals due within 1 year	1,826	1,816	0	3,642
3,510	3,697	Due within 1 to 2 years	1,855	1,890	0	3,745
11,223	11,293	Due within 2 to 5 years	5,795	5,595	0	11,390
44,190	39,670	Due after 5 years	7,455	31,235	21,380	60,070
62,578	58,512	Total	16,931	40,536	21,380	78,847
2013	2014	Less Interest Element	EACH	AMU	NACH	2015 Total
£'000	£'000		£'000	£'000	£'000	£'000
(3,213)	(3,245)	Rentals due within 1 year	(1,463)	(1,470)	0	(2,933)
(2,993)	(2,907)	Due within 1 to 2 years	(1,383)	(1,470)	0	(2,853)
(8,632)	(8,145)	Due within 2 to 5 years	(3,408)	(4,174)	0	(7,582)
(20,928)	(18,126)	Due after 5 years	(1,656)	(16,840)	0	(18,496)
(35,766)	(32,423)	Total	(7,910)	(23,954)	0	(31,864)
2013	2014	Present value of minimum lease payments	EACH	AMU	NACH	2015 Total
2013 £'000	2014 £'000	Present value of minimum lease payments	EACH £'000	AMU £'000	NACH £'000	2015 Total £'000
		Present value of minimum lease payments Rentals due within 1 year				£'000 709
£'000	£'000		£'000	£'000	£'000	£'000 709 892
£'000 442	£'000 607	Rentals due within 1 year	£'000 363 472 2,387	£'000 346	£'000 0	£'000 709
£'000 442 517	£'000 607 790	Rentals due within 1 year Due within 1 to 2 years	£'000 363 472 2,387 5,799	£'000 346 420 1,421 14,395	£'000 0 0 21,380	£'000 709 892 3,808 41,574
£'000 442 517 2,591	£'000 607 790 3,148	Rentals due within 1 year Due within 1 to 2 years Due within 2 to 5 years	£'000 363 472 2,387	£'000 346 420 1,421	£'000 0 0 0	£'000 709 892 3,808
£'000 442 517 2,591 23,262	£'000 607 790 3,148 21,544	Rentals due within 1 year Due within 1 to 2 years Due within 2 to 5 years Due after 5 years	£'000 363 472 2,387 5,799 9,021	£'000 346 420 1,421 14,395	£'000 0 0 21,380	£'000 709 892 3,808 41,574
£'000 442 517 2,591 23,262	£'000 607 790 3,148 21,544	Rentals due within 1 year Due within 1 to 2 years Due within 2 to 5 years Due after 5 years	£'000 363 472 2,387 5,799	£'000 346 420 1,421 14,395	£'000 0 0 21,380	£'000 709 892 3,808 41,574
£'000 442 517 2,591 23,262 26,812	£'000 607 790 3,148 21,544 26,089	Rentals due within 1 year Due within 1 to 2 years Due within 2 to 5 years Due after 5 years	£'000 363 472 2,387 5,799 9,021 2015 Total	£'000 346 420 1,421 14,395	£'000 0 0 21,380	£'000 709 892 3,808 41,574
£'000 442 517 2,591 23,262 26,812 2013	£'000 607 790 3,148 21,544 26,089 2014	Rentals due within 1 year Due within 1 to 2 years Due within 2 to 5 years Due after 5 years	£'000 363 472 2,387 5,799 9,021 2015 Total £'000	£'000 346 420 1,421 14,395	£'000 0 0 21,380	£'000 709 892 3,808 41,574
£'000 442 517 2,591 23,262 26,812 2013 Total	£'000 607 790 3,148 21,544 26,089 2014 Total	Rentals due within 1 year Due within 1 to 2 years Due within 2 to 5 years Due after 5 years	£'000 363 472 2,387 5,799 9,021 2015 Total £'000 1,779	£'000 346 420 1,421 14,395	£'000 0 0 21,380	£'000 709 892 3,808 41,574
£'000 442 517 2,591 23,262 26,812 2013 Total £'000	£'000 607 790 3,148 21,544 26,089 2014 Total £'000	Rentals due within 1 year Due within 1 to 2 years Due within 2 to 5 years Due after 5 years Total	£'000 363 472 2,387 5,799 9,021 2015 Total £'000 1,779 3,495	£'000 346 420 1,421 14,395	£'000 0 0 21,380	£'000 709 892 3,808 41,574
£'000 442 517 2,591 23,262 26,812 2013 Total £'000 1,687	£'000 607 790 3,148 21,544 26,089 2014 Total £'000 1,724	Rentals due within 1 year Due within 1 to 2 years Due within 2 to 5 years Due after 5 years Total	£'000 363 472 2,387 5,799 9,021 2015 Total £'000 1,779	£'000 346 420 1,421 14,395	£'000 0 0 21,380	£'000 709 892 3,808 41,574

2013	2014		2015
£'000	£'000		£'000
189	126	Contingent rents (included in Other charges)	146

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

24. PENSION COSTS

(a)The Board participates in the NHS Superannuation Scheme (Scotland). The scheme is an unfunded statutory public service pension scheme with benefits underwritten by the UK Government. The scheme is financed by payments from employers and from those current employees who are members of the scheme and paying contributions at progressively higher marginal rates based on pensionable pay, as specified in the regulations. The rate of employer contributions is set with reference to a funding valuation undertaken by the scheme actuary. The last four-yearly valuation was undertaken as at 31st March 2012. The next valuation will be as at 31 March 2016 and this will set contribution rates from 1 April 2019.

(b) The Board has no liability for other employers obligations to the multi-employer scheme.

(c) As the scheme is unfunded there can be no deficit or surplus to distribute on the wind-up of the scheme or withdrawal from the scheme.

(d) (i) The scheme is an unfunded multi-employer defined benefit scheme.

(ii) It is accepted that the scheme can be treated for accounting purposes as a defined contribution scheme in circumstances where the Board is unable to identify its share of the underlying assets and liabilities of the scheme.

(iii) The employer contribution rate for the period from 1 April 2015 will be 14.9% of pensionable pay. While the employee rate applied is a variable it will provide an actuarial yield of 9.8% of pensionable pay.

(iv) At the last valuation a shortfall of £1.4 billion was identified in the notional fund which will be repaid by a supplementary rate of 2.6% of employers pension contributions for fifteen years from 1 April 2015. This contribution is included in the 14.9% employers contribution rate.

(v) The Board's level of contribution was 5.3 % based on the proportion of employer contributions paid in 2013-14.

	2015 £'000	2014 £'000
Pension cost charge for the year	35,221	34,038
Additional Costs arising from early retirement	769	603
Provisions/Liabiltities/Pre-payments included in the Balance Sheet	1,934	1,954

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

25. EXCEPTIONAL ITEMS AND PRIOR YEAR ADJUSTMENTS

Prior year adjustments which have been recognised in these Accounts are:

		Dr. £000	Cr. £000
Adjustment 1	Retrospective Restatement Dr Compensation Payments (Note 7) Cr Provisions (Note 17)	8,158	8,158
	To effect retrospective restatement in these accounts arising from the changes to the accounting treatment for CNORIS as set out at Notes 1 and 17(b)		
	Opening balance adjustment Dr General Fund Cr Provisions (Note 17)	17,106	17,106
	The opening general fund balance for 2013/14 has been		

The opening general fund balance for 2013/14 has been reduced by £17,106k. This amount represents the Board's share of the total liability of NHSScotland as at 31st March 2013 as advised by the Scottish Government and based on information prepared by NHS Boards and the Central Legal Office. This amount is also recognised at Note 17.

NHS AYRSHIRE AND ARRAN NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 MARCH 2015

26a. RESTATED SOCNE

	Previous Accounts £'000	Adjustment 1 £'000	These Accounts £'000
Clinical Services Costs	2000	2,000	2.000
Hospital and Community	580,901		580,901
Less: Hospital and Community Income	24,714		24,714
	556,187	0	556,187
Family Health Services	176,132		176,132
Less: Family Health Services Income	5,243		5,243
	170,889	0	170,889
Total Clinical Services Costs	727,076	0	727,076
Administration Costs	2,958		2,958
Less: Administration Income	14		14
	2,944	0	2,944
Other Non Clinical Services	12,609	8,158	20,767
Less: Other Operating Income	15,780		15,780
	(3,171)	8,158	4,987
Net Operating Costs	726,849	8,158	735,007

NHS AYRSHIRE AND ARRAN NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 MARCH 2015

26b. RESTATED BALANCE SHEET	Previous Accounts £'000	Adjustment 1 £'000	These Accounts £'000
Non-current assets Property, plant and equipment Intangible assets Financial assets:	315,735 0		315,735 0
Available for sale financial assets Trade and other receivables	0 23,078 338,813	0	0 <u>23,078</u> 338,813
CURRENT ASSETS Inventories	3,767		3,767
Financial assets: Trade and other receivables Cash and cash equivalents Available for sale financial assets	18,816 115 0		18,816 115 0
Available for sale infancial assets Assets classified as held for sale	3,870 26,568	0	3,870 26,568
TOTAL ASSETS	365,381	0	365,381
CURRENT LIABILITIES Provisions Financial liabilities:	(10,653)		(10,653)
Trade and other payables TOTAL CURRENT LIABILITIES	(53,204) (63,857)	0	(53,204) (63,857)
NON-CURRENT ASSETS PLUS/LESS NET CURRENT ASSETS/LIABILITIES	301,524	0	301,524
Non-current liabilities Provisions	(30,325)	(25,264)	(55,589)
Financial liabilities: Trade and other payables	(27,037)		(27,037)
Total non-current liabilities	(57,362)	(25,264)	(82,626)
Assets less liabilities	244,162	(25,264)	218,898
TAXPAYERS' EQUITY General Fund Revaluation Reserve	176,514 67,648	(25,264)	151,250 67,648
Total taxpayers' equity	244,162	(25,264)	218,898

NHS AYRSHIRE AND ARRAN NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 MARCH 2015

26c. RESTATED CASH FLOW STATEMENT

Previous AccountsAdjustment 1 £'000These Accounts £'000Cash flows from operating activities(3,158)(735,007)Net operating cost(726,849)(8,158)(735,007)Adjustments for non-cash transactions21,51321,51321,513Add back interest payable recognised in net operating cost(320)(320)(Increase) / decrease in trade and other receivables(11,722)(11,722)(Increase) / decrease in inventories11,3058,15819,463Net cash outflow from operating activities(708,726)0(708,726)Cash flows from investing activities(708,726)0(708,726)Purchase of property, plant and equipment interest received(8,141)(8,141)(8,141)Investment additions(2,119)(2,119)(2,119)Proceeds of disposal of property, plant and equipment interest received320320320Net cash outflow from investing activities720,687720,687720,687Funding720,6870720,687028,69Movement in general fund working capital on-balance sheet PFI contracts interest paid(3,404)(3,404)(3,404)Net finance leases and on-balance sheet PFi/PPP contracts(1,1331,1331,133Cash and cash equivalents at the beginning of the period1250125Reconciliation of net cash flow to movement in net debt/cash at 1 April1,25801,258Net debt/cash at 31 March1,25801,258<	26c. RESTATED CASH FLOW STATEMENT			
Cash flows from operating activities(726,849)(8,158)(735,007)Adjustments for non-cash transactions21,51321,5133,773Adjustments for non-cash transactions21,513(320)(320)(increase) / decrease in trade and other receivables(11,722)(11,722)(increase) / decrease in inventories		Accounts	- 1	Accounts
Adjustments for non-cash transactions21,513(1,00)(1,00)Add back: interest payable recognised in net operating cost3,7733,773Deduct: interest receivables contrasts(11,722)(11,722)(Increase) / decrease in inventories(11,722)(11,722)(Increase) / decrease) in trade and other payables(5,955)(5,955)Increase / (decrease) in trade and other payables(5,955)(708,726)Increase / (decrease) in trade and other payables(11,722)(11,722)(Increase) / decrease) in trade and other payables(5,955)(708,726)Cash flows from investing activities(708,726)0(708,726)Purchase of property, plant and equipment(8,141)(8,141)(8,141)Investment additions(2,119)(2,119)(2,119)Proceeds of disposal of property, plant and equipment355355Stop (1,00)320032003200Net cash outflow from investing activities(7,315)0(7,315)Cash flows from financing activities(7,315)0(7,315)Cash flows from financing activities(369)(369)0Capital element of payments in respect of finance leases(369)(369)Interest element of finance leases and on-balance sheet(748)(748)Pi//PPP contracts(3404)(3,404)(3,404)Net lenent of finance leases and on-balance sheet1,25801,256Pi//PPP contracts(369)(369)(369)(369)Interest element	Cash flows from operating activities			2000
Adjustments for non-cash transactions21,51321,513Add back: interest payable recognised in net operating cost(320)(320)(Increase) / decrease in inventories(11,722)(11,722)(Increase) / decrease in inventories(471)(471)Increase / (decrease) in trade and other payables(5,955)(5,955)Increase / (decrease) in provisions11,3058,158Net cash outflow from operating activities(708,726)0Purchase of property, plant and equipment(8,141)(8,141)Investment additions(2,119)(2,119)Proceeds of disposal of property, plant and equipment355355Cash flows from investing activities(7,315)0Purchase / decrease in received32003220Net cash outflow from investing activities(7,315)0(7,315)Cash flows from financing activities720,687720,6870Funding720,6870720,6870Movement in general fund working capital000Cash drawn down720,6870720,687Capital element of finance leases and on-balance sheet(748)(748)Pir/PPP contracts(3404)(3,404)Pir/PPP contracts(369)(369)Cash and cash equivalents at the beginning of the period1250Cash and cash equivalents at the end of the period1,2580Cash and cash equivalents at the end of the period1,2580Cash and cash equivalents at the end of	Net operating cost	(726,849)	(8,158)	(735.007)
Add back: interest payable recognised in net operating cost3,7733,773Deduct: interest receivable recognised in net operating cost(320)(320)(Increase) / decrease in trade and other receivables(11,722)(11,722)(Increase) / decrease in inventories(471)(471)Increase / (decrease) in trade and other payables(5,955)(5,955)Increase / (decrease) in provisions(1,3058,158Net cash outflow from operating activities(708,726)0Cash flows from investing activities(2,119)(2,119)Proceeds of disposal of property, plant and equipment(3553555receipts from the sale of investing activities(7,315)0(7,315)Cash flows from financing activities(7,315)0(7,315)Cash flows from financing activities720,687720,687720,687Funding720,6870720,6870Movement in general fund working capital000Cash flows from financing activities(748)(748)(748)Interest paid(369)(369)(369)(369)Interest paid(369)(369)(369)(369)Interest paid1250125Net Increase / (decrease) in cash and cash equivalents1,25801,258In the period1,25801,25801,258Reconciliation of net cash flow to movement in net debt/cash1,1031,1331,133Increase / (decrease) in cash in year125	Adjustments for non-cash transactions		(-)/	
Deduct: interest receivable recognised in net operating cost(320)(320)(Increase) / decrease in inventories(11,722)(11,722)(Increase) / decrease in inventories(471)(471)Increase / (decrease) in trade and other payables(5,955)(5,955)Increase / (decrease) in provisions11,3058,15819,463Net cash outflow from operating activities(708,726)0(708,726)Cash flows from investing activities(2,119)(2,119)(2,119)Purchase of property, plant and equipment(8,141)(8,141)(8,141)Investment additions(2,270)32203220Interest received320320320Net cash outflow from investing activities(7,316)0(7,316)Cash flows from financing activities720,687720,687720,687Funding720,6870720,6870Movement in general fund working capital000Cash drawn down720,6870720,6870Cash drawn down720,6870720,6870Cash and cash equivalents at the beginning of the period(3,404)(3,404)(3,404)Net finance leases and on-balance sheet(1,1331,1331,133Pri/PPP contracts(1,25801,256Reconciliation of net cash flow to movement in net debt/cash12501,256Net debt/cash at 1 April1,1331,1331,1331,133Net debt/cash at 1 April1,255 <t< td=""><td>Add back: interest payable recognised in net operating cost</td><td></td><td></td><td></td></t<>	Add back: interest payable recognised in net operating cost			
(Increase) / decrease in trade and other receivables(11,722)(11,722)(Increase) / decrease) in trade and other payables(471)(471)Increase / (decrease) in trade and other payables(5,955)(5,955)Increase / (decrease) in provisions11,3058,15819,463Net cash outflow from operating activities(708,726)0(708,726)Cash flows from investing activities(2,119)(2,119)(2,119)Purchase of property, plant and equipment355355receipts from the sale of investments2,2702,270Interest received320320Net cash outflow from investing activities(7,316)0Funding720,687720,687Movement in general fund working capital00Cash flows from financing activities(748)(748)Funding720,6870720,687Movement in general fund working capital00Cash drawn down720,6870Cash drawn down720,6870Cash and cash equivalents at the beginning of the period(3,404)(3,404)Net Increase / (decrease) in cash and cash equivalents at the beginning of the period1250Reconciliation of net cash flow to movement in net debt/cash at 1 April1,1331,133Net debt/cash at 1 April1,1331,133Net debt/cash at 1 April1,1331,133	Deduct: interest receivable recognised in net operating cost	(320)		
(Increase / (decrease) in trade and other payables(471)(471)Increase / (decrease) in provisions11.3058.15819.463Net cash outflow from operating activities(708,726)0(708,726)Cash flows from investing activities(708,726)0(708,726)Purchase of property, plant and equipment(8.141)(8.141)(8.141)Investment additions(2.119)(2.119)(2.119)Proceeds of disposal of property, plant and equipment355355receipts from the sale of investments2.2702.270Interest received320320Net cash outflow from investing activities(7.315)0Funding720,687720,687Movement in general fund working capital00Cash flows from finance leases and on-balance sheet(369)(369)Interest paid(1133)(1,33)(1,33)Interest paid(125)0125Net Increase / (decrease) in cash and cash equivalents1250125Net Increase / (decrease) in cash and cash equivalents1,1331,133Cash and cash equivalents at the end of the period1,25801,258Reconciliation of net cash flow to movement in net1250125Net debt/cash1,25801,2581,258Net debt/cash at 1 April1,1331,1331,133Net bet/cash at 1 April1,1331,1331,133		(11,722)		
Increase / (decrease) in trade and other payables(5,955)(5,955)Increase / (decrease) in provisions11,3058,15819,463Net cash outflow from operating activities(708,726)0(708,726)Cash flows from investing activities(8,141)(8,141)Purchase of property, plant and equipment(8,141)(8,141)Investment additions(2,119)(2,119)Proceeds of disposal of property, plant and equipment355355receipts from the sale of investments2,2702,270Interest received320320Net cash outflow from investing activities(7,315)0Funding720,6870720,687Movement in general fund working capital00Cash drawn down720,6870720,687Capital element of payments in respect of finance leases(369)(369)Interest paid(3404)(3,404)(3,404)Net Financing716,1660716,166Net Increase / (decrease) in cash and cash equivalents1250125Net cash equivalents at the beginning of the period1,25801,258Cash and cash equivalents at the end of the period1,25801,258Reconcillation of net cash flow to movement in net debt/cash at 1 April1,1331,133Net debt/cash at 1 April1,1331,1331,133				
Increase / (decrease) in provisions11,3058,15819,463Net cash outflow from operating activities(708,726)0(708,726)Cash flows from investing activities(8,141)(8,141)(8,141)Purchase of property, plant and equipment(8,141)(8,141)(8,141)Investment additions(2,119)(2,119)(2,119)Proceeds of disposal of property, plant and equipment355355receipts from the sale of investments2,2702,270Interest received3220320Net cash outflow from investing activities(7,315)0Cash flows from financing activities720,687720,687Funding720,6870720,687Movement in general fund working capital00Cash drawn down720,6870720,687Capital element of payments in respect of finance leases(369)(369)Interest paid(3,404)(3,404)Net marcing716,1660Net Increase / (decrease) in cash and cash equivalents1250In the period1,1331,133Cash and cash equivalents at the end of the period1,2580Reconciliation of net cash flow to movement in net debt/cash at 1 April1,1331,133Net debt/cash at 1 April1,1331,133	Increase / (decrease) in trade and other payables	(5,955)		
Net cash outflow from operating activities(708,726)0(708,726)Cash flows from investing activitiesPurchase of property, plant and equipment(8,141)(8,141)Investment additions(2,119)(2,119)(2,119)Proceeds of disposal of property, plant and equipment355355receipts from the sale of investments2,2702,270Interest received320320Net cash outflow from investing activities(7,315)0(7,315)Cash flows from financing activities720,687720,6870Funding720,6870720,6870Movement in general fund working capital000Cash drawn down720,6870720,6870Capital element of payments in respect of finance leases(748)(748)(748)Interest paid(369)(369)(369)(369)Interest paid(3404)(3,404)(3,404)(3,404)Net Increase / (decrease) in cash and cash equivalents at the beginning of the period1,25801,258Cash and cash equivalents at the end of the period1,25801,2580Reconciliation of net cash flow to movement in net debt/cash1250125125Net debt/cash at 1 April1,1331,1331,1331,133		11,305	8,158	
Purchase of property, plant and equipment(8,141)(8,141)Investment additions(2,119)(2,119)Proceeds of disposal of property, plant and equipment355355receipts from the sale of investments2,2702,270Interest received320320Net cash outflow from investing activities(7,315)0(7,315)Cash flows from financing activities720,687720,6870Funding720,6870720,6870Movement in general fund working capital000Cash drawn down720,6870720,6870Capital element of payments in respect of finance leases(369)(369)(369)Interest paid(369)(369)(369)(369)Interest paid(3404)(3,404)(3,404)(3,404)Net Increase / (decrease) in cash and cash equivalents11331,1331,133Cash and cash equivalents at the beginning of the period1,25801,258Reconciliation of net cash flow to movement in net debt/cash1250125Net debt/cash1,1331,1331,1331,133Net debt/cash at 1 April1,1331,1331,133Net debt/cash at 1 April1,1331,1331,133	Net cash outflow from operating activities	(708,726)	0	
Purchase of property, plant and equipment(8,141)(8,141)Investment additions(2,119)(2,119)Proceeds of disposal of property, plant and equipment355355receipts from the sale of investments2,2702,270Interest received320320Net cash outflow from investing activities(7,315)0(7,315)Cash flows from financing activities720,687720,6870Funding720,6870720,6870Movement in general fund working capital000Cash drawn down720,6870720,6870Capital element of payments in respect of finance leases(369)(369)(369)Interest paid(369)(369)(369)(369)Interest paid(3404)(3,404)(3,404)(3,404)Net Increase / (decrease) in cash and cash equivalents11331,1331,133Cash and cash equivalents at the beginning of the period1,25801,258Reconciliation of net cash flow to movement in net debt/cash1250125Net debt/cash1,1331,1331,1331,133Net debt/cash at 1 April1,1331,1331,133Net debt/cash at 1 April1,1331,1331,133	Cash flows from investing activities			
Investment additions(2,119)(2,119)Proceeds of disposal of property, plant and equipment355355receipts from the sale of investments2,2702,270Interest received320320Net cash outflow from investing activities(7,315)0Cash flows from financing activities(7,315)0Funding720,687720,687Movement in general fund working capital00Capital element of payments in respect of finance leases720,6870and on-balance sheet PFI contracts(748)(748)Interest paid(369)(369)(369)Interest paid(3,404)(3,404)PFI/PPP contracts(3,404)(1,404)Net Increase / (decrease) in cash and cash equivalents1250In the period1,1331,133Cash and cash equivalents at the end of the period1,2580Reconciliation of net cash flow to movement in net1250125Net debt/cash1,1331,1331,133Increase/(decrease) in cash in year1250125Net debt/cash t1 April1,1331,1331,133	Purchase of property, plant and equipment	(0 1 4 1)		(0.4.44)
Proceeds of disposal of property, plant and equipment receipts from the sale of investments(1, 110) 355(1, 110) receipts from the sale of investments2,270320320Net cash outflow from investing activities(7,315)0(7,315)Cash flows from financing activities720,687720,6870Funding720,6870720,6870Movement in general fund working capital000Cash flows from finance sheet of payments in respect of finance leases and on-balance sheet PFI contracts(748)(748)Interest paid(369)(369)(369)(369)Interest element of finance leases and on-balance sheet(3,404)(3,404)PFI/PPP contracts(3,404)(3,404)(3,404)Net Increase / (decrease) in cash and cash equivalents in the period1250125Reconciliation of net cash flow to movement in net debt/cash1250125Net debt/cash1,1331,1331,133Net debt/cash at 1 April1,1331,1331,133				
receipts from the sale of investments2,2702,270Interest received320320Net cash outflow from investing activities(7,315)0Cash flows from financing activities720,687720,687Funding720,68700Movement in general fund working capital00Cash drawn down720,6870720,687Capital element of payments in respect of finance leases748)(748)Interest paid(369)(369)(369)Interest paid(369)(3404)Interest element of finance leases and on-balance sheet716,1660PFI/PPP contracts(3,404)(3,404)Net Increase / (decrease) in cash and cash equivalents in the period1,2580Cash and cash equivalents at the beginning of the period1,25801,258Reconciliation of net cash flow to movement in net debt/cash1,1331,1331,133Increase/(decrease) in cash in year1250125Net debt/cash at 1 April1,1331,1331,133Net debt/cash1,2681,2581,133Net debt/cash1,2681,2581,133Net debt/cash1,2681,255Net debt/cash1,1331,133Net debt/cash1,2681,133Net debt/cash1,1331,133Net debt/cash1,2681,258Net debt/cash1,2681,258Net debt/cash1,2681,258Net debt/cash1,268 <td></td> <td></td> <td></td> <td></td>				
Interest received320320Net cash outflow from investing activities(7,315)0(7,315)Cash flows from financing activities(7,315)0(7,315)Funding720,687720,68700Movement in general fund working capital000Cash drawn down0720,6870720,687Capital element of payments in respect of finance leases748)(748)(748)Interest paid(369)(369)(369)(369)Interest element of finance leases and on-balance sheet(3404)(3,404)(3,404)PFI/PPP contracts(3404)(3,404)(3,404)(3,404)Net Increase / (decrease) in cash and cash equivalents in the period1250125Cash and cash equivalents at the beginning of the period1,1331,1331,258Reconciliation of net cash flow to movement in net debt/cash1250125Increase/(decrease) in cash in year1250125Net debt/cash at 1 April1,1331,1331,133Net debt/cash1 April1,1331,133	receipts from the sale of investments			
Net cash outflow from investing activities320Cash flows from financing activitiesFunding(7,315)Cash flows from financing activitiesFunding720,687Movement in general fund working capital0Cash drawn down720,687Capital element of payments in respect of finance leasesand on-balance sheet PFI contracts(748)Interest paid(369)Interest paid(369)Interest element of finance leases and on-balance sheetPFI/PPP contracts(3,404)Net Increase / (decrease) in cash and cash equivalentsin the period1,133Cash and cash equivalents at the beginning of the periodCash and cash equivalents at the end of the period1,258Reconciliation of net cash flow to movement in net debt/cashIncrease/(decrease) in cash in year125Net debt/cash at 1 April1,133Net debt/cash at 1 April1,133Net debt/cash at 1 April1,133				
Cash flows from financing activitiesFunding720,687Movement in general fund working capital0Cash drawn down720,687Capital element of payments in respect of finance leasesand on-balance sheet PFI contracts(748)Interest paid(369)Interest paid(3404)Interest element of finance leases and on-balance sheetPFI/PPP contracts(3,404)Net Increase / (decrease) in cash and cash equivalentsin the period1,133Cash and cash equivalents at the beginning of the periodperiod1,133Cash and cash equivalents at the end of the periodReconciliation of net cash flow to movement in net debt/cashIncrease/(decrease) in cash in yearNet debt/cashNet debt/cash at 1 AprilNet debt/cash at 1 AprilNet debt/cash				
Funding720,687720,687Movement in general fund working capital00Cash drawn down720,6870Capital element of payments in respect of finance leases720,6870and on-balance sheet PFI contracts(748)(748)Interest paid(369)(369)(369)Interest element of finance leases and on-balance sheet(3404)(3,404)PFI/PPP contracts(3,404)(3,404)Net Financing716,1660716,166Net Increase / (decrease) in cash and cash equivalents in the period1250125Cash and cash equivalents at the beginning of the period1,25801,258Reconciliation of net cash flow to movement in net debt/cash Increase/(decrease) in cash in year1250125Net debt/cash and cash equivalents at 1 April1,1331,1331,133Net debt/cash and cash at 1 April1,1331,1331,133		(1,010)	V	(7,315)
Funding720,687720,687Movement in general fund working capital00Cash drawn down720,6870Capital element of payments in respect of finance leases720,6870and on-balance sheet PFI contracts(748)(748)Interest paid(369)(369)(369)Interest element of finance leases and on-balance sheet(3404)(3,404)PFI/PPP contracts(3,404)(3,404)Net Financing716,1660716,166Net Increase / (decrease) in cash and cash equivalents in the period1250125Cash and cash equivalents at the beginning of the period1,1331,1331,133Cash and cash equivalents at the end of the period1,25801,258Reconciliation of net cash flow to movement in net debt/cash Increase/(decrease) in cash in year1250125Net debt/cash a lncrease/increase in cash in year1250125Net debt/cash at 1 April1,1331,1331,133	Cash flows from financing activities			
Movement in general fund working capital00Cash drawn down720,6870720,687Capital element of payments in respect of finance leases748)(748)Interest paid(369)(369)(369)Interest element of finance leases and on-balance sheet(369)(369)PFI/PPP contracts(3,404)(3,404)Net Financing716,1660Net Increase / (decrease) in cash and cash equivalents1250In the period1,1331,133Cash and cash equivalents at the beginning of the period1,2580Reconciliation of net cash flow to movement in net debt/cash1250125Net debt/cash1,1331,1331,133Net debt/cash at 1 April1,1331,1331,133	Funding	720 687		720 687
Cash drawn down720,6870720,687Capital element of payments in respect of finance leases and on-balance sheet PFI contracts(748)(748)Interest paid(369)(369)(369)Interest element of finance leases and on-balance sheet(3,404)(3,404)PFI/PPP contracts(3,404)(3,404)Net Financing716,1660Net Increase / (decrease) in cash and cash equivalents in the period1250Cash and cash equivalents at the beginning of the period1,1331,133Cash and cash equivalents at the end of the period1,25801,258Reconciliation of net cash flow to movement in net debt/cash Increase/(decrease) in cash in year1250125Net debt/cash at 1 April1,1331,1331,133Net debt/cash at 1 April1,1331,1331,133	Movement in general fund working capital	· · ·		
Capital element of payments in respect of finance leases and on-balance sheet PFI contracts(748)Interest paid(369)(369)Interest element of finance leases and on-balance sheet(3404)(3404)PFI/PPP contracts(3,404)(3,404)Net Financing716,1660716,166Net Increase / (decrease) in cash and cash equivalents in the period1250125Cash and cash equivalents at the beginning of the period1,1331,133Cash and cash equivalents at the end of the period1,25801,258Reconciliation of net cash flow to movement in net debt/cash Increase/(decrease) in cash in year1250125Net debt/cash at 1 April1,1331,1331,133Net debt/cash at 1 April1,1331,1331,133		-	٥	-
Interest paid(110)Interest paid(369)Interest element of finance leases and on-balance sheet(369)PFI/PPP contracts(3,404)Net Financing(3,404)Net Increase / (decrease) in cash and cash equivalents in the period(3,404)Cash and cash equivalents at the beginning of the period125Cash and cash equivalents at the end of the period1,133Cash and cash equivalents at the end of the period1,258Reconciliation of net cash flow to movement in net debt/cash Increase/(decrease) in cash in year125Net debt/cash at 1 April1,133Net debt/cash at 1 April1,133Net debt/cash at 1 April1,133	Capital element of payments in respect of finance leases	0,001	Ŭ	120,001
Interest paid Interest element of finance leases and on-balance sheet PFI/PPP contracts(369)(369)Net Financing(3,404)(3,404)Net Increase / (decrease) in cash and cash equivalents in the period716,1660Cash and cash equivalents at the beginning of the period1250125Cash and cash equivalents at the end of the period1,1331,133Cash and cash equivalents at the end of the period1,25801,258Reconciliation of net cash flow to movement in net debt/cash Increase/(decrease) in cash in year1250125Net debt/cash at 1 April1,1331,1331,133Net debt/cash at 1 April1,1331,1331,133	and on-balance sheet PFI contracts	(748)		(748)
Interest element of finance leases and on-balance sheet(3,404)PFI/PPP contracts(3,404)Net Financing716,166Net Increase / (decrease) in cash and cash equivalents in the period125Cash and cash equivalents at the beginning of the period1,133Cash and cash equivalents at the end of the period1,133Cash and cash equivalents at the end of the period1,258Reconciliation of net cash flow to movement in net debt/cash Increase/(decrease) in cash in year125Net debt/cash at 1 April1,133Net debt/cash at 1 April1,133Net debt/cash at 1 April1,133Net debt/cash at 1 April1,133Net debt/cash at 1 April1,133				• •
Net Financing(0,404)Net Increase / (decrease) in cash and cash equivalents in the period Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period12501251,1331,1331,25801,25801,25801,25801,25801,25801,25801,2581,2581,1331,1331,1331,1331,1331,1331,1331,1331,1331,1331,1331,1331,1331,133		(/		(000)
Net Financing716,1660716,166Net Increase / (decrease) in cash and cash equivalents in the period Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period12501251,1331,1331,1331,133Cash and cash equivalents at the end of the period1,25801,258Reconciliation of net cash flow to movement in net debt/cash Increase/(decrease) in cash in year1250125Net debt/cash at 1 April1,1331,1331,133Net debt/cash at 1 April1,1331,1331,133	PFI/PPP contracts	(3,404)		(3 404)
in the period1250125Cash and cash equivalents at the beginning of the period1,1331,133Cash and cash equivalents at the end of the period1,25801,258Reconciliation of net cash flow to movement in net debt/cash Increase/(decrease) in cash in year1250125Net debt/cash at 1 April1,1331,1331,133	Net Financing		0	
in the period1250125Cash and cash equivalents at the beginning of the period1,1331,133Cash and cash equivalents at the end of the period1,25801,258Reconciliation of net cash flow to movement in net debt/cash Increase/(decrease) in cash in year1250125Net debt/cash at 1 April1,1331,1331,133	Net Increase ((decrease) in each and each equivalente			
Cash and cash equivalents at the beginning of the period1200123Cash and cash equivalents at the end of the period1,1331,133Cash and cash equivalents at the end of the period1,25801,258Reconciliation of net cash flow to movement in net debt/cash Increase/(decrease) in cash in year1250125Net debt/cash at 1 April1,1331,1331,133		405	_	
period1,1331,133Cash and cash equivalents at the end of the period1,25801,258Reconciliation of net cash flow to movement in net debt/cash Increase/(decrease) in cash in year1250125Net debt/cash at 1 April1,1331,1331,133		125	00	125
Cash and cash equivalents at the end of the period1,100Reconciliation of net cash flow to movement in net debt/cash Increase/(decrease) in cash in year1,25801,2581,1031,2581,25801,25801,25801,25801,2581,2581,1331,133		4 400		
Reconciliation of net cash flow to movement in net debt/cash Increase/(decrease) in cash in year1250125Net debt/cash at 1 April1,1331,133				
debt/cashIncrease/(decrease) in cash in year125Net debt/cash at 1 April1,1331,133		1,258	U	1,258
Net debt/cash at 1 April1,1331,133	debt/cash			
Net debt/cash at 1 April1,1331,133	Increase/(decrease) in cash in year	125	0	125
Net debt/cash at 31 March1,2581,258	Net debt/cash at 1 April		-	
1,258 <u>0 1,258</u>	Net debt/cash at 31 March	4 050		
		1,258	0	1,258

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

27. FINANCIAL INSTRUMENTS

a FINANCIAL INSTRUMENTS BY CATEGORY

Financial Assets

CONSOLIDATED		Loans and Receivables	Available for sale	Total
At 31 March 2015	Note	£'000	£'000	£'000
Assets per balance sheet Investments I rade and other receivables excluding prepayments,	<u>14</u>		12,563	12,563
reimbursements of provisions and VAT recoverable. Cash and cash equivalents	<u>13</u> 15	4,878 607		4,878 607
	_	5,485	12,563	18,048
BOARD At 31 March 2015	Note	Loans and Receivables £'000	Available for sale £'000	Total £'000
Assets per balance sheet Investments	14		0	0
I rade and other receivables excluding prepayments, reimbursements of provisions and VAT recoverable.	<u>13</u>	4,877	·	4,877
Cash and cash equivalents	<u>15</u>	117		117
		4,994	0	4,994
CONSOLIDATED (Prior Year)		Loans and Receivables	Available for sale	Total
At 31 March 2014 Assets per balance sheet	Note	£'000	£'000	£'000
Investments I rade and other receivables excluding prepayments,	<u>14</u>		11,102	11,102
reimbursements of provisions and VAT recoverable. Cash and cash equivalents	<u>13</u> 15	3,988 1,258		3,988 1,258
		5,246	11,102	16,348
BOARD (Prior Year) At 31 March 2014	Note	5,246 Loans and Receivables £'000	11,102 Available for sale £'000	16,348 Total £'000
		Loans and Receivables	Available for sale	Total
At 31 March 2014 Assets per balance sheet Investments I rade and other receivables excluding prepayments,	<u>14</u>	Loans and Receivables £'000	Available for sale £'000	Total £'000 0
At 31 March 2014 Assets per balance sheet Investments		Loans and Receivables	Available for sale £'000	Total £'000
At 31 March 2014 Assets per balance sheet Investments I rade and other receivables excluding prepayments, reimbursements of provisions and VAT recoverable.	<u>14</u> <u>13</u>	Loans and Receivables £'000 3,992	Available for sale £'000	Total £'000 0 3,992

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

27. FINANCIAL INSTRUMENTS (cont.)

Financial Liabilities

CONSOLIDATED

At 31 March 2015 Liabilities per balance sheet Finance lease liabilities PFI Liabilities Frade and other payables excluding statutory liabilities (VAT and income tax and social security), deferred income and superannuation	Note <u>16</u> <u>16</u> <u>16</u>	Other financial liabilities £'000 304 46,983 37,880
BOARD		
At 31 March 2015 Liabilities per balance sheet Finance lease liabilities PFI Liabilities rade and other payables excluding statutory liabilities (VAT and income tax and social security), deferred income and superannuation	Note <u>16</u> <u>16</u> <u>16</u>	Other financial liabilities £'000 304 46,983 37,818 <u>85,105</u>
CONSOLIDATED (Prior Year) At 31 March 2014 Liabilities per balance sheet Finance lease liabilities PFI Liabilities Trade and other payables excluding statutory liabilities (VAT and income tax and social security) and superannuation	Note <u>16</u> <u>16</u> <u>16</u>	Other financial liabilities £'000 319 26,089 37,449 63,857

BOARD (Prior Year)		Other financial liabilities
At 31 March 2014	Note	£'000
Liabilities per balance sheet		
Finance lease liabilities	<u>16</u>	319
PFI Liabilities Trade and other payables excluding statutory	<u>16</u>	26,089
liabilities (VAT and income tax and social security) and superannuation	<u>16</u>	
		37,411
		63,819

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

27. FINANCIAL INSTRUMENTS, cont.

b FINANCIAL RISK FACTORS

Exposure to Risk

The NHS Board's activities expose it to a variety of financial risks:

Credit risk - the possibility that other parties might fail to pay amounts due.

Liquidity risk - the possibility that the NHS Board might not have funds available to meet its commitments to make payments.

Market risk - the possibility that financial loss might arise as a result of changes in such measures as interest rates, stock market movements or foreign exchange rates.

Because of the largely non-trading nature of its activities and the way in which government departments are financed, the NHS Board is not exposed to the degree of financial risk faced by business entities.

a) Credit Risk

Credit risk arises from cash and cash equivalents, deposits with banks and other institutions, as well as credit exposures to customers, including outstanding receivables and committed transactions.

For banks and other institutions, only independently rated parties with an minimum rating of 'A' are accepted.

Customers are assessed, taking into account their financial position, past experience and other factors, with individual credit limits being set in accordance with internal ratings in accordance with parameters set by the NHS Board.

The utilisation of credit limits is regularly monitored.

No credit limits were exceeded during the reporting period and no losses are expected from non-performance by any counterparties in relation to deposits.

b) Liquidity Risk

The Scottish Parliament makes provision for the use of resources by the NHS Board for revenue and capital purposes in a Budget Act for each financial year. Resources and accruing resources may be used only for the purposes specified and up to the amounts specified in the Budget Act. The Act also specifies an overall cash authorisation to operate for the financial year. The NHS Board is not therefore exposed to significant liquidity risks.

The table below analyses the financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet to contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances as the impact of discounting is not significant.

	Less than 1 year	Between 1 and 2 years	Between 2 and 5 years	Over 5 years
At 31 March 2015	£'000	£'000	£,000	£'000
PFI Liabilities	3,642	3,745	11,390	60,070
Finance lease liabilities	33	33	99	256
Trade and other payables excluding statutory				
liabilities	37,880			
Total	41,555	3,778	11,489	60,326
	Less than 1 year	Between 1 and 2 vears	Between 2 and 5 vears	Over 5 years
At 31 March 2014	Less than 1 year £'000			Over 5 years £'000
At 31 March 2014 PFI Liabilities		years	years	•
	£'000	vears £'000	vears £'000 11,293	£'000
PFI Liabilities	£'000 3,852	years £'000 3,697	vears £'000 11,293	£'000 39,670
PFI Liabilities Finance lease liabilities	£'000 3,852	years £'000 3,697	vears £'000 11,293 99	£'000 39,670

c) Market Risk

The NHS Board has no powers to borrow or invest surplus funds. Financial assets and liabilities are generated by day-to-day operational activities and are not held to manage the risks facing the NHS Board in undertaking its activities.

I) Cash flow and fair value interest rate risk

The NHS Board has no significant interest bearing assets or liabilities and as such income and expenditure cash flows are substantially independent of changes in market interest rates.

ii) Foreign Currency Risk

The NHS Board is not exposed to foreign currency risk.

iii) Price risk

The NHS Board is not exposed to equity security price risk.

c FAIR VALUE ESTIMATION

The fair value of financial liabilities for disclosure purposes is estimated by discounting the future contractual cash flows at the current HM Treasury interest rate that is available for similar financial instruments.

The carrying value less impairment provision of trade receivables and payables are assumed to approximate their fair value.

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

28. DERIVATIVE FINANCIAL INSTRUMENTS (Consolidated and Board)

There are no derivative financial instruments in 2014/15 or prior years.

29. RELATED PARTY TRANSACTIONS

Ayrshire and Arran Endowment Funds are managed by Trustees who are also Directors of the Board (as notified in the remuneration report) and is therefor a related party. During the year the Board received payments from Endowments of £708k and made payments of £233k with a balance of £16k due to the Board outstanding at year end. Additionally £324k was received in the form of Donated assets and these are shown as income in Note 8 and additions in note 11(b).

NHS Ayrshire and Arran is a sponsored body of the Scottish Government Health and Social Care Directorate which is regarded as a related party.

30. SEGMENT INFORMATION

Segmental information as required under IFRS has been reported for each strategic objective

		Acute	Acute Health & Social Care Partnerships	Corporate		
	Note	£'000	£'000	£'000	2015 £'000	
Net operating cost		297,397	340,241	101,592	739,230	

SEGMENT INFORMATION - PRIOR YEAR

Segmental information as required under IFRS has been reported for each strategic objective

		Acute	Health & Social Care Partnerships	Corporate	
	Note	£'000	£'000	£'000	2014 £'000
Net operating cost		282,873	329,679	122,455	735,007

31. THIRD PARTY ASSETS

Third Party Assets managed by the Board consist of balances on Patients' Private Funds Accounts

These are not departmental assets and are not included in the accounts. The assets held at the reporting period date to which it was practical to ascribe monetary values comprised monetary assets, such as bank balances and monies on deposit, and listed securities. They are set out in the table immediately below.

	2014	Gross Inflows	Gross Outflows	2015
Monotony amounto auch as hank helenges and maning an always'	£'000	£'000	£'000	£'000
Monetary amounts such as bank balances and monies on deposit	772	422	(462)	732

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

32. EXIT PACKAGES

2015

Exit package cost band	Number of compulsory redundancies	Number of other departures agreed	Total number of exit packages by cost band
<£10,000	0	0	0
£10,000 - £25,000	0	0	0
£25,000 - £50,000	0	1	1
 Total number exit packages by type 	0	1	1
Total resource cost (£'000)		30	30

EXIT PACKAGES - PRIOR YEAR

2014

Exit package cost band	Number of compulsory redundancies	Number of other departures agreed	Total number of exit packages by cost band
<£10,000	0	0	0
£10,000 - £25,000	0	0	0
£25,000 - £50,000	0	2	2
 Total number exit packages by type	0	2	2
Total resource cost (£'000)	0	68	68

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

33a. CONSOLIDATED STATEMENT OF COMPREHENSIVE NET EXPENDITURE

	Board 2015 £'000	Endowments 2015 £'000	Intra Group adj. 2015 £'000	Consolidated 2015 £'000
Clinical Services Costs				
Hospital and Community	591,991			591,991
Less: Hospital and Community Income	26,060			26,060
	565,931	0		0 565,931
•	181,552			181,552
Less: Family Health Income	5,632			5,632
	175,920	0		0 175,920
Total Clinical Services Costs	741,851	0	(0 741,851
Administration Costs	2.790			2,790
Less: Administration Income	25			2,730
	2,765	0		
Other Non Clinical Services	9,852	1.604	(941	
Less: Other Operating Income	15,178			
	(5,326)	(60)		
Net Operating Costs	739,290	(60)		739,230
	Hospital and Community Less: Hospital and Community Income Family Health Less: Family Health Income Total Clinical Services Costs Administration Costs Less: Administration Income Other Non Clinical Services Less: Other Operating Income	2015 £'000 Clinical Services Costs Hospital and Community Less: Hospital and Community Income 26,060 Family Health 181,552 Less: Family Health 181,552 Total Clinical Services Costs 741,851 Administration Costs 2,790 Less: Administration Income 25 Other Non Clinical Services 9,852 Less: Other Operating Income 15,178 (5,326)	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

The Intra Group adjustments relate to transactions between the Endowment Funds and the Board which are eliminated on consolidation. These are the payments received by the Board from Endowments of £708k and the payments of £233k from the Board to Endowments.

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

33b. CONSOLIDATED GROUP BALANCE SHEET

Group 2014 £'000		Note	Board 2015 £'000	Endowment 2015 £'000	Intra Group adjustment 2015 £'000	Group 2015 £'000
	Non-current assets:					
315,735	Property, plant and equipment	<u>11</u>	348,429			348,429
0	Intangible assets	<u>10</u>	0			0
44.400	Financial assets:			40 500		10 500
11,102	Available for sale financial assets	<u>14</u>	0	12,563		12,563
23,078 349,915	Trade and other receivables Total non-current assets	<u>13</u>	27,350	40.000		27,350
349,915	Total non-current assets	_	3/5,//9	12,563	0	388,342
	Current Assets:					
3,767	Inventories	12	3,849			3,849
	Financial assets:		• • • •			-,
18,812	Trade and other receivables	<u>13</u>	8,763	31	(30)	8,764
1,258	Cash and cash equivalents	<u>15</u>	117	490	. ,	607
0	Available for sale financial assets	<u>14</u>	0			0
3,870	Assets classified as held for sale	<u>11c</u>	2,050			2,050
27,707	Total current assets		14,779	521	(30)	15,270
377,622	Total assets		390,558	13,084	(30)	403,612
	Current liabilities					
(10,653)	Provisions	17	(15,750)			(15,750)
	Financial liabilities:		((
(53,242)	Trade and other payables	<u>16</u>	(54,349)	(92)	30	(54,411)
(63,895)	Total current liabilities		(70,099)	(92)	30	(70,161)
313,727	Non autrent papata pluallaga pat autrent ag		320,459	12,992	0	000 454
313,121	Non-current assets plus/less net current ass	etsmannties	320,459	12,992	0	333,451
	Non-current liabilities					
(55,589)	Provisions	<u>17</u>	(43,666)			(43,666)
	Financial liabilities:					
(27,037)	Trade and other payables	<u>16</u>	(47,735)			(47,735)
(82,626)	Total non-current liabilities	_	(91,401)	0	0	(91,401)
231,101	Assets less liabilities		229,058	12,992	0	242.050
201,101	Assets less habilities		229,000	12,552	U	242,050
	Taxpayers' Equity					
151,250	General fund	SOCTE	153,445			153,445
67,648	Revaluation reserve	SOCTE	75,613			75,613
12,203	Funds Held on Trust	SOCTE	0	12,992		12,992
231,101	Total taxpayers' equity		229,058	12,992	0	242,050

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2015

33c. CONSOLIDATED STATEMENT OF CASHFLOWS

Board £'000	Endowment £'000	Group £'000
(735,024)	17	(735,007)
21,513	0	21,513
3,773	0	3,773
0	(320)	(320)
(11,717)	(5)	(11,722)
(471)	0	(471)
(5,917)	(38)	(5,955)
19,463	0	19,463
(708,380)	(346)	(708,726)
(8,141)	0	(8,141)
0	(2,119)	(2,119)
355	0	355
0	2,270	2,270
0	320	320
(7,786)	471	(7,315)
720,687	0	720,687
0	0	0
720,687	0	720,687
(748)	0	(748)
(369)	õ	(369)
(3,404)	0	(3,404)
716,166	0	716,166
0	125	125
115	1,018	1,133
115	1,143	1,258
0	125	125
115	1,018	1,133
115	1,143	1,258

	£'000	£'000	£'000
Cash flows from operating activities			
Net operating cost	(739,290)	60	(739,230)
Adjustments for non-cash transactions	16,333		16,333
Add back: interest payable recognised in net operating cost	3,841		3,841
Deduct: interest receivable recognised in net operating cost	0,041	(397)	(397)
(Increase) / decrease in trade and other receivables	5.781	9	5,790
(Increase) / decrease in inventories	(82)	5	(82)
increase / (decrease) in trade and other payables	512	9	521
Increase / (decrease) in provisions	(6,826)	5	(6,826)
Net cash outflow from operating activities	(719,731)	(319)	(720,050)
Cash flows from investing activities			
Purchase of property, plant and equipment	(36,191)		(36,191)
Investment Additions	Ó	(4,880)	(4,880)
Proceeds of disposal of property, plant and equipment	1,611	(),,	1,611
Receipts from sale of investments	0	4,149	4,149
Interest and dividends received	Ō	397	397
Net cash outflow from investing activities	(34,580)	(334)	(34,914)
Cash flows from financing activities			
Funding	737,273		737.273
Movement in general fund working capital	2		2
Cash drawn down	737,275	0	737,275
Capital element of payments in respect of finance leases and			
on-balance sheet PFI contracts	20,879		20,879
Interest paid Interest element of finance leases and on-balance sheet	(326)		(326)
PFI/PPP contracts	(3,515)		(3,515)
Net Financing	754,313	0	754,313
Net Increase / (decrease) in cash and cash equivalents in			
the period	2	(653)	(651)
Cash and cash equivalents at the beginning of the period	115	1,143	1,258
Cash and cash equivalents at the end of the period	117	490	607
Reconciliation of net cash flow to movement in net debt/cash			
Increase/(decrease) in cash in year	2	(653)	(651)
Net debt/cash at 1 April	115	1,143	1,258
Net debt/cash at 31 March	. 117	490	607

Board

Endowment

Group

Direction by the Scottish Ministers



Ayrshire and Arran Health Board

DIRECTION BY THE SCOTTISH MINISTERS

- 1. The Scottish Ministers, in pursuance of sections 86(1), (1B) and (3) of the National Health Services (Scotland) Act 1978, hereby give the following direction.
- 2. The statement of accounts for the financial year ended 31 March 2006, and subsequent years, shall comply with the accounting principles and disclosure requirements of the edition of the Government Financial Reporting Manual (FReM) which is in force for the year for which the statement of accounts are prepared.
- Subject to the foregoing requirements, the accounts shall also comply with any accounts format, disclosure and accounting requirements issued by the Scottish Ministers from time to time.
- 4. The accounts shall be prepared so as to give a true and fair view of the income and expenditure and cash flows for the financial year, and of the state, of affairs as at the end of the financial year.
- 5. This direction shall be reproduced as an appendix to the statement of accounts. The direction given on 30 December 2002 is hereby revoked.

Signed by the authority of the Scottish Ministers

Dated 10/2 2006

Page 96 of 96

.